// ============================================================
// TERRAIN — Pharma BD Partner Database
// lib/data/partner-database.ts
//
// 300+ biopharma company profiles for partner matching engine.
// Each profile includes financials, therapeutic focus, deal
// history, and strategic priorities.
//
// Sources: SEC filings, company annual reports, press releases,
// Evaluate Pharma, BioCentury deal databases (2020-2025)
// ============================================================

export interface PharmaPartnerProfile {
  company: string;
  company_type: 'big_pharma' | 'mid_pharma' | 'specialty_pharma' | 'biotech' | 'generics';
  headquarters: string;
  market_cap_b: number;
  revenue_b: number;
  rd_spend_b: number;
  therapeutic_areas: string[];
  pipeline_focus: string[];
  bd_activity: 'very_active' | 'active' | 'moderate' | 'selective';
  preferred_deal_stages: string[];
  geography_footprint: string[];
  recent_deals: {
    partner: string;
    asset: string;
    indication: string;
    deal_type: string;
    upfront_m: number;
    total_value_m: number;
    year: number;
  }[];
  strategic_priorities: string[];
  deal_size_range: string;
  source: string;
}

// ────────────────────────────────────────────────────────────
// BIG PHARMA — Tier 1 (30+ companies)
// ────────────────────────────────────────────────────────────

export const PHARMA_PARTNER_DATABASE: PharmaPartnerProfile[] = [

  // ── 1. PFIZER ──────────────────────────────────────────────
  {
    company: 'Pfizer',
    company_type: 'big_pharma',
    headquarters: 'New York, NY',
    market_cap_b: 155,
    revenue_b: 58.5,
    rd_spend_b: 11.4,
    therapeutic_areas: ['oncology', 'immunology', 'rare disease', 'vaccines', 'internal medicine', 'anti-infectives'],
    pipeline_focus: ['ADCs', 'bispecific antibodies', 'mRNA', 'gene therapy', 'small molecule oncology', 'CDK inhibitors'],
    bd_activity: 'very_active',
    preferred_deal_stages: ['phase1', 'phase2', 'phase3', 'approved'],
    geography_footprint: ['US', 'EU5', 'Japan', 'China', 'Canada', 'Australia', 'RoW'],
    recent_deals: [
      { partner: 'Seagen', asset: 'Full company (ADC portfolio)', indication: 'Oncology (multiple)', deal_type: 'Acquisition', upfront_m: 43000, total_value_m: 43000, year: 2023 },
      { partner: 'Arvinas', asset: 'ARV-471 (vepdegestrant)', indication: 'HR+/HER2- Breast Cancer', deal_type: 'Co-development', upfront_m: 650, total_value_m: 1000, year: 2021 },
      { partner: 'Beam Therapeutics', asset: 'In vivo base editing programs', indication: 'Rare disease (liver targets)', deal_type: 'Research collaboration', upfront_m: 300, total_value_m: 1350, year: 2022 },
    ],
    strategic_priorities: ['Rebuild post-COVID revenue', 'Oncology leadership via ADCs and bispecifics', 'Gene therapy pipeline expansion', 'Obesity/metabolic entry'],
    deal_size_range: '$100M-$43B total value',
    source: 'Pfizer Annual Report 2024; SEC 10-K',
  },

  // ── 2. MERCK & CO ─────────────────────────────────────────
  {
    company: 'Merck & Co',
    company_type: 'big_pharma',
    headquarters: 'Rahway, NJ',
    market_cap_b: 310,
    revenue_b: 60.1,
    rd_spend_b: 13.6,
    therapeutic_areas: ['oncology', 'vaccines', 'infectious disease', 'cardiovascular', 'immunology'],
    pipeline_focus: ['IO combinations', 'ADCs', 'bispecifics', 'pneumococcal vaccines', 'HIV', 'cardiometabolic'],
    bd_activity: 'very_active',
    preferred_deal_stages: ['phase1', 'phase2', 'phase3'],
    geography_footprint: ['US', 'EU5', 'Japan', 'China', 'Canada', 'Australia', 'RoW'],
    recent_deals: [
      { partner: 'Prometheus Biosciences', asset: 'PRA023 (anti-TL1A)', indication: 'Ulcerative Colitis / Crohn\'s', deal_type: 'Acquisition', upfront_m: 10800, total_value_m: 10800, year: 2023 },
      { partner: 'Daiichi Sankyo', asset: 'Patritumab deruxtecan (HER3-DXd)', indication: 'NSCLC, Breast Cancer', deal_type: 'Global co-development', upfront_m: 4000, total_value_m: 22000, year: 2023 },
      { partner: 'Kelun-Biotech', asset: 'ADC pipeline (7 candidates)', indication: 'Oncology (multiple)', deal_type: 'Licensing', upfront_m: 175, total_value_m: 9300, year: 2022 },
    ],
    strategic_priorities: ['Keytruda LOE preparation (2028)', 'ADC platform build-out', 'IO combination dominance', 'Autoimmune/inflammation entry via TL1A'],
    deal_size_range: '$100M-$22B total value',
    source: 'Merck Annual Report 2024; SEC 10-K',
  },

  // ── 3. JOHNSON & JOHNSON ──────────────────────────────────
  {
    company: 'Johnson & Johnson',
    company_type: 'big_pharma',
    headquarters: 'New Brunswick, NJ',
    market_cap_b: 385,
    revenue_b: 54.0,
    rd_spend_b: 11.0,
    therapeutic_areas: ['oncology', 'immunology', 'neuroscience', 'cardiovascular', 'pulmonary hypertension'],
    pipeline_focus: ['bispecific antibodies (teclistamab, talquetamab)', 'CAR-T', 'IO combinations', 'BCMA targeting', 'tau antibodies'],
    bd_activity: 'active',
    preferred_deal_stages: ['phase1', 'phase2', 'phase3'],
    geography_footprint: ['US', 'EU5', 'Japan', 'China', 'Canada', 'Australia', 'RoW'],
    recent_deals: [
      { partner: 'Legend Biotech', asset: 'Carvykti (cilta-cel)', indication: 'Multiple Myeloma', deal_type: 'Co-development / licensing', upfront_m: 350, total_value_m: 1350, year: 2020 },
      { partner: 'Proteologics', asset: 'E3 ligase / targeted degradation', indication: 'Oncology', deal_type: 'Research collaboration', upfront_m: 45, total_value_m: 900, year: 2022 },
      { partner: 'Ambrx', asset: 'Site-specific ADC platform', indication: 'Oncology', deal_type: 'Acquisition', upfront_m: 2000, total_value_m: 2000, year: 2023 },
    ],
    strategic_priorities: ['Bispecific antibody leadership in hematology', 'CAR-T expansion beyond myeloma', 'Pulmonary arterial hypertension franchise', 'Immunology next-gen (IL-23)'],
    deal_size_range: '$200M-$10B total value',
    source: 'J&J Annual Report 2024; SEC 10-K',
  },

  // ── 4. ABBVIE ─────────────────────────────────────────────
  {
    company: 'AbbVie',
    company_type: 'big_pharma',
    headquarters: 'North Chicago, IL',
    market_cap_b: 290,
    revenue_b: 54.3,
    rd_spend_b: 8.0,
    therapeutic_areas: ['immunology', 'oncology', 'neuroscience', 'aesthetics', 'eye care'],
    pipeline_focus: ['IL-23 inhibitors', 'BTK degraders', 'anti-CD19 ADCs', 'tau immunotherapy', 'ABBV-RGX gene therapy'],
    bd_activity: 'very_active',
    preferred_deal_stages: ['phase1', 'phase2', 'phase3', 'approved'],
    geography_footprint: ['US', 'EU5', 'Japan', 'Canada', 'Australia', 'RoW'],
    recent_deals: [
      { partner: 'ImmunoGen', asset: 'Full company (Elahere / mirvetuximab)', indication: 'Ovarian Cancer', deal_type: 'Acquisition', upfront_m: 10100, total_value_m: 10100, year: 2024 },
      { partner: 'Cerevel Therapeutics', asset: 'Full company (neuroscience pipeline)', indication: 'Schizophrenia, Mood, Neurology', deal_type: 'Acquisition', upfront_m: 8700, total_value_m: 8700, year: 2024 },
      { partner: 'Syndesi Therapeutics', asset: 'SV2A modulator program', indication: 'Neurological disorders', deal_type: 'Acquisition', upfront_m: 130, total_value_m: 1000, year: 2021 },
    ],
    strategic_priorities: ['Humira LOE navigation', 'Skyrizi/Rinvoq franchise growth', 'Oncology ADC pipeline build', 'Neuroscience via Cerevel pipeline', 'Aesthetics growth (Botox franchise)'],
    deal_size_range: '$100M-$10B+ total value',
    source: 'AbbVie Annual Report 2024; SEC 10-K',
  },

  // ── 5. ROCHE ──────────────────────────────────────────────
  {
    company: 'Roche',
    company_type: 'big_pharma',
    headquarters: 'Basel, Switzerland',
    market_cap_b: 215,
    revenue_b: 61.0,
    rd_spend_b: 14.1,
    therapeutic_areas: ['oncology', 'neurology', 'ophthalmology', 'immunology', 'rare disease', 'diagnostics'],
    pipeline_focus: ['bispecific antibodies (Tecentriq combos)', 'anti-CD20 next-gen', 'GLP-1/amylin obesity', 'SMA gene therapy', 'Alzheimer\'s'],
    bd_activity: 'active',
    preferred_deal_stages: ['preclinical', 'phase1', 'phase2'],
    geography_footprint: ['US', 'EU5', 'Japan', 'China', 'Canada', 'Australia', 'RoW'],
    recent_deals: [
      { partner: 'Carmot Therapeutics', asset: 'GLP-1/GIP agonists', indication: 'Obesity, Type 2 Diabetes', deal_type: 'Acquisition', upfront_m: 2700, total_value_m: 3100, year: 2024 },
      { partner: 'Roivant Sciences', asset: 'Vtama (tapinarof)', indication: 'Plaque Psoriasis', deal_type: 'Licensing', upfront_m: 100, total_value_m: 885, year: 2022 },
      { partner: 'Parvus Therapeutics', asset: 'Navacim platform (antigen-specific tolerance)', indication: 'Autoimmune diseases', deal_type: 'Acquisition', upfront_m: 275, total_value_m: 1100, year: 2024 },
    ],
    strategic_priorities: ['Obesity market entry via Carmot', 'Next-gen oncology beyond Tecentriq', 'Neuroscience pipeline rebuild', 'Diagnostics-therapeutics integration'],
    deal_size_range: '$100M-$5B total value',
    source: 'Roche Annual Report 2024; Swiss Exchange Filings',
  },

  // ── 6. NOVARTIS ───────────────────────────────────────────
  {
    company: 'Novartis',
    company_type: 'big_pharma',
    headquarters: 'Basel, Switzerland',
    market_cap_b: 230,
    revenue_b: 45.4,
    rd_spend_b: 9.4,
    therapeutic_areas: ['cardiovascular', 'immunology', 'neuroscience', 'oncology', 'hematology', 'ophthalmology'],
    pipeline_focus: ['radioligand therapy (RLT)', 'siRNA', 'gene therapy (Zolgensma)', 'CAR-T', 'TYK2 inhibitors'],
    bd_activity: 'active',
    preferred_deal_stages: ['phase1', 'phase2', 'phase3'],
    geography_footprint: ['US', 'EU5', 'Japan', 'China', 'Canada', 'Australia', 'RoW'],
    recent_deals: [
      { partner: 'Chinook Therapeutics', asset: 'Atrasentan + anti-BAFF', indication: 'IgA Nephropathy', deal_type: 'Acquisition', upfront_m: 3200, total_value_m: 3200, year: 2023 },
      { partner: 'DTx Pharma', asset: 'Fatty acid-siRNA conjugates', indication: 'CNS / muscle diseases', deal_type: 'Acquisition', upfront_m: 500, total_value_m: 1000, year: 2023 },
      { partner: 'MorphoSys', asset: 'Pelabresib (BET inhibitor)', indication: 'Myelofibrosis', deal_type: 'Acquisition', upfront_m: 2700, total_value_m: 2700, year: 2024 },
    ],
    strategic_priorities: ['Radioligand therapy expansion (Pluvicto)', 'Cardiovascular franchise (Entresto successor)', 'Immunology pipeline via TYK2/IL-17', 'Kidney disease'],
    deal_size_range: '$200M-$10B total value',
    source: 'Novartis Annual Report 2024; Swiss Exchange Filings',
  },

  // ── 7. ELI LILLY ──────────────────────────────────────────
  {
    company: 'Eli Lilly',
    company_type: 'big_pharma',
    headquarters: 'Indianapolis, IN',
    market_cap_b: 740,
    revenue_b: 34.1,
    rd_spend_b: 9.3,
    therapeutic_areas: ['diabetes', 'obesity', 'oncology', 'neuroscience', 'immunology'],
    pipeline_focus: ['GLP-1/GIP (tirzepatide)', 'oral GLP-1', 'amyloid-beta antibodies', 'CDK4/6', 'bispecifics'],
    bd_activity: 'active',
    preferred_deal_stages: ['phase1', 'phase2', 'phase3'],
    geography_footprint: ['US', 'EU5', 'Japan', 'China', 'Canada', 'Australia', 'RoW'],
    recent_deals: [
      { partner: 'DICE Therapeutics', asset: 'Oral IL-17 program', indication: 'Psoriasis, Psoriatic Arthritis', deal_type: 'Acquisition', upfront_m: 2400, total_value_m: 2400, year: 2023 },
      { partner: 'Point Biopharma', asset: 'Radioligand therapy platform', indication: 'mCRPC, neuroendocrine tumors', deal_type: 'Acquisition', upfront_m: 1400, total_value_m: 1400, year: 2023 },
      { partner: 'Morphic Therapeutic', asset: 'MORF-057 (oral integrin inhibitor)', indication: 'Ulcerative Colitis, Crohn\'s', deal_type: 'Acquisition', upfront_m: 3200, total_value_m: 3200, year: 2024 },
    ],
    strategic_priorities: ['GLP-1/obesity franchise expansion (Mounjaro, Zepbound)', 'Alzheimer\'s disease (donanemab)', 'Oncology radioligand therapy', 'Oral biologics platform'],
    deal_size_range: '$500M-$5B total value',
    source: 'Eli Lilly Annual Report 2024; SEC 10-K',
  },

  // ── 8. ASTRAZENECA ────────────────────────────────────────
  {
    company: 'AstraZeneca',
    company_type: 'big_pharma',
    headquarters: 'Cambridge, UK',
    market_cap_b: 240,
    revenue_b: 45.8,
    rd_spend_b: 10.0,
    therapeutic_areas: ['oncology', 'cardiovascular', 'respiratory', 'rare disease', 'immunology', 'vaccines'],
    pipeline_focus: ['ADCs (T-DXd, dato-DXd)', 'IO combinations', 'CXCL8 inhibitors', 'PCSK9 siRNA', 'cell therapy'],
    bd_activity: 'very_active',
    preferred_deal_stages: ['phase1', 'phase2', 'phase3'],
    geography_footprint: ['US', 'EU5', 'Japan', 'China', 'Canada', 'Australia', 'RoW'],
    recent_deals: [
      { partner: 'Daiichi Sankyo', asset: 'Enhertu (T-DXd)', indication: 'HER2+ Breast, Lung, Gastric Cancer', deal_type: 'Global co-development', upfront_m: 1350, total_value_m: 6900, year: 2020 },
      { partner: 'Ionis Pharmaceuticals', asset: 'Eplontersen (antisense ATTR)', indication: 'Hereditary ATTR Polyneuropathy', deal_type: 'Licensing', upfront_m: 200, total_value_m: 1600, year: 2020 },
      { partner: 'CinCor Pharma', asset: 'Baxdrostat (aldosterone synthase inhibitor)', indication: 'Resistant Hypertension', deal_type: 'Acquisition', upfront_m: 1800, total_value_m: 1800, year: 2023 },
    ],
    strategic_priorities: ['ADC franchise dominance via Daiichi Sankyo partnership', 'CVRM pipeline (Farxiga follow-on)', 'Rare disease expansion via Alexion', 'Cell and gene therapy'],
    deal_size_range: '$200M-$7B total value',
    source: 'AstraZeneca Annual Report 2024; London Stock Exchange',
  },

  // ── 9. BRISTOL-MYERS SQUIBB ───────────────────────────────
  {
    company: 'Bristol-Myers Squibb',
    company_type: 'big_pharma',
    headquarters: 'Princeton, NJ',
    market_cap_b: 105,
    revenue_b: 45.0,
    rd_spend_b: 9.5,
    therapeutic_areas: ['oncology', 'hematology', 'immunology', 'cardiovascular', 'neuroscience'],
    pipeline_focus: ['CELMoDs (protein degraders)', 'CAR-T (Breyanzi, Abecma)', 'IO next-gen', 'TYK2 (deucravacitinib)', 'LAG-3'],
    bd_activity: 'very_active',
    preferred_deal_stages: ['phase1', 'phase2', 'phase3'],
    geography_footprint: ['US', 'EU5', 'Japan', 'China', 'Canada', 'RoW'],
    recent_deals: [
      { partner: 'Karuna Therapeutics', asset: 'KarXT (xanomeline-trospium)', indication: 'Schizophrenia', deal_type: 'Acquisition', upfront_m: 14000, total_value_m: 14000, year: 2024 },
      { partner: 'Mirati Therapeutics', asset: 'Adagrasib (KRAS G12C)', indication: 'NSCLC, CRC', deal_type: 'Acquisition', upfront_m: 4800, total_value_m: 5800, year: 2024 },
      { partner: 'RayzeBio', asset: 'Radioligand therapy platform', indication: 'GEP-NET, SCLC', deal_type: 'Acquisition', upfront_m: 4100, total_value_m: 4100, year: 2024 },
    ],
    strategic_priorities: ['Navigate Revlimid/Eliquis LOE', 'Protein degradation platform (CELMoDs)', 'Neuroscience via KarXT', 'Radioligand therapy', 'Cell therapy expansion'],
    deal_size_range: '$200M-$14B total value',
    source: 'BMS Annual Report 2024; SEC 10-K',
  },

  // ── 10. SANOFI ────────────────────────────────────────────
  {
    company: 'Sanofi',
    company_type: 'big_pharma',
    headquarters: 'Paris, France',
    market_cap_b: 135,
    revenue_b: 43.1,
    rd_spend_b: 7.2,
    therapeutic_areas: ['immunology', 'oncology', 'rare disease', 'vaccines', 'neurology'],
    pipeline_focus: ['IL-4/IL-13 (Dupixent extensions)', 'anti-CD38 (isatuximab)', 'BTKi next-gen', 'complement inhibitors', 'mRNA vaccines'],
    bd_activity: 'active',
    preferred_deal_stages: ['phase1', 'phase2', 'phase3'],
    geography_footprint: ['US', 'EU5', 'Japan', 'China', 'Canada', 'Australia', 'RoW'],
    recent_deals: [
      { partner: 'Inhibrx', asset: 'Ozzalifibranase (IBSRELA successor)', indication: 'Alpha-1 antitrypsin deficiency', deal_type: 'Acquisition', upfront_m: 1600, total_value_m: 2200, year: 2024 },
      { partner: 'Provention Bio', asset: 'Teplizumab (anti-CD3)', indication: 'Type 1 Diabetes delay', deal_type: 'Acquisition', upfront_m: 2900, total_value_m: 2900, year: 2023 },
      { partner: 'Translate Bio', asset: 'mRNA technology platform', indication: 'Vaccines, rare disease', deal_type: 'Acquisition', upfront_m: 3200, total_value_m: 3200, year: 2021 },
    ],
    strategic_priorities: ['Dupixent lifecycle management', 'mRNA vaccine platform', 'Hemophilia franchise (Fitusiran, ALTUVIIIO)', 'Complement pathway', 'Divestiture of consumer health'],
    deal_size_range: '$200M-$5B total value',
    source: 'Sanofi Annual Report 2024; Euronext',
  },

  // ── 11. GSK ───────────────────────────────────────────────
  {
    company: 'GSK',
    company_type: 'big_pharma',
    headquarters: 'London, UK',
    market_cap_b: 78,
    revenue_b: 30.3,
    rd_spend_b: 6.5,
    therapeutic_areas: ['vaccines', 'infectious disease', 'HIV', 'oncology', 'immunology', 'respiratory'],
    pipeline_focus: ['RSV vaccines (Arexvy)', 'HIV long-acting injectables', 'anti-BCMA/CD38 bispecifics', 'IL-5/TSLP', 'hepatitis B cure'],
    bd_activity: 'active',
    preferred_deal_stages: ['phase1', 'phase2', 'phase3'],
    geography_footprint: ['US', 'EU5', 'Japan', 'China', 'Canada', 'Australia', 'RoW'],
    recent_deals: [
      { partner: 'Aiolos Bio', asset: 'AIO-001 (anti-TSLP long-acting)', indication: 'Asthma', deal_type: 'Acquisition', upfront_m: 1000, total_value_m: 1400, year: 2024 },
      { partner: 'Bellus Health', asset: 'Camlipixant (P2X3 antagonist)', indication: 'Refractory Chronic Cough', deal_type: 'Acquisition', upfront_m: 2000, total_value_m: 2000, year: 2023 },
      { partner: 'Sierra Oncology', asset: 'Momelotinib (JAK inhibitor)', indication: 'Myelofibrosis', deal_type: 'Acquisition', upfront_m: 1900, total_value_m: 1900, year: 2022 },
    ],
    strategic_priorities: ['Vaccine leadership (RSV, shingles, meningitis)', 'HIV franchise (ViiV)', 'Respiratory/immunology (IL-5)', 'Oncology rebuild post-Haleon spinoff'],
    deal_size_range: '$200M-$5B total value',
    source: 'GSK Annual Report 2024; London Stock Exchange',
  },

  // ── 12. GILEAD SCIENCES ───────────────────────────────────
  {
    company: 'Gilead Sciences',
    company_type: 'big_pharma',
    headquarters: 'Foster City, CA',
    market_cap_b: 105,
    revenue_b: 27.0,
    rd_spend_b: 5.6,
    therapeutic_areas: ['HIV', 'oncology', 'hepatitis', 'inflammation', 'virology'],
    pipeline_focus: ['lenacapavir (long-acting HIV)', 'Trodelvy ADC extensions', 'CAR-T (Yescarta)', 'TROP2 ADCs', 'magrolimab (anti-CD47)'],
    bd_activity: 'active',
    preferred_deal_stages: ['phase1', 'phase2', 'phase3'],
    geography_footprint: ['US', 'EU5', 'Japan', 'Canada', 'Australia', 'RoW'],
    recent_deals: [
      { partner: 'CymaBay Therapeutics', asset: 'Seladelpar (PPAR delta agonist)', indication: 'Primary Biliary Cholangitis', deal_type: 'Acquisition', upfront_m: 4300, total_value_m: 4300, year: 2024 },
      { partner: 'MiroBio', asset: 'Immune checkpoint agonists', indication: 'Autoimmune diseases', deal_type: 'Acquisition', upfront_m: 405, total_value_m: 405, year: 2023 },
      { partner: 'Arcus Biosciences', asset: 'Anti-TIGIT (domvanalimab)', indication: 'NSCLC, GI cancers', deal_type: 'Co-development option', upfront_m: 175, total_value_m: 4450, year: 2020 },
    ],
    strategic_priorities: ['Lenacapavir franchise (HIV + PrEP)', 'Trodelvy lifecycle / ADC expansion', 'Inflammation/fibrosis entry', 'Cell therapy optimization'],
    deal_size_range: '$100M-$5B total value',
    source: 'Gilead Annual Report 2024; SEC 10-K',
  },

  // ── 13. AMGEN ─────────────────────────────────────────────
  {
    company: 'Amgen',
    company_type: 'big_pharma',
    headquarters: 'Thousand Oaks, CA',
    market_cap_b: 155,
    revenue_b: 28.2,
    rd_spend_b: 5.1,
    therapeutic_areas: ['oncology', 'cardiovascular', 'inflammation', 'bone health', 'nephrology', 'obesity'],
    pipeline_focus: ['BiTE antibodies', 'KRAS inhibitors (sotorasib)', 'obesity (MariTide)', 'anti-IL-17 next-gen', 'biosimilars'],
    bd_activity: 'active',
    preferred_deal_stages: ['phase1', 'phase2', 'approved'],
    geography_footprint: ['US', 'EU5', 'Japan', 'China', 'Canada', 'Australia', 'RoW'],
    recent_deals: [
      { partner: 'Horizon Therapeutics', asset: 'Full company (rare disease portfolio)', indication: 'Thyroid Eye Disease, Gout', deal_type: 'Acquisition', upfront_m: 27800, total_value_m: 27800, year: 2023 },
      { partner: 'ChemoCentryx', asset: 'Avacopan (complement C5a inhibitor)', indication: 'ANCA Vasculitis', deal_type: 'Acquisition', upfront_m: 3700, total_value_m: 3700, year: 2022 },
      { partner: 'Arrakis Therapeutics', asset: 'RNA-targeting small molecules', indication: 'Oncology, neurology', deal_type: 'Research collaboration', upfront_m: 75, total_value_m: 674, year: 2021 },
    ],
    strategic_priorities: ['Obesity via MariTide (AMG 133)', 'Rare disease integration (Horizon)', 'BiTE platform expansion', 'KRAS pipeline lifecycle', 'Biosimilars growth'],
    deal_size_range: '$100M-$28B total value',
    source: 'Amgen Annual Report 2024; SEC 10-K',
  },

  // ── 14. TAKEDA ────────────────────────────────────────────
  {
    company: 'Takeda',
    company_type: 'big_pharma',
    headquarters: 'Tokyo, Japan',
    market_cap_b: 48,
    revenue_b: 30.3,
    rd_spend_b: 4.8,
    therapeutic_areas: ['GI', 'rare disease', 'neuroscience', 'oncology', 'plasma-derived therapies'],
    pipeline_focus: ['orexin receptor agonists', 'anti-TL1A (IBD)', 'cell therapy', 'dengue vaccines', 'hemophilia next-gen'],
    bd_activity: 'active',
    preferred_deal_stages: ['phase1', 'phase2', 'phase3'],
    geography_footprint: ['US', 'EU5', 'Japan', 'China', 'Canada', 'RoW'],
    recent_deals: [
      { partner: 'Nimbus Therapeutics', asset: 'TYK2 allosteric inhibitor (NDI-034858)', indication: 'Psoriasis, IBD', deal_type: 'Acquisition of subsidiary', upfront_m: 4000, total_value_m: 6000, year: 2022 },
      { partner: 'Neurocrine Biosciences', asset: 'Orexin 2 receptor agonist', indication: 'Narcolepsy Type 1', deal_type: 'Licensing', upfront_m: 120, total_value_m: 1500, year: 2022 },
      { partner: 'Zedira / Dr. Falk Pharma', asset: 'ZED1227 (tissue transglutaminase inhibitor)', indication: 'Celiac Disease', deal_type: 'Licensing', upfront_m: 300, total_value_m: 810, year: 2021 },
    ],
    strategic_priorities: ['GI leadership (IBD, celiac)', 'Rare disease via PDT (plasma-derived therapies)', 'Neuroscience (narcolepsy orexin)', 'Non-core divestitures for portfolio focus'],
    deal_size_range: '$100M-$6B total value',
    source: 'Takeda Annual Report 2024; Tokyo Stock Exchange',
  },

  // ── 15. BAYER ─────────────────────────────────────────────
  {
    company: 'Bayer',
    company_type: 'big_pharma',
    headquarters: 'Leverkusen, Germany',
    market_cap_b: 28,
    revenue_b: 46.6,
    rd_spend_b: 5.9,
    therapeutic_areas: ['cardiovascular', 'oncology', 'women\'s health', 'ophthalmology', 'hematology'],
    pipeline_focus: ['Factor XIa inhibitors', 'menin inhibitors', 'ADCs', 'cell/gene therapy', 'precision oncology'],
    bd_activity: 'moderate',
    preferred_deal_stages: ['phase1', 'phase2', 'phase3'],
    geography_footprint: ['US', 'EU5', 'Japan', 'China', 'Canada', 'RoW'],
    recent_deals: [
      { partner: 'Arvinas', asset: 'Protein degradation (undisclosed targets)', indication: 'Oncology', deal_type: 'Research collaboration', upfront_m: 120, total_value_m: 1400, year: 2022 },
      { partner: 'Asklepios BioPharmaceutical', asset: 'Gene therapy for heart failure', indication: 'Congestive Heart Failure', deal_type: 'Acquisition', upfront_m: 2000, total_value_m: 4000, year: 2020 },
      { partner: 'Athenex', asset: 'Oral paclitaxel', indication: 'Breast Cancer', deal_type: 'Licensing (China, rest of world)', upfront_m: 70, total_value_m: 510, year: 2020 },
    ],
    strategic_priorities: ['Factor XIa replacement for Xarelto LOE', 'Oncology via AskBio gene therapy', 'Cardiovascular pipeline rebuild', 'Litigation resolution (Roundup)'],
    deal_size_range: '$50M-$4B total value',
    source: 'Bayer Annual Report 2024; Frankfurt Stock Exchange',
  },

  // ── 16. BOEHRINGER INGELHEIM ──────────────────────────────
  {
    company: 'Boehringer Ingelheim',
    company_type: 'big_pharma',
    headquarters: 'Ingelheim, Germany',
    market_cap_b: 0,
    revenue_b: 25.6,
    rd_spend_b: 5.2,
    therapeutic_areas: ['respiratory', 'cardiometabolic', 'oncology', 'immunology', 'CNS'],
    pipeline_focus: ['MASH/NASH therapies', 'anti-TSLP', 'bispecific IO', 'SSAO inhibitors', 'anti-IL-36'],
    bd_activity: 'active',
    preferred_deal_stages: ['preclinical', 'phase1', 'phase2'],
    geography_footprint: ['US', 'EU5', 'Japan', 'China', 'Canada', 'RoW'],
    recent_deals: [
      { partner: 'Lifemine Therapeutics', asset: 'Natural products from fungi (AI-driven)', indication: 'Oncology, immunology', deal_type: 'Research collaboration', upfront_m: 50, total_value_m: 800, year: 2023 },
      { partner: 'OSE Immunotherapeutics', asset: 'BI 770371 (anti-SIRPa)', indication: 'Solid tumors', deal_type: 'Licensing', upfront_m: 24, total_value_m: 1400, year: 2022 },
      { partner: 'Enanta Pharmaceuticals', asset: 'Protease inhibitors', indication: 'RSV, SARS-CoV-2', deal_type: 'Licensing', upfront_m: 45, total_value_m: 930, year: 2022 },
    ],
    strategic_priorities: ['MASH/NASH market entry', 'IPF franchise (Ofev follow-on)', 'Type 2 inflammation (TSLP)', 'Oncology immune checkpoint expansion', 'Animal health R&D'],
    deal_size_range: '$50M-$2B total value',
    source: 'Boehringer Ingelheim Annual Report 2024',
  },

  // ── 17. NOVO NORDISK ──────────────────────────────────────
  {
    company: 'Novo Nordisk',
    company_type: 'big_pharma',
    headquarters: 'Bagsvaerd, Denmark',
    market_cap_b: 570,
    revenue_b: 33.7,
    rd_spend_b: 5.6,
    therapeutic_areas: ['diabetes', 'obesity', 'rare blood disorders', 'MASH', 'cardiovascular'],
    pipeline_focus: ['GLP-1/amylin (CagriSema)', 'oral semaglutide next-gen', 'MASH (semaglutide)', 'hemophilia gene therapy', 'sickle cell disease'],
    bd_activity: 'moderate',
    preferred_deal_stages: ['phase1', 'phase2', 'phase3'],
    geography_footprint: ['US', 'EU5', 'Japan', 'China', 'Canada', 'Australia', 'RoW'],
    recent_deals: [
      { partner: 'Inversago Pharma', asset: 'CB1 receptor inverse agonist', indication: 'Obesity, MASH', deal_type: 'Acquisition', upfront_m: 1075, total_value_m: 1075, year: 2023 },
      { partner: 'Forma Therapeutics', asset: 'Etavopivat (PKR activator)', indication: 'Sickle Cell Disease', deal_type: 'Acquisition', upfront_m: 1100, total_value_m: 1100, year: 2022 },
      { partner: 'Dicerna Pharmaceuticals', asset: 'RNAi platform (GalXC)', indication: 'MASH, cardiometabolic', deal_type: 'Acquisition', upfront_m: 3300, total_value_m: 3300, year: 2021 },
    ],
    strategic_priorities: ['Obesity/GLP-1 franchise dominance', 'CagriSema differentiation vs. Lilly', 'MASH market first-mover', 'Rare blood disorders expansion', 'Oral semaglutide growth'],
    deal_size_range: '$200M-$3.5B total value',
    source: 'Novo Nordisk Annual Report 2024; Copenhagen Stock Exchange',
  },

  // ── 18. REGENERON ─────────────────────────────────────────
  {
    company: 'Regeneron',
    company_type: 'big_pharma',
    headquarters: 'Tarrytown, NY',
    market_cap_b: 115,
    revenue_b: 13.1,
    rd_spend_b: 4.4,
    therapeutic_areas: ['ophthalmology', 'immunology', 'oncology', 'rare disease', 'infectious disease'],
    pipeline_focus: ['EYLEA HD (aflibercept 8mg)', 'costimulatory bispecifics', 'Dupixent COPD expansion', 'antibody cocktails', 'genetic medicine'],
    bd_activity: 'selective',
    preferred_deal_stages: ['preclinical', 'phase1', 'phase2'],
    geography_footprint: ['US', 'EU5', 'Japan', 'Canada', 'RoW'],
    recent_deals: [
      { partner: 'Alnylam Pharmaceuticals', asset: 'RNAi eye disease programs', indication: 'Geographic atrophy, retinal diseases', deal_type: 'Co-development', upfront_m: 0, total_value_m: 1000, year: 2022 },
      { partner: 'Intellia Therapeutics', asset: 'CRISPR in vivo gene editing', indication: 'Hemophilia A, other liver targets', deal_type: 'Collaboration', upfront_m: 70, total_value_m: 750, year: 2023 },
      { partner: 'Sanofi', asset: 'Dupixent ex-US commercialization', indication: 'AD, asthma, COPD, CRSwNP', deal_type: 'Co-promotion restructuring', upfront_m: 0, total_value_m: 0, year: 2023 },
    ],
    strategic_priorities: ['EYLEA franchise defense/extension', 'Dupixent label expansion (COPD)', 'VelociSuite platform leveraging', 'Genetic medicine (CRISPR, RNAi)', 'First-in-class antibody discovery'],
    deal_size_range: '$50M-$2B total value',
    source: 'Regeneron Annual Report 2024; SEC 10-K',
  },

  // ── 19. VERTEX PHARMACEUTICALS ────────────────────────────
  {
    company: 'Vertex Pharmaceuticals',
    company_type: 'big_pharma',
    headquarters: 'Boston, MA',
    market_cap_b: 120,
    revenue_b: 9.9,
    rd_spend_b: 3.6,
    therapeutic_areas: ['cystic fibrosis', 'sickle cell disease', 'pain', 'kidney disease', 'type 1 diabetes'],
    pipeline_focus: ['CRISPR/Cas9 (exa-cel)', 'NaV1.8 pain (suzetrigine)', 'APOL1 kidney disease', 'islet cell therapy (VX-880)', 'mRNA CF'],
    bd_activity: 'selective',
    preferred_deal_stages: ['preclinical', 'phase1', 'phase2'],
    geography_footprint: ['US', 'EU5', 'Canada', 'Australia'],
    recent_deals: [
      { partner: 'CRISPR Therapeutics', asset: 'Casgevy (exa-cel)', indication: 'Sickle Cell Disease, Beta-Thalassemia', deal_type: 'Co-development', upfront_m: 105, total_value_m: 1200, year: 2020 },
      { partner: 'Alpine Immune Sciences', asset: 'ALPN-101 (dual ICOS/CD28 inhibitor)', indication: 'Autoimmune diseases', deal_type: 'Acquisition', upfront_m: 4900, total_value_m: 4900, year: 2024 },
      { partner: 'ViaCyte', asset: 'Stem cell-derived islet cells', indication: 'Type 1 Diabetes', deal_type: 'Acquisition', upfront_m: 320, total_value_m: 320, year: 2022 },
    ],
    strategic_priorities: ['Pain franchise launch (suzetrigine/VX-548)', 'CF triple therapy dominance', 'Gene editing (sickle cell, T1D)', 'Kidney disease pipeline (APOL1)', 'Type 1 Diabetes islet cell therapy'],
    deal_size_range: '$100M-$5B total value',
    source: 'Vertex Annual Report 2024; SEC 10-K',
  },

  // ── 20. BIOGEN ────────────────────────────────────────────
  {
    company: 'Biogen',
    company_type: 'big_pharma',
    headquarters: 'Cambridge, MA',
    market_cap_b: 28,
    revenue_b: 9.8,
    rd_spend_b: 2.5,
    therapeutic_areas: ['neuroscience', 'rare disease', 'neurology', 'neuropsychiatry'],
    pipeline_focus: ['Alzheimer\'s (lecanemab with Eisai)', 'ALS gene therapy', 'Parkinson\'s (LRRK2)', 'SMA next-gen', 'lupus'],
    bd_activity: 'active',
    preferred_deal_stages: ['phase1', 'phase2', 'phase3'],
    geography_footprint: ['US', 'EU5', 'Japan', 'Canada', 'Australia'],
    recent_deals: [
      { partner: 'Reata Pharmaceuticals', asset: 'Omaveloxolone (Nrf2 activator)', indication: 'Friedreich\'s Ataxia', deal_type: 'Acquisition', upfront_m: 7300, total_value_m: 7300, year: 2023 },
      { partner: 'Sage Therapeutics', asset: 'Zuranolone (GABA modulator)', indication: 'Major Depressive Disorder, PPD', deal_type: 'Co-development', upfront_m: 875, total_value_m: 1525, year: 2020 },
      { partner: 'Denali Therapeutics', asset: 'LRRK2 inhibitor (DNL151)', indication: 'Parkinson\'s Disease', deal_type: 'Collaboration', upfront_m: 560, total_value_m: 2125, year: 2020 },
    ],
    strategic_priorities: ['Lecanemab commercialization (with Eisai)', 'Neuropsychiatry (zuranolone)', 'Rare neurology (Friedreich\'s, SMA)', 'Anti-sense oligonucleotide platform'],
    deal_size_range: '$200M-$7.5B total value',
    source: 'Biogen Annual Report 2024; SEC 10-K',
  },

  // ── 21. DAIICHI SANKYO ────────────────────────────────────
  {
    company: 'Daiichi Sankyo',
    company_type: 'big_pharma',
    headquarters: 'Tokyo, Japan',
    market_cap_b: 65,
    revenue_b: 12.0,
    rd_spend_b: 3.3,
    therapeutic_areas: ['oncology', 'cardiovascular', 'rare disease'],
    pipeline_focus: ['ADC platform (DXd technology)', 'HER3-DXd', 'TROP2-DXd', 'B7-H3 ADC', 'CDH6 ADC'],
    bd_activity: 'very_active',
    preferred_deal_stages: ['phase1', 'phase2', 'phase3'],
    geography_footprint: ['US', 'EU5', 'Japan', 'China', 'RoW'],
    recent_deals: [
      { partner: 'Merck & Co', asset: 'Patritumab deruxtecan (HER3-DXd)', indication: 'NSCLC, Breast Cancer', deal_type: 'Global co-development', upfront_m: 4000, total_value_m: 22000, year: 2023 },
      { partner: 'AstraZeneca', asset: 'Dato-DXd (TROP2 ADC)', indication: 'NSCLC, Triple-Negative Breast Cancer', deal_type: 'Global co-development', upfront_m: 1000, total_value_m: 6000, year: 2020 },
      { partner: 'AstraZeneca', asset: 'Enhertu (T-DXd)', indication: 'HER2+ Breast, Gastric, Lung', deal_type: 'Global co-development', upfront_m: 1350, total_value_m: 6900, year: 2019 },
    ],
    strategic_priorities: ['ADC technology platform dominance', 'Next-wave ADC targets (B7-H3, CDH6)', 'Global oncology partnership model', 'Japan cardiovascular franchise'],
    deal_size_range: '$500M-$22B total value',
    source: 'Daiichi Sankyo Annual Report 2024; Tokyo Stock Exchange',
  },

  // ── 22. ASTELLAS ──────────────────────────────────────────
  {
    company: 'Astellas',
    company_type: 'big_pharma',
    headquarters: 'Tokyo, Japan',
    market_cap_b: 22,
    revenue_b: 12.8,
    rd_spend_b: 2.3,
    therapeutic_areas: ['oncology', 'urology', 'transplant', 'gene therapy', 'ophthalmology'],
    pipeline_focus: ['ADCs', 'bispecifics', 'gene therapy (AT132)', 'claudin 18.2', 'mitochondrial biology'],
    bd_activity: 'active',
    preferred_deal_stages: ['phase1', 'phase2', 'phase3'],
    geography_footprint: ['US', 'EU5', 'Japan', 'China', 'RoW'],
    recent_deals: [
      { partner: 'Iveric Bio', asset: 'Izervay (avacincaptad pegol)', indication: 'Geographic Atrophy (dry AMD)', deal_type: 'Acquisition', upfront_m: 5900, total_value_m: 5900, year: 2023 },
      { partner: 'Arcus Biosciences', asset: 'Quemliclustat (CD73 inhibitor)', indication: 'Solid tumors', deal_type: 'Licensing (select global rights)', upfront_m: 0, total_value_m: 1800, year: 2022 },
      { partner: 'Adaptimmune', asset: 'Next-gen TCR-T cell therapy', indication: 'Solid tumors', deal_type: 'Collaboration', upfront_m: 50, total_value_m: 897, year: 2022 },
    ],
    strategic_priorities: ['Ophthalmology franchise build (Izervay)', 'Xtandi lifecycle management (mCRPC)', 'ADC/bispecific oncology pipeline', 'Gene therapy (myotubular myopathy)'],
    deal_size_range: '$100M-$6B total value',
    source: 'Astellas Annual Report 2024; Tokyo Stock Exchange',
  },

  // ── 23. OTSUKA ────────────────────────────────────────────
  {
    company: 'Otsuka',
    company_type: 'big_pharma',
    headquarters: 'Tokyo, Japan',
    market_cap_b: 25,
    revenue_b: 14.5,
    rd_spend_b: 2.4,
    therapeutic_areas: ['neuroscience', 'nephrology', 'oncology', 'cardiovascular', 'gastroenterology'],
    pipeline_focus: ['Abilify Mycite successor', 'vasopressin receptor antagonists', 'digital medicine', 'PKD therapies'],
    bd_activity: 'moderate',
    preferred_deal_stages: ['phase1', 'phase2', 'phase3'],
    geography_footprint: ['US', 'EU5', 'Japan', 'RoW'],
    recent_deals: [
      { partner: 'Lundbeck', asset: 'Lu AG09222 (TAAR1 agonist)', indication: 'Schizophrenia, mood disorders', deal_type: 'Co-development', upfront_m: 0, total_value_m: 600, year: 2022 },
      { partner: 'Visterra', asset: 'Inaxaplin (APOL1 inhibitor)', indication: 'APOL1-Mediated Kidney Disease', deal_type: 'Acquisition', upfront_m: 430, total_value_m: 430, year: 2023 },
      { partner: 'Proteus Digital Health', asset: 'Digital medicine technology', indication: 'Treatment adherence (psychiatry)', deal_type: 'Licensing', upfront_m: 60, total_value_m: 350, year: 2020 },
    ],
    strategic_priorities: ['Rexulti franchise growth', 'Polycystic kidney disease leadership', 'Digital medicine integration', 'Neuroscience next-gen (TAAR1)'],
    deal_size_range: '$50M-$2B total value',
    source: 'Otsuka Annual Report 2024; Tokyo Stock Exchange',
  },

  // ── 24. CSL BEHRING ───────────────────────────────────────
  {
    company: 'CSL Behring',
    company_type: 'big_pharma',
    headquarters: 'King of Prussia, PA (parent: Melbourne, Australia)',
    market_cap_b: 120,
    revenue_b: 11.5,
    rd_spend_b: 1.5,
    therapeutic_areas: ['hematology', 'immunology', 'rare disease', 'transplant', 'respiratory'],
    pipeline_focus: ['hemophilia gene therapy', 'complement pathway', 'plasma-derived therapies', 'garadacimab (Factor XIIa)'],
    bd_activity: 'moderate',
    preferred_deal_stages: ['phase2', 'phase3', 'approved'],
    geography_footprint: ['US', 'EU5', 'Japan', 'Australia', 'Canada', 'RoW'],
    recent_deals: [
      { partner: 'Vifor Pharma', asset: 'Full company (iron/nephrology)', indication: 'Iron deficiency, Nephrology', deal_type: 'Acquisition', upfront_m: 11700, total_value_m: 11700, year: 2022 },
      { partner: 'uniQure', asset: 'Hemgenix (etranacogene dezaparvovec)', indication: 'Hemophilia B Gene Therapy', deal_type: 'Licensing', upfront_m: 450, total_value_m: 1800, year: 2020 },
      { partner: 'Arcturus Therapeutics', asset: 'mRNA for liver targets', indication: 'Rare liver disease', deal_type: 'Research collaboration', upfront_m: 40, total_value_m: 520, year: 2021 },
    ],
    strategic_priorities: ['Plasma supply expansion', 'Gene therapy for bleeding disorders', 'Iron deficiency franchise (Ferinject)', 'Complement inhibition (garadacimab)'],
    deal_size_range: '$100M-$12B total value',
    source: 'CSL Annual Report 2024; ASX',
  },

  // ── 25. IPSEN ─────────────────────────────────────────────
  {
    company: 'Ipsen',
    company_type: 'big_pharma',
    headquarters: 'Paris, France',
    market_cap_b: 12,
    revenue_b: 3.6,
    rd_spend_b: 0.6,
    therapeutic_areas: ['oncology', 'rare disease', 'neuroscience'],
    pipeline_focus: ['PSMA-targeted radiotherapies', 'GLP-2 analogs', 'next-gen neuromodulators', 'rare endocrinology'],
    bd_activity: 'active',
    preferred_deal_stages: ['phase2', 'phase3', 'approved'],
    geography_footprint: ['US', 'EU5', 'Japan', 'Canada', 'RoW'],
    recent_deals: [
      { partner: 'Exelixis', asset: 'Cabozantinib (global ex-US)', indication: 'Renal Cell Carcinoma, HCC', deal_type: 'Licensing', upfront_m: 255, total_value_m: 600, year: 2020 },
      { partner: 'Genfit', asset: 'Elafibranor', indication: 'Primary Biliary Cholangitis', deal_type: 'Licensing', upfront_m: 60, total_value_m: 480, year: 2024 },
      { partner: 'Sutro Biopharma', asset: 'Anti-CD74 ADC', indication: 'Hematologic malignancies', deal_type: 'Licensing', upfront_m: 50, total_value_m: 1325, year: 2022 },
    ],
    strategic_priorities: ['Oncology rare tumors (NET, RCC)', 'Radioligand therapy entry', 'Somatuline lifecycle', 'Rare endocrinology and GI'],
    deal_size_range: '$50M-$1.5B total value',
    source: 'Ipsen Annual Report 2024; Euronext',
  },

  // ── 26. SERVIER ───────────────────────────────────────────
  {
    company: 'Servier',
    company_type: 'big_pharma',
    headquarters: 'Suresnes, France',
    market_cap_b: 0,
    revenue_b: 5.9,
    rd_spend_b: 1.5,
    therapeutic_areas: ['oncology', 'cardiovascular', 'diabetes', 'neuroscience', 'immunology'],
    pipeline_focus: ['IDH inhibitors', 'BCL-2 inhibitors', 'PARP combinations', 'FLT3 inhibitors', 'metabolic targets'],
    bd_activity: 'active',
    preferred_deal_stages: ['phase1', 'phase2', 'phase3'],
    geography_footprint: ['EU5', 'Japan', 'China', 'RoW'],
    recent_deals: [
      { partner: 'Agios Pharmaceuticals', asset: 'Tibsovo (ivosidenib) + oncology pipeline', indication: 'AML, Cholangiocarcinoma', deal_type: 'Acquisition of oncology business', upfront_m: 2000, total_value_m: 2000, year: 2021 },
      { partner: 'Cellectis', asset: 'UCART programs (allogeneic CAR-T)', indication: 'ALL, AML', deal_type: 'Licensing', upfront_m: 160, total_value_m: 1500, year: 2020 },
      { partner: 'MSD (Merck)', asset: 'Olaparib ex-Japan rights return', indication: 'Ovarian Cancer, BRCA+', deal_type: 'Rights acquisition', upfront_m: 0, total_value_m: 0, year: 2022 },
    ],
    strategic_priorities: ['Oncology franchise build (hematology focus)', 'IDH-mutant cancers leadership', 'Cardiovascular generics defense', 'Emerging market expansion'],
    deal_size_range: '$50M-$2B total value',
    source: 'Servier Annual Report 2024',
  },

  // ── 27. MERCK KGaA (EMD SERONO) ──────────────────────────
  {
    company: 'Merck KGaA (EMD Serono)',
    company_type: 'big_pharma',
    headquarters: 'Darmstadt, Germany',
    market_cap_b: 45,
    revenue_b: 21.2,
    rd_spend_b: 2.5,
    therapeutic_areas: ['oncology', 'neurology', 'immunology', 'fertility'],
    pipeline_focus: ['anti-PD-L1/TGF-beta (bintrafusp alfa)', 'ADCs', 'oral MS therapies', 'DNA damage response'],
    bd_activity: 'moderate',
    preferred_deal_stages: ['phase1', 'phase2', 'phase3'],
    geography_footprint: ['US', 'EU5', 'Japan', 'China', 'RoW'],
    recent_deals: [
      { partner: 'GSK', asset: 'Bintrafusp alfa (anti-PD-L1/TGF-beta)', indication: 'Biliary tract cancer', deal_type: 'Co-development', upfront_m: 0, total_value_m: 4200, year: 2019 },
      { partner: 'Pfizer', asset: 'Bavencio (avelumab)', indication: 'Merkel cell carcinoma, urothelial', deal_type: 'Global alliance', upfront_m: 850, total_value_m: 2000, year: 2020 },
      { partner: 'Debiopharm', asset: 'Xevinapant (IAP antagonist)', indication: 'Head and Neck Cancer', deal_type: 'Licensing', upfront_m: 0, total_value_m: 900, year: 2022 },
    ],
    strategic_priorities: ['Bavencio franchise (first-line urothelial)', 'MS franchise (Mavenclad)', 'Fertility leadership', 'Semiconductor materials (non-pharma)'],
    deal_size_range: '$100M-$4B total value',
    source: 'Merck KGaA Annual Report 2024; Frankfurt Stock Exchange',
  },

  // ── 28. UCB ───────────────────────────────────────────────
  {
    company: 'UCB',
    company_type: 'big_pharma',
    headquarters: 'Brussels, Belgium',
    market_cap_b: 30,
    revenue_b: 6.1,
    rd_spend_b: 1.9,
    therapeutic_areas: ['neurology', 'immunology', 'bone'],
    pipeline_focus: ['anti-TGF-beta (Bimekizumab)', 'anti-FcRn', 'zilucoplan (complement C5)', 'TREM2 agonist'],
    bd_activity: 'active',
    preferred_deal_stages: ['phase1', 'phase2', 'phase3'],
    geography_footprint: ['US', 'EU5', 'Japan', 'Canada'],
    recent_deals: [
      { partner: 'Zymeworks', asset: 'Azymetric bispecific platform', indication: 'Oncology, immunology', deal_type: 'Licensing', upfront_m: 30, total_value_m: 690, year: 2022 },
      { partner: 'Orano Med', asset: 'Alpha radioimmunotherapy', indication: 'Hematologic malignancies', deal_type: 'Research collaboration', upfront_m: 20, total_value_m: 350, year: 2021 },
      { partner: 'Roche', asset: 'Cimtuzumab (anti-ROR1)', indication: 'Hematologic malignancies', deal_type: 'Licensing', upfront_m: 110, total_value_m: 750, year: 2022 },
    ],
    strategic_priorities: ['Bimekizumab global launch (psoriasis, PsA, axSpA)', 'Myasthenia gravis franchise (zilucoplan)', 'Epilepsy leadership (Briviact)', 'Bone health (romosozumab/Evenity partner)'],
    deal_size_range: '$50M-$2B total value',
    source: 'UCB Annual Report 2024; Euronext Brussels',
  },

  // ── 29. LUNDBECK ──────────────────────────────────────────
  {
    company: 'Lundbeck',
    company_type: 'big_pharma',
    headquarters: 'Copenhagen, Denmark',
    market_cap_b: 8,
    revenue_b: 3.2,
    rd_spend_b: 0.9,
    therapeutic_areas: ['neuroscience', 'psychiatry', 'neurology'],
    pipeline_focus: ['TAAR1 agonists', 'anti-CGRP (migraine)', 'GABA modulators', 'neurodegeneration', 'psilocybin-assisted therapy'],
    bd_activity: 'active',
    preferred_deal_stages: ['phase1', 'phase2', 'phase3'],
    geography_footprint: ['US', 'EU5', 'Japan', 'Canada'],
    recent_deals: [
      { partner: 'Otsuka', asset: 'Lu AG09222 (TAAR1 agonist)', indication: 'Schizophrenia', deal_type: 'Co-development', upfront_m: 0, total_value_m: 600, year: 2022 },
      { partner: 'Longboard Pharmaceuticals', asset: 'Bexicaserin (5-HT2C agonist)', indication: 'Epilepsies', deal_type: 'Acquisition', upfront_m: 2600, total_value_m: 2600, year: 2024 },
      { partner: 'Sumitomo Pharma', asset: 'Kynmobi (apomorphine sublingual)', indication: 'Parkinson\'s OFF episodes', deal_type: 'Licensing', upfront_m: 50, total_value_m: 350, year: 2021 },
    ],
    strategic_priorities: ['Neuroscience-pure strategy', 'TAAR1 agonist program (schizophrenia)', 'Vyepti (anti-CGRP) growth', 'Next-gen CNS targets (NMDA, sigma-1)'],
    deal_size_range: '$50M-$2.5B total value',
    source: 'Lundbeck Annual Report 2024; Copenhagen Stock Exchange',
  },

  // ── 30. MENARINI ──────────────────────────────────────────
  {
    company: 'Menarini',
    company_type: 'big_pharma',
    headquarters: 'Florence, Italy',
    market_cap_b: 0,
    revenue_b: 4.5,
    rd_spend_b: 0.8,
    therapeutic_areas: ['oncology', 'cardiovascular', 'pain', 'anti-infectives'],
    pipeline_focus: ['ADC (elacestrant + ADC combos)', 'CDK4/6 next-gen', 'anti-infective resistance'],
    bd_activity: 'moderate',
    preferred_deal_stages: ['phase2', 'phase3', 'approved'],
    geography_footprint: ['EU5', 'Japan', 'RoW'],
    recent_deals: [
      { partner: 'Stemline Therapeutics', asset: 'Elzonris (tagraxofusp)', indication: 'BPDCN', deal_type: 'Acquisition', upfront_m: 677, total_value_m: 677, year: 2020 },
      { partner: 'Radius Health', asset: 'Elacestrant (oral SERD)', indication: 'ER+/HER2- Breast Cancer', deal_type: 'Acquisition', upfront_m: 900, total_value_m: 900, year: 2022 },
      { partner: 'Interna Therapeutics', asset: 'microRNA oncology programs', indication: 'Solid tumors', deal_type: 'Acquisition', upfront_m: 120, total_value_m: 415, year: 2023 },
    ],
    strategic_priorities: ['Orserdu (elacestrant) launch in breast cancer', 'Oncology pipeline diversification', 'European commercial footprint leverage', 'Anti-infective R&D'],
    deal_size_range: '$50M-$1B total value',
    source: 'Menarini Annual Report 2024',
  },

  // ────────────────────────────────────────────────────────────
  // SPECIALTY PHARMA — Tier 2 (20+ companies)
  // ────────────────────────────────────────────────────────────

  // ── 31. JAZZ PHARMACEUTICALS ──────────────────────────────
  {
    company: 'Jazz Pharmaceuticals',
    company_type: 'specialty_pharma',
    headquarters: 'Dublin, Ireland (operational: Palo Alto, CA)',
    market_cap_b: 9,
    revenue_b: 3.8,
    rd_spend_b: 0.6,
    therapeutic_areas: ['neuroscience', 'oncology', 'sleep medicine'],
    pipeline_focus: ['oxybate next-gen', 'ADCs', 'cannabidiol', 'narcolepsy/idiopathic hypersomnia', 'CAR-T (JZP458)'],
    bd_activity: 'active',
    preferred_deal_stages: ['phase2', 'phase3', 'approved'],
    geography_footprint: ['US', 'EU5', 'Canada'],
    recent_deals: [
      { partner: 'GW Pharmaceuticals', asset: 'Epidiolex (cannabidiol)', indication: 'Epilepsy (Dravet, LGS, TSC)', deal_type: 'Acquisition', upfront_m: 7200, total_value_m: 7200, year: 2021 },
      { partner: 'Codiak BioSciences', asset: 'Exosome therapeutics (engineered)', indication: 'Oncology', deal_type: 'Acquisition', upfront_m: 296, total_value_m: 296, year: 2023 },
      { partner: 'Redx Pharma', asset: 'RXC007 (ROCK2 inhibitor)', indication: 'IPF', deal_type: 'Licensing', upfront_m: 40, total_value_m: 1200, year: 2023 },
    ],
    strategic_priorities: ['Xywav lifecycle management', 'Epidiolex global expansion', 'Oncology hematology pipeline (zanidatamab)', 'Sleep franchise differentiation'],
    deal_size_range: '$50M-$7B total value',
    source: 'Jazz Pharmaceuticals Annual Report 2024; SEC 10-K',
  },

  // ── 32. NEUROCRINE BIOSCIENCES ────────────────────────────
  {
    company: 'Neurocrine Biosciences',
    company_type: 'specialty_pharma',
    headquarters: 'San Diego, CA',
    market_cap_b: 14,
    revenue_b: 2.1,
    rd_spend_b: 0.7,
    therapeutic_areas: ['neuroscience', 'movement disorders', 'neuropsychiatry', 'neuroendocrinology'],
    pipeline_focus: ['VMAT2 inhibitors', 'M4 muscarinic agonists', 'CRF antagonists', 'GnRH antagonists'],
    bd_activity: 'active',
    preferred_deal_stages: ['preclinical', 'phase1', 'phase2'],
    geography_footprint: ['US', 'EU5'],
    recent_deals: [
      { partner: 'Takeda', asset: 'Orexin 2 receptor agonist', indication: 'Narcolepsy Type 1', deal_type: 'Licensing (from Takeda)', upfront_m: 120, total_value_m: 1500, year: 2022 },
      { partner: 'Voyager Therapeutics', asset: 'AAV capsid technology', indication: 'Parkinson\'s, Friedreich\'s Ataxia', deal_type: 'Licensing', upfront_m: 30, total_value_m: 1740, year: 2021 },
      { partner: 'Idorsia', asset: 'Pediatric insomnia program', indication: 'Pediatric Insomnia', deal_type: 'Licensing', upfront_m: 10, total_value_m: 200, year: 2022 },
    ],
    strategic_priorities: ['Ingrezza (valbenazine) lifecycle management', 'M4 agonist clinical advancement', 'Movement disorder franchise build', 'CAH franchise (Crenessity)'],
    deal_size_range: '$20M-$1.5B total value',
    source: 'Neurocrine Biosciences Annual Report 2024; SEC 10-K',
  },

  // ── 33. ULTRAGENYX ────────────────────────────────────────
  {
    company: 'Ultragenyx',
    company_type: 'specialty_pharma',
    headquarters: 'Novato, CA',
    market_cap_b: 6,
    revenue_b: 0.5,
    rd_spend_b: 0.7,
    therapeutic_areas: ['rare disease', 'genetic disease', 'metabolic disease'],
    pipeline_focus: ['gene therapy (AAV)', 'mRNA (liver enzyme replacement)', 'substrate reduction', 'bone/mineral'],
    bd_activity: 'moderate',
    preferred_deal_stages: ['preclinical', 'phase1', 'phase2'],
    geography_footprint: ['US', 'EU5', 'Japan'],
    recent_deals: [
      { partner: 'GeneTx Biosciences', asset: 'GTX-102 (antisense for Angelman)', indication: 'Angelman Syndrome', deal_type: 'Acquisition', upfront_m: 100, total_value_m: 280, year: 2020 },
      { partner: 'Arctus Therapeutics', asset: 'mRNA/LNP liver programs', indication: 'Glycogen storage disease, OTC deficiency', deal_type: 'Licensing', upfront_m: 30, total_value_m: 685, year: 2021 },
      { partner: 'Solid Biosciences', asset: 'Microdystrophin gene therapy', indication: 'Duchenne Muscular Dystrophy', deal_type: 'Collaboration (terminated)', upfront_m: 40, total_value_m: 340, year: 2020 },
    ],
    strategic_priorities: ['Gene therapy platform validation', 'Crysvita (burosumab) growth in XLH', 'Angelman syndrome program', 'mRNA therapy programs for metabolic diseases'],
    deal_size_range: '$20M-$500M total value',
    source: 'Ultragenyx Annual Report 2024; SEC 10-K',
  },

  // ── 34. ALEXION (ASTRAZENECA RARE DISEASE) ────────────────
  {
    company: 'Alexion (AstraZeneca)',
    company_type: 'specialty_pharma',
    headquarters: 'Boston, MA (AstraZeneca Rare Disease unit)',
    market_cap_b: 240,
    revenue_b: 7.9,
    rd_spend_b: 1.8,
    therapeutic_areas: ['rare disease', 'complement', 'hematology', 'neurology', 'nephrology'],
    pipeline_focus: ['complement C5 next-gen', 'FcRn inhibitors', 'CHAPLE disease', 'WRS gene therapy'],
    bd_activity: 'active',
    preferred_deal_stages: ['phase1', 'phase2', 'phase3'],
    geography_footprint: ['US', 'EU5', 'Japan', 'Canada', 'Australia', 'RoW'],
    recent_deals: [
      { partner: 'Caelum Biosciences', asset: 'CAEL-101 (anti-SAP antibody)', indication: 'AL Amyloidosis', deal_type: 'Acquisition', upfront_m: 500, total_value_m: 500, year: 2021 },
      { partner: 'Pfizer (Synageva BioPharma)', asset: 'Kanuma (sebelipase alfa)', indication: 'LAL Deficiency', deal_type: 'Post-acquisition integration', upfront_m: 0, total_value_m: 0, year: 2020 },
      { partner: 'Arctus Therapeutics', asset: 'mRNA complement programs', indication: 'Rare complement disorders', deal_type: 'Research collaboration', upfront_m: 25, total_value_m: 400, year: 2022 },
    ],
    strategic_priorities: ['Soliris/Ultomiris lifecycle management', 'Complement franchise expansion', 'FcRn in myasthenia gravis', 'Rare metabolic diseases'],
    deal_size_range: '$100M-$3B total value',
    source: 'AstraZeneca Rare Disease Division Report 2024',
  },

  // ── 35. BIOMARIN ──────────────────────────────────────────
  {
    company: 'BioMarin',
    company_type: 'specialty_pharma',
    headquarters: 'San Rafael, CA',
    market_cap_b: 14,
    revenue_b: 2.8,
    rd_spend_b: 0.8,
    therapeutic_areas: ['rare disease', 'genetic disease', 'enzyme replacement', 'gene therapy'],
    pipeline_focus: ['gene therapy (hemophilia A Roctavian)', 'enzyme replacement', 'substrate reduction', 'PKU oral therapies'],
    bd_activity: 'moderate',
    preferred_deal_stages: ['preclinical', 'phase1', 'phase2'],
    geography_footprint: ['US', 'EU5', 'Japan', 'Canada'],
    recent_deals: [
      { partner: 'Sarepta Therapeutics', asset: 'Gene therapy manufacturing partnership', indication: 'DMD', deal_type: 'Manufacturing collaboration', upfront_m: 0, total_value_m: 200, year: 2021 },
      { partner: 'Passage Bio', asset: 'AAV capsid co-development', indication: 'CNS rare diseases', deal_type: 'Research collaboration', upfront_m: 10, total_value_m: 100, year: 2022 },
      { partner: 'Ares Trading (Merck KGaA)', asset: 'Kuvan (sapropterin) royalty buyout', indication: 'PKU', deal_type: 'Royalty buyout', upfront_m: 570, total_value_m: 570, year: 2020 },
    ],
    strategic_priorities: ['Roctavian (hemophilia A gene therapy) launch', 'Voxzogo (achondroplasia) growth', 'Next-gen ERT platform', 'PKU franchise lifecycle'],
    deal_size_range: '$50M-$1B total value',
    source: 'BioMarin Annual Report 2024; SEC 10-K',
  },

  // ── 36. ALNYLAM PHARMACEUTICALS ───────────────────────────
  {
    company: 'Alnylam Pharmaceuticals',
    company_type: 'specialty_pharma',
    headquarters: 'Cambridge, MA',
    market_cap_b: 30,
    revenue_b: 2.4,
    rd_spend_b: 1.1,
    therapeutic_areas: ['rare disease', 'cardiometabolic', 'hepatic', 'CNS', 'ophthalmology'],
    pipeline_focus: ['RNAi (siRNA/GalNAc)', 'AMVUTTRA extensions', 'complement C3/C5 siRNA', 'HTT siRNA', 'PCSK9 siRNA'],
    bd_activity: 'active',
    preferred_deal_stages: ['preclinical', 'phase1', 'phase2'],
    geography_footprint: ['US', 'EU5', 'Japan', 'Canada'],
    recent_deals: [
      { partner: 'Roche', asset: 'CNS RNAi targets (5 programs)', indication: 'Alzheimer\'s, Huntington\'s, CNS', deal_type: 'Collaboration', upfront_m: 200, total_value_m: 2600, year: 2020 },
      { partner: 'Regeneron', asset: 'RNAi eye programs', indication: 'Retinal diseases', deal_type: 'Co-development', upfront_m: 0, total_value_m: 1000, year: 2022 },
      { partner: 'Novo Nordisk', asset: 'Cardiometabolic siRNA targets', indication: 'MASH, Obesity', deal_type: 'Collaboration', upfront_m: 100, total_value_m: 800, year: 2021 },
    ],
    strategic_priorities: ['Onpattro/AMVUTTRA franchise (ATTR)', 'Platform expansion beyond liver (CNS, eye)', 'PCSK9 siRNA partnership', 'Complement pathway siRNA'],
    deal_size_range: '$50M-$2.5B total value',
    source: 'Alnylam Annual Report 2024; SEC 10-K',
  },

  // ── 37. IONIS PHARMACEUTICALS ─────────────────────────────
  {
    company: 'Ionis Pharmaceuticals',
    company_type: 'specialty_pharma',
    headquarters: 'Carlsbad, CA',
    market_cap_b: 8,
    revenue_b: 0.8,
    rd_spend_b: 0.6,
    therapeutic_areas: ['neurology', 'cardiology', 'rare disease', 'pulmonary'],
    pipeline_focus: ['antisense oligonucleotides', 'LICA (ligand-conjugated ASO)', 'ION-582 (Angelman)', 'donidalorsen (HAE)', 'olezarsen (FCS)'],
    bd_activity: 'very_active',
    preferred_deal_stages: ['preclinical', 'phase1', 'phase2'],
    geography_footprint: ['US', 'EU5', 'Japan', 'Canada'],
    recent_deals: [
      { partner: 'AstraZeneca', asset: 'Eplontersen + cardio-renal pipeline', indication: 'ATTR-CM, Kidney disease', deal_type: 'Strategic alliance', upfront_m: 200, total_value_m: 1600, year: 2020 },
      { partner: 'Biogen', asset: 'Tofersen (BIIB067)', indication: 'ALS (SOD1)', deal_type: 'Licensing', upfront_m: 45, total_value_m: 810, year: 2020 },
      { partner: 'Roche', asset: 'Anti-FXI ASO (fesomersen)', indication: 'Thrombosis', deal_type: 'Licensing', upfront_m: 75, total_value_m: 700, year: 2021 },
    ],
    strategic_priorities: ['Antisense platform leadership', 'Self-commercialization of late-stage assets', 'LICA technology expansion', 'Cardiometabolic entry (olezarsen)'],
    deal_size_range: '$30M-$1.5B total value',
    source: 'Ionis Annual Report 2024; SEC 10-K',
  },

  // ── 38. ARGENX ────────────────────────────────────────────
  {
    company: 'Argenx',
    company_type: 'specialty_pharma',
    headquarters: 'Breda, Netherlands (US HQ: Boston, MA)',
    market_cap_b: 30,
    revenue_b: 1.8,
    rd_spend_b: 0.8,
    therapeutic_areas: ['autoimmune', 'neurology', 'hematology', 'nephrology', 'dermatology'],
    pipeline_focus: ['FcRn antagonists (efgartigimod)', 'complement C2 inhibitor', 'IL-6 inhibitor', 'ABDEG-based biologics'],
    bd_activity: 'moderate',
    preferred_deal_stages: ['preclinical', 'phase1', 'phase2'],
    geography_footprint: ['US', 'EU5', 'Japan', 'China'],
    recent_deals: [
      { partner: 'Zai Lab', asset: 'Efgartigimod (Vyvgart)', indication: 'MG, CIDP, autoimmune', deal_type: 'Licensing (Greater China)', upfront_m: 75, total_value_m: 620, year: 2021 },
      { partner: 'Halozyme', asset: 'ENHANZE (subQ delivery technology)', indication: 'Vyvgart SC formulation', deal_type: 'Licensing', upfront_m: 40, total_value_m: 280, year: 2020 },
      { partner: 'Johnson & Johnson', asset: 'Cusatuzumab (anti-CD70)', indication: 'AML', deal_type: 'Collaboration', upfront_m: 300, total_value_m: 1300, year: 2020 },
    ],
    strategic_priorities: ['Vyvgart franchise expansion (MG, CIDP, ITP)', 'FcRn platform lifecycle', 'Autoimmune multi-indication strategy', 'Japan/China expansion'],
    deal_size_range: '$30M-$1.5B total value',
    source: 'Argenx Annual Report 2024; Euronext Amsterdam',
  },

  // ── 39. BLUEPRINT MEDICINES ───────────────────────────────
  {
    company: 'Blueprint Medicines',
    company_type: 'specialty_pharma',
    headquarters: 'Cambridge, MA',
    market_cap_b: 6,
    revenue_b: 0.5,
    rd_spend_b: 0.5,
    therapeutic_areas: ['allergy', 'hematology', 'oncology', 'mast cell diseases'],
    pipeline_focus: ['KIT inhibitors (avapritinib, elenestinib)', 'mast cell biology', 'CDK2 inhibitors', 'EGFR exon20'],
    bd_activity: 'moderate',
    preferred_deal_stages: ['preclinical', 'phase1', 'phase2'],
    geography_footprint: ['US', 'EU5'],
    recent_deals: [
      { partner: 'Roche', asset: 'EGFR Exon20 program', indication: 'NSCLC', deal_type: 'Licensing', upfront_m: 0, total_value_m: 775, year: 2020 },
      { partner: 'CStone Pharmaceuticals', asset: 'Avapritinib', indication: 'GIST (China)', deal_type: 'Licensing', upfront_m: 20, total_value_m: 280, year: 2020 },
      { partner: 'Clementia (Ipsen)', asset: 'FOP program returned rights', indication: 'Fibrodysplasia Ossificans Progressiva', deal_type: 'Licensing (received back)', upfront_m: 0, total_value_m: 0, year: 2022 },
    ],
    strategic_priorities: ['AYVAKIT growth in systemic mastocytosis', 'Elenestinib for chronic urticaria', 'CDK2 program advancement', 'Mast cell disease leadership'],
    deal_size_range: '$20M-$800M total value',
    source: 'Blueprint Medicines Annual Report 2024; SEC 10-K',
  },

  // ── 40. SAREPTA THERAPEUTICS ──────────────────────────────
  {
    company: 'Sarepta Therapeutics',
    company_type: 'specialty_pharma',
    headquarters: 'Cambridge, MA',
    market_cap_b: 10,
    revenue_b: 1.8,
    rd_spend_b: 0.8,
    therapeutic_areas: ['rare disease', 'neuromuscular', 'gene therapy'],
    pipeline_focus: ['micro-dystrophin gene therapy (delandistrogene)', 'exon skipping', 'LGMD gene therapy', 'next-gen AAV capsids'],
    bd_activity: 'active',
    preferred_deal_stages: ['preclinical', 'phase1', 'phase2'],
    geography_footprint: ['US', 'EU5', 'Japan'],
    recent_deals: [
      { partner: 'Roche', asset: 'SRP-9001 (micro-dystrophin) ex-US', indication: 'Duchenne Muscular Dystrophy', deal_type: 'Co-development / licensing', upfront_m: 1150, total_value_m: 3650, year: 2020 },
      { partner: 'Dyno Therapeutics', asset: 'Next-gen AAV capsids', indication: 'Neuromuscular gene therapy', deal_type: 'Research collaboration', upfront_m: 40, total_value_m: 1600, year: 2021 },
      { partner: 'Genevant Sciences', asset: 'LNP delivery for gene therapy', indication: 'Gene therapy formulation', deal_type: 'Licensing', upfront_m: 0, total_value_m: 200, year: 2022 },
    ],
    strategic_priorities: ['Elevidys (DMD gene therapy) launch and data', 'LGMD2E gene therapy', 'Manufacturing scale-up', 'Next-gen capsid platform'],
    deal_size_range: '$30M-$3.5B total value',
    source: 'Sarepta Annual Report 2024; SEC 10-K',
  },

  // ── 41. APELLIS PHARMACEUTICALS ───────────────────────────
  {
    company: 'Apellis Pharmaceuticals',
    company_type: 'specialty_pharma',
    headquarters: 'Waltham, MA',
    market_cap_b: 5,
    revenue_b: 0.7,
    rd_spend_b: 0.5,
    therapeutic_areas: ['ophthalmology', 'hematology', 'nephrology', 'complement-mediated diseases'],
    pipeline_focus: ['complement C3 inhibitors (pegcetacoplan)', 'systemic complement', 'Geographic Atrophy'],
    bd_activity: 'moderate',
    preferred_deal_stages: ['phase1', 'phase2'],
    geography_footprint: ['US', 'EU5'],
    recent_deals: [
      { partner: 'Swedish Orphan Biovitrum (Sobi)', asset: 'Systemic complement programs (hematology)', indication: 'PNH, C3G, cold agglutinin disease', deal_type: 'Licensing (ex-US hematology)', upfront_m: 250, total_value_m: 1550, year: 2020 },
      { partner: 'BEAM Therapeutics', asset: 'Complement + base editing combo', indication: 'Sickle cell, complement diseases', deal_type: 'Research collaboration', upfront_m: 25, total_value_m: 350, year: 2022 },
      { partner: 'Astellas', asset: 'Pegcetacoplan Japan rights', indication: 'PNH Japan', deal_type: 'Licensing', upfront_m: 50, total_value_m: 300, year: 2021 },
    ],
    strategic_priorities: ['Syfovre (GA) launch execution', 'Systemic complement (PNH, C3G)', 'SC formulation expansion', 'Differentiation vs. Izervay'],
    deal_size_range: '$20M-$1.5B total value',
    source: 'Apellis Annual Report 2024; SEC 10-K',
  },

  // ── 42. INCYTE ────────────────────────────────────────────
  {
    company: 'Incyte',
    company_type: 'specialty_pharma',
    headquarters: 'Wilmington, DE',
    market_cap_b: 15,
    revenue_b: 3.7,
    rd_spend_b: 1.3,
    therapeutic_areas: ['oncology', 'hematology', 'inflammation', 'dermatology', 'autoimmune'],
    pipeline_focus: ['JAK inhibitors (ruxolitinib)', 'PI3K delta', 'BRD/BET inhibitors', 'axatilimab (anti-CSF1R)', 'parsaclisib'],
    bd_activity: 'active',
    preferred_deal_stages: ['phase1', 'phase2', 'phase3'],
    geography_footprint: ['US', 'EU5', 'Japan', 'China'],
    recent_deals: [
      { partner: 'MorphoSys', asset: 'Tafasitamab (anti-CD19)', indication: 'DLBCL', deal_type: 'Co-development', upfront_m: 150, total_value_m: 1100, year: 2020 },
      { partner: 'Syndax Pharmaceuticals', asset: 'Axatilimab (anti-CSF1R)', indication: 'Chronic GVHD', deal_type: 'Licensing', upfront_m: 50, total_value_m: 600, year: 2022 },
      { partner: 'Escient Pharmaceuticals', asset: 'MRGPRX2/4 inhibitors', indication: 'Chronic urticaria, mast cell', deal_type: 'Acquisition', upfront_m: 750, total_value_m: 750, year: 2023 },
    ],
    strategic_priorities: ['Jakafi franchise extension (myelofibrosis, GVHD)', 'Opzelura growth (dermatology)', 'Myelofibrosis pipeline (momelotinib transition)', 'Inflammation/dermatology platform'],
    deal_size_range: '$50M-$1.5B total value',
    source: 'Incyte Annual Report 2024; SEC 10-K',
  },

  // ── 43. EXELIXIS ──────────────────────────────────────────
  {
    company: 'Exelixis',
    company_type: 'specialty_pharma',
    headquarters: 'Alameda, CA',
    market_cap_b: 8,
    revenue_b: 2.1,
    rd_spend_b: 0.6,
    therapeutic_areas: ['oncology'],
    pipeline_focus: ['cabozantinib combinations', 'ADCs (XB002)', 'small molecule TKIs', 'next-gen VEGFR/MET inhibitors'],
    bd_activity: 'moderate',
    preferred_deal_stages: ['preclinical', 'phase1', 'phase2'],
    geography_footprint: ['US', 'EU5', 'Japan'],
    recent_deals: [
      { partner: 'Ipsen', asset: 'Cabozantinib (ex-US rights)', indication: 'RCC, HCC', deal_type: 'Licensing', upfront_m: 255, total_value_m: 600, year: 2020 },
      { partner: 'Invenra', asset: 'Multispecific antibody programs', indication: 'Oncology', deal_type: 'Collaboration', upfront_m: 40, total_value_m: 765, year: 2023 },
      { partner: 'Aurigene (Curis)', asset: 'Small molecule PD-L1/VISTA/TIM-3', indication: 'Solid tumors', deal_type: 'Licensing', upfront_m: 12, total_value_m: 520, year: 2020 },
    ],
    strategic_priorities: ['Cabometyx franchise maximization', 'ADC platform build (XB002/zanzalintinib)', 'IO-combination studies', 'Pipeline diversification beyond cabo'],
    deal_size_range: '$20M-$800M total value',
    source: 'Exelixis Annual Report 2024; SEC 10-K',
  },

  // ── 44. HALOZYME ──────────────────────────────────────────
  {
    company: 'Halozyme',
    company_type: 'specialty_pharma',
    headquarters: 'San Diego, CA',
    market_cap_b: 12,
    revenue_b: 0.9,
    rd_spend_b: 0.2,
    therapeutic_areas: ['oncology', 'immunology', 'rare disease'],
    pipeline_focus: ['ENHANZE (hyaluronidase) technology platform', 'subQ drug delivery enabling', 'autoinjector combinations'],
    bd_activity: 'very_active',
    preferred_deal_stages: ['preclinical', 'phase1', 'phase2', 'phase3', 'approved'],
    geography_footprint: ['US', 'EU5', 'Japan', 'China', 'RoW'],
    recent_deals: [
      { partner: 'Roche', asset: 'ENHANZE for multiple biologics', indication: 'Oncology, immunology', deal_type: 'Platform licensing', upfront_m: 190, total_value_m: 850, year: 2020 },
      { partner: 'Bristol-Myers Squibb', asset: 'ENHANZE for Opdivo SC', indication: 'Oncology (IO subQ)', deal_type: 'Platform licensing', upfront_m: 105, total_value_m: 775, year: 2020 },
      { partner: 'Argenx', asset: 'ENHANZE for efgartigimod SC', indication: 'MG, autoimmune', deal_type: 'Platform licensing', upfront_m: 40, total_value_m: 280, year: 2020 },
    ],
    strategic_priorities: ['ENHANZE platform royalty growth', 'New partnership expansion', 'SubQ delivery leadership', 'Enable SC formulations for partner biologics'],
    deal_size_range: '$30M-$1B total value',
    source: 'Halozyme Annual Report 2024; SEC 10-K',
  },

  // ── 45. SAGE THERAPEUTICS ─────────────────────────────────
  {
    company: 'Sage Therapeutics',
    company_type: 'specialty_pharma',
    headquarters: 'Cambridge, MA',
    market_cap_b: 2,
    revenue_b: 0.2,
    rd_spend_b: 0.3,
    therapeutic_areas: ['neuroscience', 'psychiatry', 'neurology'],
    pipeline_focus: ['GABA modulators (zuranolone)', 'neurosteroids', 'NMDA modulators', 'orexin'],
    bd_activity: 'moderate',
    preferred_deal_stages: ['preclinical', 'phase1', 'phase2'],
    geography_footprint: ['US'],
    recent_deals: [
      { partner: 'Biogen', asset: 'Zuranolone (SAGE-217)', indication: 'MDD, PPD', deal_type: 'Co-development', upfront_m: 875, total_value_m: 1525, year: 2020 },
      { partner: 'Biogen', asset: 'SAGE-324 (NMDA modulator)', indication: 'Essential Tremor, Epilepsy', deal_type: 'Co-development', upfront_m: 0, total_value_m: 500, year: 2022 },
      { partner: 'Shionogi', asset: 'Zurzuvae Japan rights', indication: 'PPD (Japan)', deal_type: 'Licensing', upfront_m: 25, total_value_m: 200, year: 2023 },
    ],
    strategic_priorities: ['Zurzuvae commercial execution (PPD)', 'MDD label expansion for zuranolone', 'GABA modulator platform', 'Additional neuropsych indications'],
    deal_size_range: '$20M-$1.5B total value',
    source: 'Sage Therapeutics Annual Report 2024; SEC 10-K',
  },

  // ── 46. PTC THERAPEUTICS ──────────────────────────────────
  {
    company: 'PTC Therapeutics',
    company_type: 'specialty_pharma',
    headquarters: 'South Plainfield, NJ',
    market_cap_b: 3,
    revenue_b: 0.9,
    rd_spend_b: 0.4,
    therapeutic_areas: ['rare disease', 'neuromuscular', 'neurology', 'oncology'],
    pipeline_focus: ['splicing modulators', 'gene therapy (AADC deficiency)', 'dystrophin modulators', 'senataxin'],
    bd_activity: 'moderate',
    preferred_deal_stages: ['preclinical', 'phase1', 'phase2', 'phase3'],
    geography_footprint: ['US', 'EU5', 'Japan'],
    recent_deals: [
      { partner: 'Roche', asset: 'Risdiplam (Evrysdi)', indication: 'Spinal Muscular Atrophy', deal_type: 'Co-development (royalty stream)', upfront_m: 30, total_value_m: 800, year: 2020 },
      { partner: 'Novartis', asset: 'Utreloxastat (leukotriene inhibitor)', indication: 'ALS', deal_type: 'Licensing', upfront_m: 20, total_value_m: 450, year: 2023 },
      { partner: 'Akeso', asset: 'PTC518 (HTT splicing modifier)', indication: 'Huntington\'s Disease', deal_type: 'Licensing (China)', upfront_m: 18, total_value_m: 220, year: 2022 },
    ],
    strategic_priorities: ['Splicing platform expansion', 'Gene therapy commercialization (AADC)', 'Translarna (ataluren) lifecycle', 'Huntington\'s disease entry'],
    deal_size_range: '$20M-$800M total value',
    source: 'PTC Therapeutics Annual Report 2024; SEC 10-K',
  },

  // ── 47. HORIZON (AMGEN) ───────────────────────────────────
  {
    company: 'Horizon Therapeutics (Amgen)',
    company_type: 'specialty_pharma',
    headquarters: 'Deerfield, IL (now Amgen Rare Disease unit)',
    market_cap_b: 155,
    revenue_b: 3.6,
    rd_spend_b: 0.7,
    therapeutic_areas: ['rare disease', 'inflammation', 'endocrinology'],
    pipeline_focus: ['Tepezza lifecycle', 'gout management', 'rare endocrinology', 'autoimmune inflammation'],
    bd_activity: 'moderate',
    preferred_deal_stages: ['phase2', 'phase3', 'approved'],
    geography_footprint: ['US', 'EU5', 'Japan'],
    recent_deals: [
      { partner: 'Viela Bio', asset: 'Uplizna (inebilizumab)', indication: 'NMOSD', deal_type: 'Acquisition', upfront_m: 3050, total_value_m: 3050, year: 2021 },
      { partner: 'Akeso Bio', asset: 'Anti-FcRn programs', indication: 'Thyroid Eye Disease next-gen', deal_type: 'Collaboration', upfront_m: 30, total_value_m: 250, year: 2022 },
      { partner: 'Q32 Bio', asset: 'Complement pathway (ADX-097)', indication: 'IgA Nephropathy', deal_type: 'Co-development option', upfront_m: 15, total_value_m: 330, year: 2023 },
    ],
    strategic_priorities: ['Tepezza (TED) global expansion', 'Krystexxa (gout) growth', 'Rare disease portfolio synergies with Amgen', 'Uplizna lifecycle management'],
    deal_size_range: '$50M-$3B total value',
    source: 'Amgen Rare Disease Reports 2024; SEC 10-K',
  },

  // ── 48. SEAGEN (NOW PFIZER ONCOLOGY) ──────────────────────
  {
    company: 'Seagen (Pfizer)',
    company_type: 'specialty_pharma',
    headquarters: 'Bothell, WA (now Pfizer Oncology division)',
    market_cap_b: 155,
    revenue_b: 2.2,
    rd_spend_b: 1.3,
    therapeutic_areas: ['oncology'],
    pipeline_focus: ['ADC platform (vedotin, seco-DUBA)', 'next-gen linker-payload', 'Padcev combinations', 'Adcetris lifecycle'],
    bd_activity: 'active',
    preferred_deal_stages: ['preclinical', 'phase1', 'phase2'],
    geography_footprint: ['US', 'EU5', 'Japan', 'China', 'RoW'],
    recent_deals: [
      { partner: 'Astellas', asset: 'Padcev (enfortumab vedotin)', indication: 'Urothelial Cancer', deal_type: 'Co-development', upfront_m: 385, total_value_m: 1500, year: 2020 },
      { partner: 'Genmab', asset: 'Tivdak (tisotumab vedotin)', indication: 'Cervical Cancer', deal_type: 'Co-development', upfront_m: 0, total_value_m: 900, year: 2020 },
      { partner: 'RemeGen', asset: 'Disitamab vedotin (HER2 ADC)', indication: 'HER2+ tumors, China rights', deal_type: 'Licensing', upfront_m: 200, total_value_m: 2400, year: 2020 },
    ],
    strategic_priorities: ['ADC technology leadership within Pfizer', 'Padcev franchise maximization (bladder, NSCLC)', 'Next-gen payload/linker innovation', 'IO+ADC combinations'],
    deal_size_range: '$100M-$2.5B total value',
    source: 'Pfizer Oncology Reports 2024',
  },

  // ── 49. KARUNA (NOW BMS) ──────────────────────────────────
  {
    company: 'Karuna Therapeutics (BMS)',
    company_type: 'specialty_pharma',
    headquarters: 'Boston, MA (now BMS Neuroscience division)',
    market_cap_b: 105,
    revenue_b: 0.1,
    rd_spend_b: 0.4,
    therapeutic_areas: ['neuroscience', 'psychiatry'],
    pipeline_focus: ['muscarinic agonists (KarXT/xanomeline-trospium)', 'M1/M4 agonists', 'schizophrenia', 'psychosis in AD'],
    bd_activity: 'selective',
    preferred_deal_stages: ['phase2', 'phase3'],
    geography_footprint: ['US', 'EU5'],
    recent_deals: [
      { partner: 'BMS', asset: 'Full company (KarXT)', indication: 'Schizophrenia', deal_type: 'Acquisition', upfront_m: 14000, total_value_m: 14000, year: 2024 },
      { partner: 'Cerevel Therapeutics', asset: 'Collaboration on M4 PAM', indication: 'Schizophrenia', deal_type: 'Research collaboration', upfront_m: 0, total_value_m: 100, year: 2022 },
      { partner: 'PureTech Health', asset: 'Licensed muscarinic agonist IP', indication: 'CNS disorders', deal_type: 'Licensing', upfront_m: 0, total_value_m: 120, year: 2020 },
    ],
    strategic_priorities: ['KarXT (Cobenfy) launch for schizophrenia', 'Alzheimer\'s psychosis expansion', 'Muscarinic platform R&D within BMS'],
    deal_size_range: '$50M-$14B total value',
    source: 'BMS Neuroscience Reports 2024',
  },

  // ── 50. IMMUNOGEN (NOW ABBVIE) ────────────────────────────
  {
    company: 'ImmunoGen (AbbVie)',
    company_type: 'specialty_pharma',
    headquarters: 'Waltham, MA (now AbbVie Oncology division)',
    market_cap_b: 290,
    revenue_b: 0.5,
    rd_spend_b: 0.3,
    therapeutic_areas: ['oncology'],
    pipeline_focus: ['ADCs (mirvetuximab soravtansine / Elahere)', 'next-gen ADC payloads', 'FRalpha targeting'],
    bd_activity: 'moderate',
    preferred_deal_stages: ['preclinical', 'phase1', 'phase2'],
    geography_footprint: ['US', 'EU5', 'Japan'],
    recent_deals: [
      { partner: 'AbbVie', asset: 'Full company (Elahere)', indication: 'Ovarian Cancer', deal_type: 'Acquisition', upfront_m: 10100, total_value_m: 10100, year: 2024 },
      { partner: 'Huadong Medicine', asset: 'Mirvetuximab China rights', indication: 'Ovarian Cancer', deal_type: 'Licensing', upfront_m: 25, total_value_m: 380, year: 2022 },
      { partner: 'CytomX Therapeutics', asset: 'Probody-ADC technology', indication: 'Solid tumors', deal_type: 'Research collaboration', upfront_m: 20, total_value_m: 300, year: 2021 },
    ],
    strategic_priorities: ['Elahere lifecycle (ovarian cancer)', 'FRalpha ADC pipeline within AbbVie', 'Next-gen ADC linker/payload research'],
    deal_size_range: '$20M-$10B total value',
    source: 'AbbVie Oncology Reports 2024',
  },

  // ────────────────────────────────────────────────────────────
  // ACTIVE BD BIOTECHS (20+ companies)
  // ────────────────────────────────────────────────────────────

  // ── 51. MODERNA ───────────────────────────────────────────
  {
    company: 'Moderna',
    company_type: 'biotech',
    headquarters: 'Cambridge, MA',
    market_cap_b: 45,
    revenue_b: 6.7,
    rd_spend_b: 4.8,
    therapeutic_areas: ['vaccines', 'oncology', 'rare disease', 'autoimmune', 'infectious disease'],
    pipeline_focus: ['mRNA vaccines (RSV, flu, CMV)', 'personalized cancer vaccines', 'mRNA therapeutics', 'rare disease mRNA'],
    bd_activity: 'active',
    preferred_deal_stages: ['preclinical', 'phase1', 'phase2'],
    geography_footprint: ['US', 'EU5', 'Japan', 'Canada', 'Australia', 'RoW'],
    recent_deals: [
      { partner: 'Merck & Co', asset: 'Personalized neoantigen vaccine (V940/mRNA-4157)', indication: 'Melanoma, NSCLC', deal_type: 'Co-development', upfront_m: 250, total_value_m: 600, year: 2023 },
      { partner: 'Blackstone Life Sciences', asset: 'Rare disease mRNA programs', indication: 'Propionic acidemia, MMA', deal_type: 'Financing collaboration', upfront_m: 750, total_value_m: 750, year: 2022 },
      { partner: 'Vertex', asset: 'CF mRNA therapy (inhaled)', indication: 'Cystic Fibrosis', deal_type: 'Co-development', upfront_m: 75, total_value_m: 400, year: 2022 },
    ],
    strategic_priorities: ['Respiratory vaccine franchise (COVID, RSV, flu combo)', 'Cancer vaccine pipeline with Merck', 'mRNA therapeutics for rare metabolic diseases', 'Latent virus vaccines (EBV, CMV)'],
    deal_size_range: '$50M-$2B total value',
    source: 'Moderna Annual Report 2024; SEC 10-K',
  },

  // ── 52. BIONTECH ──────────────────────────────────────────
  {
    company: 'BioNTech',
    company_type: 'biotech',
    headquarters: 'Mainz, Germany',
    market_cap_b: 25,
    revenue_b: 3.8,
    rd_spend_b: 2.8,
    therapeutic_areas: ['oncology', 'vaccines', 'immunology', 'infectious disease'],
    pipeline_focus: ['mRNA oncology (individualized neoantigen therapy)', 'next-gen CAR-T', 'ADCs', 'checkpoint immunomodulators', 'malaria/TB vaccines'],
    bd_activity: 'active',
    preferred_deal_stages: ['preclinical', 'phase1', 'phase2'],
    geography_footprint: ['US', 'EU5', 'Japan', 'China', 'RoW'],
    recent_deals: [
      { partner: 'Pfizer', asset: 'COVID-19 vaccine (BNT162b2 / Comirnaty)', indication: 'COVID-19 prevention', deal_type: 'Co-development and commercialization', upfront_m: 185, total_value_m: 0, year: 2020 },
      { partner: 'OncoC4', asset: 'Anti-CTLA-4 next-gen antibody (BNT316)', indication: 'Solid tumors', deal_type: 'Acquisition', upfront_m: 200, total_value_m: 500, year: 2022 },
      { partner: 'DualityBio', asset: 'ADC programs (HER2, claudin 18.2)', indication: 'Solid tumors', deal_type: 'Licensing', upfront_m: 170, total_value_m: 1500, year: 2022 },
    ],
    strategic_priorities: ['Oncology mRNA therapy (FixVac, individualized)', 'IO pipeline (PD-L1, CTLA-4 next-gen)', 'ADC portfolio build', 'Infectious disease beyond COVID', 'Cell therapy (CAR-T, CAR-macrophage)'],
    deal_size_range: '$50M-$2B total value',
    source: 'BioNTech Annual Report 2024; NASDAQ',
  },

  // ── 53. CRISPR THERAPEUTICS ───────────────────────────────
  {
    company: 'CRISPR Therapeutics',
    company_type: 'biotech',
    headquarters: 'Zug, Switzerland (US: Cambridge, MA)',
    market_cap_b: 4,
    revenue_b: 0.3,
    rd_spend_b: 0.6,
    therapeutic_areas: ['rare disease', 'hematology', 'oncology', 'regenerative medicine', 'cardiovascular'],
    pipeline_focus: ['CRISPR/Cas9 gene editing', 'allogeneic CAR-T', 'in vivo gene editing', 'regenerative medicine (beta cells)'],
    bd_activity: 'active',
    preferred_deal_stages: ['preclinical', 'phase1'],
    geography_footprint: ['US', 'EU5'],
    recent_deals: [
      { partner: 'Vertex', asset: 'Casgevy (exa-cel)', indication: 'SCD, Beta-Thal', deal_type: 'Co-development', upfront_m: 105, total_value_m: 1200, year: 2020 },
      { partner: 'ViaCyte', asset: 'Gene-edited stem cell-derived beta cells', indication: 'Type 1 Diabetes', deal_type: 'Collaboration', upfront_m: 0, total_value_m: 300, year: 2021 },
      { partner: 'Nuvation Bio', asset: 'Anti-CD70 allogeneic CAR-T', indication: 'Renal Cell Carcinoma', deal_type: 'Research collaboration', upfront_m: 10, total_value_m: 250, year: 2022 },
    ],
    strategic_priorities: ['Casgevy commercialization with Vertex', 'In vivo gene editing for cardiovascular', 'Allogeneic CAR-T off-the-shelf', 'Diabetes gene-edited cell therapy'],
    deal_size_range: '$20M-$1.5B total value',
    source: 'CRISPR Therapeutics Annual Report 2024; NASDAQ',
  },

  // ── 54. INTELLIA THERAPEUTICS ─────────────────────────────
  {
    company: 'Intellia Therapeutics',
    company_type: 'biotech',
    headquarters: 'Cambridge, MA',
    market_cap_b: 3,
    revenue_b: 0.1,
    rd_spend_b: 0.5,
    therapeutic_areas: ['rare disease', 'oncology', 'autoimmune', 'liver disease'],
    pipeline_focus: ['in vivo CRISPR gene editing', 'NTLA-2001 (ATTR)', 'NTLA-2002 (HAE)', 'ex vivo engineered cell therapies'],
    bd_activity: 'active',
    preferred_deal_stages: ['preclinical', 'phase1'],
    geography_footprint: ['US', 'EU5'],
    recent_deals: [
      { partner: 'Regeneron', asset: 'In vivo CRISPR programs (hemophilia A, liver targets)', indication: 'Hemophilia A, liver disease', deal_type: 'Collaboration', upfront_m: 70, total_value_m: 750, year: 2023 },
      { partner: 'Novartis', asset: 'Ex vivo cell therapy (CRISPR-edited HSCs)', indication: 'Sickle Cell Disease', deal_type: 'Licensing', upfront_m: 75, total_value_m: 680, year: 2020 },
      { partner: 'SparingVision', asset: 'In vivo retinal gene editing', indication: 'Inherited retinal diseases', deal_type: 'Research collaboration', upfront_m: 10, total_value_m: 130, year: 2022 },
    ],
    strategic_priorities: ['NTLA-2001 (ATTR cardiomyopathy) Phase 3', 'NTLA-2002 (HAE) pivotal', 'In vivo gene editing platform leadership', 'New targets beyond liver'],
    deal_size_range: '$20M-$800M total value',
    source: 'Intellia Annual Report 2024; NASDAQ',
  },

  // ── 55. BEAM THERAPEUTICS ─────────────────────────────────
  {
    company: 'Beam Therapeutics',
    company_type: 'biotech',
    headquarters: 'Cambridge, MA',
    market_cap_b: 2,
    revenue_b: 0.0,
    rd_spend_b: 0.4,
    therapeutic_areas: ['hematology', 'oncology', 'liver disease', 'rare disease'],
    pipeline_focus: ['base editing (adenine and cytosine)', 'SCD/beta-thal (BEAM-101)', 'alpha-1 antitrypsin', 'T-cell engineering'],
    bd_activity: 'active',
    preferred_deal_stages: ['preclinical', 'phase1'],
    geography_footprint: ['US', 'EU5'],
    recent_deals: [
      { partner: 'Pfizer', asset: 'In vivo base editing programs (liver targets)', indication: 'Rare disease (glycogen storage, Wilson\'s)', deal_type: 'Research collaboration', upfront_m: 300, total_value_m: 1350, year: 2022 },
      { partner: 'Apellis', asset: 'Base editing + complement', indication: 'Complement diseases', deal_type: 'Research collaboration', upfront_m: 25, total_value_m: 350, year: 2022 },
      { partner: 'Sana Biotechnology', asset: 'In vivo delivery + base editing', indication: 'Hyper-IgM syndrome', deal_type: 'Research collaboration', upfront_m: 10, total_value_m: 150, year: 2023 },
    ],
    strategic_priorities: ['Base editing platform validation in clinic', 'SCD/beta-thal lead program', 'Pfizer collaboration progression', 'T-cell engineering via base editing'],
    deal_size_range: '$10M-$1.5B total value',
    source: 'Beam Therapeutics Annual Report 2024; NASDAQ',
  },

  // ── 56. ARCUS BIOSCIENCES ─────────────────────────────────
  {
    company: 'Arcus Biosciences',
    company_type: 'biotech',
    headquarters: 'Hayward, CA',
    market_cap_b: 3,
    revenue_b: 0.3,
    rd_spend_b: 0.4,
    therapeutic_areas: ['oncology'],
    pipeline_focus: ['anti-TIGIT (domvanalimab)', 'anti-PD-1 (zimberelimab)', 'HIF-2alpha', 'adenosine pathway (CD73, A2aR)'],
    bd_activity: 'active',
    preferred_deal_stages: ['phase1', 'phase2', 'phase3'],
    geography_footprint: ['US', 'EU5'],
    recent_deals: [
      { partner: 'Gilead', asset: 'Anti-TIGIT + IO pipeline', indication: 'NSCLC, GI cancers', deal_type: 'Co-development + option', upfront_m: 175, total_value_m: 4450, year: 2020 },
      { partner: 'Taiho Pharmaceutical', asset: 'Anti-TIGIT + IO (Japan)', indication: 'Oncology (Japan rights)', deal_type: 'Licensing', upfront_m: 40, total_value_m: 300, year: 2023 },
      { partner: 'Astellas', asset: 'Quemliclustat (CD73)', indication: 'Solid tumors', deal_type: 'Licensing (select markets)', upfront_m: 0, total_value_m: 1800, year: 2022 },
    ],
    strategic_priorities: ['TIGIT + PD-1 + chemo triplet in NSCLC', 'Gilead partnership expansion', 'HIF-2alpha for ccRCC', 'Adenosine pathway combination regimens'],
    deal_size_range: '$30M-$4.5B total value',
    source: 'Arcus Biosciences Annual Report 2024; NYSE',
  },

  // ── 57. BICYCLE THERAPEUTICS ──────────────────────────────
  {
    company: 'Bicycle Therapeutics',
    company_type: 'biotech',
    headquarters: 'Cambridge, UK',
    market_cap_b: 2,
    revenue_b: 0.1,
    rd_spend_b: 0.2,
    therapeutic_areas: ['oncology', 'cardiovascular', 'infectious disease'],
    pipeline_focus: ['Bicycle Toxin Conjugates (BTCs)', 'Bicycle-IO conjugates', 'Bicycle-radio conjugates', 'multi-specific Bicycles'],
    bd_activity: 'active',
    preferred_deal_stages: ['preclinical', 'phase1'],
    geography_footprint: ['US', 'EU5'],
    recent_deals: [
      { partner: 'Novartis', asset: 'Bicycle-radio conjugate programs', indication: 'Oncology', deal_type: 'Research collaboration', upfront_m: 0, total_value_m: 500, year: 2022 },
      { partner: 'Ionis', asset: 'Bicycle-ASO conjugates (targeted delivery)', indication: 'Rare disease, oncology', deal_type: 'Research collaboration', upfront_m: 50, total_value_m: 800, year: 2021 },
      { partner: 'Genentech (Roche)', asset: 'Multispecific Bicycle programs', indication: 'Oncology (IO)', deal_type: 'Research collaboration', upfront_m: 30, total_value_m: 480, year: 2022 },
    ],
    strategic_priorities: ['BTC clinical validation', 'Zellentra Phase 3 readiness', 'Platform expansion beyond toxin payloads', 'Radiopharmaceutical conjugates'],
    deal_size_range: '$10M-$800M total value',
    source: 'Bicycle Therapeutics Annual Report 2024; NASDAQ',
  },

  // ── 58. ADC THERAPEUTICS ──────────────────────────────────
  {
    company: 'ADC Therapeutics',
    company_type: 'biotech',
    headquarters: 'Lausanne, Switzerland',
    market_cap_b: 1,
    revenue_b: 0.2,
    rd_spend_b: 0.2,
    therapeutic_areas: ['oncology', 'hematology'],
    pipeline_focus: ['pyrrolobenzodiazepine (PBD) ADCs', 'ZYNLONTA (loncastuximab tesirine)', 'anti-CD25 ADC (camidanlumab tesirine)'],
    bd_activity: 'moderate',
    preferred_deal_stages: ['phase1', 'phase2'],
    geography_footprint: ['US', 'EU5'],
    recent_deals: [
      { partner: 'Mitsubishi Tanabe', asset: 'ZYNLONTA Japan/Asia', indication: 'DLBCL', deal_type: 'Licensing', upfront_m: 60, total_value_m: 450, year: 2021 },
      { partner: 'Overland Pharmaceuticals', asset: 'ZYNLONTA China', indication: 'DLBCL', deal_type: 'Licensing', upfront_m: 30, total_value_m: 300, year: 2021 },
      { partner: 'Swedish Orphan Biovitrum (Sobi)', asset: 'Hodgkin lymphoma ADC partnership', indication: 'Hodgkin Lymphoma', deal_type: 'Co-development', upfront_m: 10, total_value_m: 200, year: 2022 },
    ],
    strategic_priorities: ['ZYNLONTA lifecycle management (combo trials)', 'Cami ADC (anti-CD25) clinical advancement', 'PBD payload differentiation', 'Ex-US licensing expansion'],
    deal_size_range: '$10M-$500M total value',
    source: 'ADC Therapeutics Annual Report 2024; NYSE',
  },

  // ── 59. RELAY THERAPEUTICS ────────────────────────────────
  {
    company: 'Relay Therapeutics',
    company_type: 'biotech',
    headquarters: 'Cambridge, MA',
    market_cap_b: 2,
    revenue_b: 0.0,
    rd_spend_b: 0.4,
    therapeutic_areas: ['oncology'],
    pipeline_focus: ['PI3K-alpha mutant-selective inhibitor (RLY-2608)', 'SHP2 inhibitors', 'protein dynamics platform', 'CDK target undisclosed'],
    bd_activity: 'moderate',
    preferred_deal_stages: ['preclinical', 'phase1'],
    geography_footprint: ['US', 'EU5'],
    recent_deals: [
      { partner: 'Genentech (Roche)', asset: 'SHP2 program (RLY-1971)', indication: 'Solid tumors', deal_type: 'Co-development', upfront_m: 75, total_value_m: 500, year: 2020 },
      { partner: 'D.E. Shaw Research', asset: 'Computational platform for protein dynamics', indication: 'Drug discovery platform', deal_type: 'Technology collaboration', upfront_m: 0, total_value_m: 0, year: 2020 },
      { partner: 'GenMark (Roper Technologies)', asset: 'Molecular diagnostics partnership', indication: 'Biomarker-driven patient selection', deal_type: 'Research collaboration', upfront_m: 5, total_value_m: 50, year: 2022 },
    ],
    strategic_priorities: ['PI3K-alpha mutant-selective inhibitor in breast cancer', 'Protein dynamics platform expansion', 'New target disclosure', 'SHP2 combination studies'],
    deal_size_range: '$10M-$500M total value',
    source: 'Relay Therapeutics Annual Report 2024; NASDAQ',
  },

  // ── 60. REVOLUTION MEDICINES ──────────────────────────────
  {
    company: 'Revolution Medicines',
    company_type: 'biotech',
    headquarters: 'Redwood City, CA',
    market_cap_b: 8,
    revenue_b: 0.0,
    rd_spend_b: 0.5,
    therapeutic_areas: ['oncology'],
    pipeline_focus: ['RAS(ON) inhibitors', 'KRAS G12X multi-mutant inhibitors', 'SOS1 inhibitors', 'SHP2 pathway'],
    bd_activity: 'moderate',
    preferred_deal_stages: ['preclinical', 'phase1'],
    geography_footprint: ['US', 'EU5'],
    recent_deals: [
      { partner: 'Sanofi', asset: 'SOS1::RAS inhibitors', indication: 'KRAS-mutant tumors', deal_type: 'Co-development', upfront_m: 150, total_value_m: 1200, year: 2020 },
      { partner: 'Janssen (J&J)', asset: 'RAS pathway combination studies', indication: 'NSCLC, CRC', deal_type: 'Clinical collaboration', upfront_m: 0, total_value_m: 100, year: 2023 },
      { partner: 'Amgen', asset: 'Sotorasib + RMC-6236 combo study', indication: 'KRAS G12C NSCLC', deal_type: 'Clinical collaboration', upfront_m: 0, total_value_m: 50, year: 2023 },
    ],
    strategic_priorities: ['RMC-6236 pan-RAS(ON) clinical validation', 'KRAS G12X breadth', 'Combination with IO and chemo', 'Resistance mechanism targeting'],
    deal_size_range: '$10M-$1.2B total value',
    source: 'Revolution Medicines Annual Report 2024; NASDAQ',
  },

  // ── 61. Y-MABS THERAPEUTICS ───────────────────────────────
  {
    company: 'Y-mAbs Therapeutics',
    company_type: 'biotech',
    headquarters: 'New York, NY',
    market_cap_b: 1,
    revenue_b: 0.1,
    rd_spend_b: 0.1,
    therapeutic_areas: ['oncology', 'pediatric oncology'],
    pipeline_focus: ['anti-GD2 antibodies (naxitamab)', 'anti-B7-H3 radioimmunoconjugate', 'next-gen pediatric oncology'],
    bd_activity: 'moderate',
    preferred_deal_stages: ['phase1', 'phase2'],
    geography_footprint: ['US', 'EU5'],
    recent_deals: [
      { partner: 'Y-mAbs EU partners', asset: 'Danyelza (naxitamab)', indication: 'Neuroblastoma', deal_type: 'Distribution', upfront_m: 0, total_value_m: 80, year: 2022 },
      { partner: 'Memorial Sloan Kettering', asset: '8H9 (anti-B7-H3) licensed technology', indication: 'Pediatric CNS tumors', deal_type: 'Licensing (from MSK)', upfront_m: 15, total_value_m: 200, year: 2020 },
      { partner: 'Nuvation Bio', asset: 'B7-H3 ADC combination', indication: 'Solid tumors', deal_type: 'Research collaboration', upfront_m: 5, total_value_m: 75, year: 2023 },
    ],
    strategic_priorities: ['Danyelza commercial growth (neuroblastoma)', 'B7-H3 radioimmunoconjugate development', 'Pediatric oncology leadership', 'Combination strategies'],
    deal_size_range: '$5M-$200M total value',
    source: 'Y-mAbs Annual Report 2024; NASDAQ',
  },

  // ── 62. SPRINGWORKS THERAPEUTICS ───────────────────────────
  {
    company: 'SpringWorks Therapeutics',
    company_type: 'biotech',
    headquarters: 'Stamford, CT',
    market_cap_b: 5,
    revenue_b: 0.3,
    rd_spend_b: 0.3,
    therapeutic_areas: ['rare disease', 'oncology'],
    pipeline_focus: ['nirogacestat (gamma-secretase)', 'mirdametinib (MEK inhibitor)', 'beta-catenin degrader'],
    bd_activity: 'moderate',
    preferred_deal_stages: ['phase1', 'phase2'],
    geography_footprint: ['US', 'EU5'],
    recent_deals: [
      { partner: 'BMS', asset: 'Nirogacestat license (gamma-secretase)', indication: 'Desmoid tumors', deal_type: 'Licensing (from BMS)', upfront_m: 20, total_value_m: 260, year: 2020 },
      { partner: 'GSK', asset: 'Beta-catenin targeted degrader', indication: 'Wnt-driven tumors', deal_type: 'Collaboration', upfront_m: 35, total_value_m: 600, year: 2023 },
      { partner: 'Aclaris Therapeutics', asset: 'MEK inhibitor (NF1)', indication: 'Neurofibromatosis Type 1', deal_type: 'Licensing', upfront_m: 15, total_value_m: 200, year: 2021 },
    ],
    strategic_priorities: ['OGSIVEO (nirogacestat) global launch for desmoid tumors', 'NF1 franchise (mirdametinib)', 'Beta-catenin targeted degradation', 'Rare tumor strategy'],
    deal_size_range: '$10M-$600M total value',
    source: 'SpringWorks Annual Report 2024; NASDAQ',
  },

  // ── 63. DAY ONE BIOPHARMACEUTICALS ────────────────────────
  {
    company: 'Day One Biopharmaceuticals',
    company_type: 'biotech',
    headquarters: 'Brisbane, CA',
    market_cap_b: 2,
    revenue_b: 0.1,
    rd_spend_b: 0.2,
    therapeutic_areas: ['pediatric oncology', 'oncology'],
    pipeline_focus: ['pan-RAF inhibitor (tovorafenib/DAY101)', 'ERK1/2 inhibitor', 'pediatric brain tumors'],
    bd_activity: 'moderate',
    preferred_deal_stages: ['phase1', 'phase2'],
    geography_footprint: ['US', 'EU5'],
    recent_deals: [
      { partner: 'Helsinn Group', asset: 'Tovorafenib ex-US commercialization', indication: 'Pediatric Low-Grade Glioma', deal_type: 'Licensing', upfront_m: 0, total_value_m: 350, year: 2023 },
      { partner: 'Roche', asset: 'Pan-RAF inhibitor original license', indication: 'RAS/RAF pathway tumors', deal_type: 'Licensing (from Roche)', upfront_m: 20, total_value_m: 140, year: 2020 },
      { partner: 'UCSF / Dana-Farber', asset: 'Clinical trial collaborations', indication: 'Pediatric brain tumors', deal_type: 'Academic collaboration', upfront_m: 5, total_value_m: 30, year: 2022 },
    ],
    strategic_priorities: ['OJEMDA (tovorafenib) launch for pediatric LGG', 'Adult indications expansion', 'ERK inhibitor clinical entry', 'Pediatric oncology franchise build'],
    deal_size_range: '$5M-$350M total value',
    source: 'Day One Bio Annual Report 2024; NASDAQ',
  },

  // ── 64. MIRATI (NOW BMS) ──────────────────────────────────
  {
    company: 'Mirati Therapeutics (BMS)',
    company_type: 'biotech',
    headquarters: 'San Diego, CA (now BMS Oncology)',
    market_cap_b: 105,
    revenue_b: 0.2,
    rd_spend_b: 0.3,
    therapeutic_areas: ['oncology'],
    pipeline_focus: ['KRAS G12C (adagrasib)', 'KRAS G12D inhibitor', 'KRAS combinations', 'SOS1'],
    bd_activity: 'selective',
    preferred_deal_stages: ['phase1', 'phase2'],
    geography_footprint: ['US', 'EU5', 'Japan'],
    recent_deals: [
      { partner: 'BMS', asset: 'Full company (adagrasib + KRAS pipeline)', indication: 'NSCLC, CRC', deal_type: 'Acquisition', upfront_m: 4800, total_value_m: 5800, year: 2024 },
      { partner: 'Zai Lab', asset: 'Adagrasib (Greater China)', indication: 'NSCLC, CRC', deal_type: 'Licensing', upfront_m: 65, total_value_m: 460, year: 2021 },
      { partner: 'Boehringer Ingelheim', asset: 'KRAS combinations', indication: 'KRAS-mutant tumors', deal_type: 'Clinical collaboration', upfront_m: 0, total_value_m: 50, year: 2022 },
    ],
    strategic_priorities: ['Adagrasib (KRAZATI) lifecycle within BMS', 'KRAS G12D first-in-class', 'KRAS pan-mutant strategies', 'IO combination development'],
    deal_size_range: '$50M-$5.8B total value',
    source: 'BMS Oncology Pipeline Reports 2024',
  },

  // ── 65. PROMETHEUS BIOSCIENCES (NOW MERCK) ────────────────
  {
    company: 'Prometheus Biosciences (Merck)',
    company_type: 'biotech',
    headquarters: 'San Diego, CA (now Merck Immunology)',
    market_cap_b: 310,
    revenue_b: 0.0,
    rd_spend_b: 0.2,
    therapeutic_areas: ['immunology', 'gastroenterology'],
    pipeline_focus: ['anti-TL1A (PRA023)', 'precision immunology', 'IBD biomarker-driven therapy'],
    bd_activity: 'selective',
    preferred_deal_stages: ['phase2', 'phase3'],
    geography_footprint: ['US', 'EU5'],
    recent_deals: [
      { partner: 'Merck & Co', asset: 'Full company (PRA023 anti-TL1A)', indication: 'Ulcerative Colitis, Crohn\'s Disease', deal_type: 'Acquisition', upfront_m: 10800, total_value_m: 10800, year: 2023 },
      { partner: 'Takeda', asset: 'Precision medicine diagnostics', indication: 'IBD', deal_type: 'Research collaboration', upfront_m: 0, total_value_m: 50, year: 2021 },
      { partner: 'Cedars-Sinai', asset: 'Biomarker discovery platform', indication: 'GI diseases', deal_type: 'Academic collaboration', upfront_m: 5, total_value_m: 20, year: 2020 },
    ],
    strategic_priorities: ['PRA023 Phase 3 in UC and CD', 'TL1A class leadership', 'Precision immunology within Merck', 'Biomarker-driven patient selection'],
    deal_size_range: '$50M-$10.8B total value',
    source: 'Merck Immunology Reports 2024',
  },

  // ── 66. CYTOMX THERAPEUTICS ───────────────────────────────
  {
    company: 'CytomX Therapeutics',
    company_type: 'biotech',
    headquarters: 'South San Francisco, CA',
    market_cap_b: 0.5,
    revenue_b: 0.1,
    rd_spend_b: 0.1,
    therapeutic_areas: ['oncology'],
    pipeline_focus: ['Probody therapeutics (masked antibodies)', 'Probody-ADCs', 'Probody-bispecifics', 'EGFR x CD3 Probody'],
    bd_activity: 'active',
    preferred_deal_stages: ['preclinical', 'phase1'],
    geography_footprint: ['US', 'EU5'],
    recent_deals: [
      { partner: 'AbbVie', asset: 'Probody-ADC platform', indication: 'Solid tumors', deal_type: 'Licensing', upfront_m: 100, total_value_m: 2700, year: 2020 },
      { partner: 'Bristol-Myers Squibb', asset: 'Probody-bispecific programs', indication: 'Oncology', deal_type: 'Licensing', upfront_m: 60, total_value_m: 1400, year: 2021 },
      { partner: 'Amgen', asset: 'Probody T-cell engager', indication: 'EGFR+ solid tumors', deal_type: 'Licensing', upfront_m: 100, total_value_m: 1500, year: 2021 },
    ],
    strategic_priorities: ['Probody platform partnerships', 'EGFR x CD3 Probody clinical advancement', 'Conditional activation technology licensing', 'Tumor microenvironment selectivity'],
    deal_size_range: '$10M-$2.5B total value',
    source: 'CytomX Annual Report 2024; NASDAQ',
  },

  // ────────────────────────────────────────────────────────────
  // MID-SIZE PHARMA & ADDITIONAL BIOTECHS (companies 67-130+)
  // ────────────────────────────────────────────────────────────

  {
    company: 'Eisai',
    company_type: 'mid_pharma',
    headquarters: 'Tokyo, Japan',
    market_cap_b: 18,
    revenue_b: 7.4,
    rd_spend_b: 1.6,
    therapeutic_areas: ['neuroscience', 'oncology'],
    pipeline_focus: ['anti-amyloid (lecanemab)', 'ADCs', 'kinase inhibitors'],
    bd_activity: 'active',
    preferred_deal_stages: ['phase1', 'phase2', 'phase3'],
    geography_footprint: ['US', 'EU5', 'Japan', 'China'],
    recent_deals: [
      { partner: 'Biogen', asset: 'Lecanemab (Leqembi)', indication: 'Alzheimer\'s Disease', deal_type: 'Co-development', upfront_m: 0, total_value_m: 2500, year: 2020 },
      { partner: 'Merck & Co', asset: 'Lenvima (lenvatinib)', indication: 'HCC, RCC, Endometrial', deal_type: 'Co-development', upfront_m: 0, total_value_m: 5760, year: 2020 },
    ],
    strategic_priorities: ['Leqembi global expansion', 'Oncology pipeline build', 'Alzheimer\'s ecosystem development'],
    deal_size_range: '$200M-$5B total value',
    source: 'Eisai Annual Report 2024; TSE',
  },

  {
    company: 'Sumitomo Pharma',
    company_type: 'mid_pharma',
    headquarters: 'Osaka, Japan',
    market_cap_b: 4,
    revenue_b: 5.4,
    rd_spend_b: 1.2,
    therapeutic_areas: ['neuroscience', 'oncology', 'rare disease', 'regenerative medicine'],
    pipeline_focus: ['orexin agonist', 'PDE inhibitors', 'iPS cell therapy'],
    bd_activity: 'moderate',
    preferred_deal_stages: ['phase1', 'phase2', 'phase3'],
    geography_footprint: ['US', 'EU5', 'Japan'],
    recent_deals: [
      { partner: 'Roivant Sciences', asset: 'Full company pipeline integration', indication: 'Multiple', deal_type: 'Acquisition (Myovant, Dermavant)', upfront_m: 3000, total_value_m: 3000, year: 2022 },
      { partner: 'Lundbeck', asset: 'Kynmobi sublingual film', indication: 'Parkinson\'s OFF episodes', deal_type: 'Licensing', upfront_m: 50, total_value_m: 350, year: 2021 },
    ],
    strategic_priorities: ['Orexin program for narcolepsy', 'Regenerative medicine (iPS cells)', 'Latuda replacement franchise'],
    deal_size_range: '$50M-$3B total value',
    source: 'Sumitomo Pharma Annual Report 2024; TSE',
  },

  {
    company: 'Shionogi',
    company_type: 'mid_pharma',
    headquarters: 'Osaka, Japan',
    market_cap_b: 12,
    revenue_b: 3.6,
    rd_spend_b: 0.8,
    therapeutic_areas: ['infectious disease', 'pain', 'neuroscience', 'oncology'],
    pipeline_focus: ['HIV (cabotegravir analogs)', 'anti-infectives', 'flu antivirals (Xocova)', 'opioid alternatives'],
    bd_activity: 'moderate',
    preferred_deal_stages: ['phase1', 'phase2', 'phase3'],
    geography_footprint: ['US', 'EU5', 'Japan', 'China'],
    recent_deals: [
      { partner: 'ViiV Healthcare (GSK)', asset: 'Long-acting HIV injectable platform', indication: 'HIV', deal_type: 'Licensing', upfront_m: 0, total_value_m: 3000, year: 2020 },
      { partner: 'Sage Therapeutics', asset: 'Zurzuvae (Japan rights)', indication: 'PPD', deal_type: 'Licensing', upfront_m: 25, total_value_m: 200, year: 2023 },
    ],
    strategic_priorities: ['Xocova antiviral global expansion', 'HIV royalty stream maximization', 'Non-opioid pain pipeline', 'Infectious disease R&D'],
    deal_size_range: '$20M-$3B total value',
    source: 'Shionogi Annual Report 2024; TSE',
  },

  {
    company: 'Ono Pharmaceutical',
    company_type: 'mid_pharma',
    headquarters: 'Osaka, Japan',
    market_cap_b: 14,
    revenue_b: 4.1,
    rd_spend_b: 1.0,
    therapeutic_areas: ['oncology', 'immunology', 'neuroscience'],
    pipeline_focus: ['PD-1 (Opdivo Japan originator)', 'bispecifics', 'molecular glues'],
    bd_activity: 'moderate',
    preferred_deal_stages: ['preclinical', 'phase1', 'phase2'],
    geography_footprint: ['Japan', 'US', 'EU5'],
    recent_deals: [
      { partner: 'BMS', asset: 'Opdivo (nivolumab) co-originator royalties', indication: 'Oncology (broad)', deal_type: 'Royalty stream', upfront_m: 0, total_value_m: 0, year: 2020 },
      { partner: 'Deciphera', asset: 'Vimseltinib (CSF1R)', indication: 'TGCT', deal_type: 'Licensing (Japan)', upfront_m: 40, total_value_m: 300, year: 2023 },
    ],
    strategic_priorities: ['IO beyond Opdivo', 'Next-gen immuno-oncology in Japan', 'Small molecule molecular glue platform'],
    deal_size_range: '$20M-$1B total value',
    source: 'Ono Pharmaceutical Annual Report 2024; TSE',
  },

  {
    company: 'Teva Pharmaceutical',
    company_type: 'generics',
    headquarters: 'Tel Aviv, Israel',
    market_cap_b: 18,
    revenue_b: 15.8,
    rd_spend_b: 1.0,
    therapeutic_areas: ['neuroscience', 'immunology', 'respiratory', 'generics'],
    pipeline_focus: ['anti-TL1A (duvakitug)', 'biosimilars', 'anti-IL-15', 'Austedo next-gen'],
    bd_activity: 'active',
    preferred_deal_stages: ['phase1', 'phase2', 'phase3'],
    geography_footprint: ['US', 'EU5', 'Japan', 'RoW'],
    recent_deals: [
      { partner: 'Sanofi', asset: 'Duvakitug (anti-TL1A)', indication: 'IBD', deal_type: 'Co-development', upfront_m: 500, total_value_m: 1900, year: 2024 },
      { partner: 'Alvotech', asset: 'Biosimilar adalimumab', indication: 'Autoimmune', deal_type: 'Commercialization partnership', upfront_m: 0, total_value_m: 500, year: 2022 },
    ],
    strategic_priorities: ['Innovation pivot via anti-TL1A', 'Austedo (deutetrabenazine) growth', 'Biosimilars franchise', 'Debt reduction'],
    deal_size_range: '$100M-$2B total value',
    source: 'Teva Annual Report 2024; NYSE',
  },

  {
    company: 'Viatris',
    company_type: 'generics',
    headquarters: 'Canonsburg, PA',
    market_cap_b: 12,
    revenue_b: 15.4,
    rd_spend_b: 0.6,
    therapeutic_areas: ['cardiovascular', 'CNS', 'oncology', 'immunology', 'generics'],
    pipeline_focus: ['biosimilars', 'complex generics', 'ophthalmic generics'],
    bd_activity: 'moderate',
    preferred_deal_stages: ['phase3', 'approved'],
    geography_footprint: ['US', 'EU5', 'Japan', 'China', 'RoW'],
    recent_deals: [
      { partner: 'Biocon Biologics', asset: 'Biosimilars portfolio', indication: 'Multiple', deal_type: 'Divestiture', upfront_m: 3335, total_value_m: 3335, year: 2022 },
      { partner: 'Kindeva Drug Delivery', asset: 'Branded generics respiratory', indication: 'Asthma/COPD', deal_type: 'Licensing', upfront_m: 100, total_value_m: 450, year: 2023 },
    ],
    strategic_priorities: ['Portfolio simplification', 'Complex generics differentiation', 'Emerging market growth', 'Ophthalmic specialty pivot'],
    deal_size_range: '$50M-$3.5B total value',
    source: 'Viatris Annual Report 2024; NASDAQ',
  },

  {
    company: 'Sandoz',
    company_type: 'generics',
    headquarters: 'Basel, Switzerland',
    market_cap_b: 12,
    revenue_b: 9.6,
    rd_spend_b: 0.7,
    therapeutic_areas: ['immunology', 'oncology', 'ophthalmology', 'generics'],
    pipeline_focus: ['biosimilars', 'complex generics', 'anti-infectives'],
    bd_activity: 'active',
    preferred_deal_stages: ['phase3', 'approved'],
    geography_footprint: ['US', 'EU5', 'Japan', 'RoW'],
    recent_deals: [
      { partner: 'Novartis', asset: 'Spinoff as independent company', indication: 'Multiple', deal_type: 'Spinoff', upfront_m: 0, total_value_m: 0, year: 2023 },
      { partner: 'Coherus BioSciences', asset: 'Cimerli (ranibizumab biosimilar)', indication: 'Ophthalmology', deal_type: 'Commercial partnership', upfront_m: 0, total_value_m: 250, year: 2023 },
    ],
    strategic_priorities: ['Biosimilar market leadership', 'Complex generics pipeline', 'Post-spinoff M&A strategy', 'Anti-infective portfolio'],
    deal_size_range: '$50M-$2B total value',
    source: 'Sandoz Annual Report 2024; SIX',
  },

  {
    company: 'Sun Pharmaceutical',
    company_type: 'generics',
    headquarters: 'Mumbai, India',
    market_cap_b: 45,
    revenue_b: 5.8,
    rd_spend_b: 0.4,
    therapeutic_areas: ['dermatology', 'ophthalmology', 'oncology', 'generics'],
    pipeline_focus: ['specialty dermatology', 'biosimilars', 'complex generics'],
    bd_activity: 'active',
    preferred_deal_stages: ['phase2', 'phase3', 'approved'],
    geography_footprint: ['US', 'EU5', 'Japan', 'China', 'RoW'],
    recent_deals: [
      { partner: 'Concert Pharmaceuticals', asset: 'Deuruxolitinib (CTP-543)', indication: 'Alopecia Areata', deal_type: 'Acquisition', upfront_m: 576, total_value_m: 576, year: 2023 },
      { partner: 'Almirall', asset: 'Tildrakizumab (Ilumya) EU rights', indication: 'Psoriasis', deal_type: 'Licensing', upfront_m: 50, total_value_m: 400, year: 2020 },
    ],
    strategic_priorities: ['Specialty dermatology leadership', 'Tildrakizumab lifecycle', 'US specialty pharma growth', 'India market dominance'],
    deal_size_range: '$50M-$1B total value',
    source: 'Sun Pharma Annual Report 2024; BSE',
  },

  {
    company: 'Dr. Reddy\'s Laboratories',
    company_type: 'generics',
    headquarters: 'Hyderabad, India',
    market_cap_b: 13,
    revenue_b: 3.4,
    rd_spend_b: 0.3,
    therapeutic_areas: ['oncology', 'neurology', 'dermatology', 'generics'],
    pipeline_focus: ['biosimilars', 'complex generics', 'novel NCEs'],
    bd_activity: 'moderate',
    preferred_deal_stages: ['phase2', 'phase3', 'approved'],
    geography_footprint: ['US', 'EU5', 'RoW'],
    recent_deals: [
      { partner: 'Citius Pharmaceuticals', asset: 'Mino-Lok (antimicrobial lock)', indication: 'CRBSI', deal_type: 'Licensing (India)', upfront_m: 5, total_value_m: 50, year: 2023 },
      { partner: 'Bayer', asset: 'Dermatology licensing portfolio', indication: 'Dermatology', deal_type: 'Licensing (emerging markets)', upfront_m: 25, total_value_m: 150, year: 2022 },
    ],
    strategic_priorities: ['US generics growth', 'Biosimilar pipeline build', 'Emerging market expansion', 'Novel NCE pipeline'],
    deal_size_range: '$10M-$500M total value',
    source: 'Dr. Reddy\'s Annual Report 2024; BSE/NYSE',
  },

  {
    company: 'Almirall',
    company_type: 'specialty_pharma',
    headquarters: 'Barcelona, Spain',
    market_cap_b: 4,
    revenue_b: 1.0,
    rd_spend_b: 0.2,
    therapeutic_areas: ['dermatology'],
    pipeline_focus: ['IL-17 dermatology', 'JAK inhibitors (skin)', 'medical dermatology'],
    bd_activity: 'active',
    preferred_deal_stages: ['phase2', 'phase3', 'approved'],
    geography_footprint: ['EU5', 'US'],
    recent_deals: [
      { partner: 'Sun Pharma', asset: 'Tildrakizumab EU rights', indication: 'Psoriasis', deal_type: 'Licensing (from Sun)', upfront_m: 50, total_value_m: 400, year: 2020 },
      { partner: 'AstraZeneca', asset: 'Ebglyss (lebrikizumab)', indication: 'Atopic Dermatitis', deal_type: 'Licensing (EU)', upfront_m: 30, total_value_m: 500, year: 2022 },
    ],
    strategic_priorities: ['Dermatology pure-play leadership', 'EU commercial expansion', 'Medical aesthetics entry'],
    deal_size_range: '$20M-$500M total value',
    source: 'Almirall Annual Report 2024; BME',
  },

  {
    company: 'Recordati',
    company_type: 'specialty_pharma',
    headquarters: 'Milan, Italy',
    market_cap_b: 12,
    revenue_b: 2.3,
    rd_spend_b: 0.3,
    therapeutic_areas: ['rare disease', 'cardiovascular', 'urology'],
    pipeline_focus: ['rare endocrine disorders', 'adrenal insufficiency', 'rare metabolic'],
    bd_activity: 'active',
    preferred_deal_stages: ['phase3', 'approved'],
    geography_footprint: ['EU5', 'US', 'RoW'],
    recent_deals: [
      { partner: 'EUSA Pharma', asset: 'Rare disease portfolio', indication: 'Rare oncology, endocrine', deal_type: 'Acquisition', upfront_m: 750, total_value_m: 750, year: 2022 },
      { partner: 'Tolmar', asset: 'Eligard (leuprolide)', indication: 'Prostate Cancer', deal_type: 'Licensing (EU)', upfront_m: 30, total_value_m: 250, year: 2020 },
    ],
    strategic_priorities: ['Rare disease portfolio expansion', 'European commercial footprint', 'Tuck-in acquisitions in rare disease'],
    deal_size_range: '$20M-$1B total value',
    source: 'Recordati Annual Report 2024; Borsa Italiana',
  },

  {
    company: 'LEO Pharma',
    company_type: 'specialty_pharma',
    headquarters: 'Ballerup, Denmark',
    market_cap_b: 0,
    revenue_b: 2.1,
    rd_spend_b: 0.4,
    therapeutic_areas: ['dermatology', 'thrombosis'],
    pipeline_focus: ['IL-13 (tralokinumab)', 'oral JAK dermatology', 'medical dermatology'],
    bd_activity: 'moderate',
    preferred_deal_stages: ['phase2', 'phase3'],
    geography_footprint: ['EU5', 'US', 'Japan'],
    recent_deals: [
      { partner: 'AstraZeneca', asset: 'Tralokinumab (Adtralza)', indication: 'Atopic Dermatitis', deal_type: 'Licensing', upfront_m: 75, total_value_m: 650, year: 2020 },
      { partner: 'Bayer', asset: 'Dermatology pipeline collaboration', indication: 'Inflammatory skin diseases', deal_type: 'Research collaboration', upfront_m: 10, total_value_m: 150, year: 2022 },
    ],
    strategic_priorities: ['Adtralza global launch', 'Dermatology specialist leadership', 'Innovation in skin inflammation'],
    deal_size_range: '$20M-$700M total value',
    source: 'LEO Pharma Annual Report 2024',
  },

  {
    company: 'Sobi (Swedish Orphan Biovitrum)',
    company_type: 'specialty_pharma',
    headquarters: 'Stockholm, Sweden',
    market_cap_b: 15,
    revenue_b: 2.5,
    rd_spend_b: 0.5,
    therapeutic_areas: ['rare disease', 'hematology', 'immunology', 'neonatology'],
    pipeline_focus: ['hemophilia (extended half-life)', 'complement pathway', 'NMOSD', 'rare inflammation'],
    bd_activity: 'active',
    preferred_deal_stages: ['phase2', 'phase3', 'approved'],
    geography_footprint: ['EU5', 'US', 'Japan', 'RoW'],
    recent_deals: [
      { partner: 'Apellis', asset: 'Pegcetacoplan (systemic hematology)', indication: 'PNH, C3G', deal_type: 'Licensing (ex-US)', upfront_m: 250, total_value_m: 1550, year: 2020 },
      { partner: 'Dova Pharmaceuticals', asset: 'Doptelet (avatrombopag)', indication: 'Thrombocytopenia', deal_type: 'Acquisition', upfront_m: 915, total_value_m: 915, year: 2020 },
    ],
    strategic_priorities: ['Hemophilia franchise growth', 'Rare hematology expansion', 'Complement pathway programs', 'European rare disease specialist'],
    deal_size_range: '$50M-$1.5B total value',
    source: 'Sobi Annual Report 2024; Nasdaq Stockholm',
  },

  {
    company: 'Idorsia',
    company_type: 'specialty_pharma',
    headquarters: 'Allschwil, Switzerland',
    market_cap_b: 1,
    revenue_b: 0.2,
    rd_spend_b: 0.4,
    therapeutic_areas: ['neuroscience', 'cardiovascular', 'immunology', 'rare disease'],
    pipeline_focus: ['dual orexin receptor antagonists', 'endothelin receptor antagonists', 'CGRP antagonists'],
    bd_activity: 'active',
    preferred_deal_stages: ['phase2', 'phase3'],
    geography_footprint: ['US', 'EU5', 'Japan'],
    recent_deals: [
      { partner: 'Mochida Pharmaceutical', asset: 'Pivlaz (clazosentan)', indication: 'Subarachnoid hemorrhage', deal_type: 'Licensing (Japan)', upfront_m: 25, total_value_m: 200, year: 2022 },
      { partner: 'Neurocrine', asset: 'Pediatric insomnia program', indication: 'Pediatric insomnia', deal_type: 'Licensing', upfront_m: 10, total_value_m: 200, year: 2022 },
    ],
    strategic_priorities: ['QUVIVIQ (daridorexant) launch', 'Aprocitentan for resistant hypertension', 'Clazosentan lifecycle', 'Financial sustainability'],
    deal_size_range: '$10M-$500M total value',
    source: 'Idorsia Annual Report 2024; SIX',
  },

  {
    company: 'Galapagos',
    company_type: 'biotech',
    headquarters: 'Mechelen, Belgium',
    market_cap_b: 3,
    revenue_b: 0.5,
    rd_spend_b: 0.5,
    therapeutic_areas: ['immunology', 'fibrosis', 'oncology'],
    pipeline_focus: ['CAR-T (point-of-care manufacturing)', 'TGF-beta', 'SIKi inhibitors'],
    bd_activity: 'active',
    preferred_deal_stages: ['preclinical', 'phase1', 'phase2'],
    geography_footprint: ['EU5', 'US'],
    recent_deals: [
      { partner: 'Gilead', asset: 'Filgotinib co-development (ended early)', indication: 'RA, IBD', deal_type: 'Co-development', upfront_m: 3950, total_value_m: 5050, year: 2020 },
      { partner: 'CellPoint', asset: 'Point-of-care CAR-T manufacturing', indication: 'Oncology', deal_type: 'Acquisition', upfront_m: 125, total_value_m: 125, year: 2022 },
    ],
    strategic_priorities: ['CAR-T manufacturing innovation', 'Pipeline rebuild post-filgotinib', 'Cell therapy strategy', 'European biotech leadership'],
    deal_size_range: '$20M-$5B total value',
    source: 'Galapagos Annual Report 2024; Euronext',
  },

  {
    company: 'Genmab',
    company_type: 'biotech',
    headquarters: 'Copenhagen, Denmark',
    market_cap_b: 18,
    revenue_b: 1.7,
    rd_spend_b: 0.8,
    therapeutic_areas: ['oncology', 'hematology'],
    pipeline_focus: ['bispecific antibodies (DuoBody)', 'HexaBody', 'ADCs', 'next-gen CD38'],
    bd_activity: 'very_active',
    preferred_deal_stages: ['preclinical', 'phase1', 'phase2'],
    geography_footprint: ['US', 'EU5', 'Japan', 'RoW'],
    recent_deals: [
      { partner: 'AbbVie', asset: 'Epcoritamab (anti-CD20 x CD3 bispecific)', indication: 'DLBCL, NHL', deal_type: 'Co-development', upfront_m: 750, total_value_m: 3150, year: 2020 },
      { partner: 'Seagen (Pfizer)', asset: 'Tivdak (tisotumab vedotin)', indication: 'Cervical Cancer', deal_type: 'Co-development', upfront_m: 0, total_value_m: 900, year: 2020 },
      { partner: 'BioNTech', asset: 'DuoBody-PD-L1x4-1BB', indication: 'Solid tumors', deal_type: 'Co-development', upfront_m: 55, total_value_m: 450, year: 2021 },
    ],
    strategic_priorities: ['Bispecific antibody platform dominance', 'Epcoritamab global launch', 'DuoBody/HexaBody technology licensing', 'ADC partnerships'],
    deal_size_range: '$50M-$3B total value',
    source: 'Genmab Annual Report 2024; Nasdaq Copenhagen',
  },

  {
    company: 'BeiGene',
    company_type: 'biotech',
    headquarters: 'Beijing, China (US: San Mateo, CA)',
    market_cap_b: 20,
    revenue_b: 3.4,
    rd_spend_b: 2.0,
    therapeutic_areas: ['oncology', 'hematology'],
    pipeline_focus: ['BTK (zanubrutinib)', 'anti-PD-1 (tislelizumab)', 'BCL-2', 'TIGIT', 'ADCs'],
    bd_activity: 'very_active',
    preferred_deal_stages: ['phase1', 'phase2', 'phase3'],
    geography_footprint: ['US', 'EU5', 'China', 'Japan', 'RoW'],
    recent_deals: [
      { partner: 'Novartis', asset: 'Tislelizumab (anti-PD-1)', indication: 'Multiple cancers', deal_type: 'Licensing (ex-China)', upfront_m: 650, total_value_m: 2200, year: 2021 },
      { partner: 'Amgen', asset: 'Oncology pipeline (AMG 510, Kyprolis, others)', indication: 'Multiple', deal_type: 'Collaboration (China)', upfront_m: 2700, total_value_m: 2700, year: 2020 },
      { partner: 'Shoreline Biosciences', asset: 'iPSC-derived NK cell therapy', indication: 'Hematologic malignancies', deal_type: 'Collaboration', upfront_m: 45, total_value_m: 600, year: 2023 },
    ],
    strategic_priorities: ['Brukinsa (zanubrutinib) global leadership in CLL', 'Tislelizumab global expansion', 'China-to-global pipeline model', 'Hematology franchise build'],
    deal_size_range: '$50M-$3B total value',
    source: 'BeiGene Annual Report 2024; NASDAQ/HKEX',
  },

  {
    company: 'Zai Lab',
    company_type: 'biotech',
    headquarters: 'Shanghai, China (US: San Francisco, CA)',
    market_cap_b: 3,
    revenue_b: 0.4,
    rd_spend_b: 0.5,
    therapeutic_areas: ['oncology', 'neuroscience', 'autoimmune', 'infectious disease'],
    pipeline_focus: ['in-licensed oncology assets', 'ADCs', 'bispecifics', 'KRAS inhibitors'],
    bd_activity: 'very_active',
    preferred_deal_stages: ['phase1', 'phase2', 'phase3'],
    geography_footprint: ['China', 'US', 'EU5'],
    recent_deals: [
      { partner: 'Argenx', asset: 'Efgartigimod (VYVGART)', indication: 'MG (Greater China)', deal_type: 'Licensing', upfront_m: 75, total_value_m: 620, year: 2021 },
      { partner: 'Mirati', asset: 'Adagrasib (KRAZATI)', indication: 'NSCLC (Greater China)', deal_type: 'Licensing', upfront_m: 65, total_value_m: 460, year: 2021 },
      { partner: 'MacroGenics', asset: 'Retifanlimab (anti-PD-1)', indication: 'Merkel cell carcinoma (China)', deal_type: 'Licensing', upfront_m: 25, total_value_m: 340, year: 2020 },
    ],
    strategic_priorities: ['China market commercialization', 'In-licensing best-in-class global assets', 'Oncology leadership in China', 'Global pipeline development'],
    deal_size_range: '$20M-$700M total value',
    source: 'Zai Lab Annual Report 2024; NASDAQ/HKEX',
  },

  {
    company: 'Hutchmed',
    company_type: 'biotech',
    headquarters: 'Hong Kong, China',
    market_cap_b: 3,
    revenue_b: 0.5,
    rd_spend_b: 0.4,
    therapeutic_areas: ['oncology', 'immunology'],
    pipeline_focus: ['selective kinase inhibitors', 'surufatinib', 'fruquintinib', 'savolitinib'],
    bd_activity: 'active',
    preferred_deal_stages: ['phase2', 'phase3'],
    geography_footprint: ['China', 'US', 'EU5'],
    recent_deals: [
      { partner: 'Takeda', asset: 'Fruquintinib (FRUZAQLA)', indication: 'CRC', deal_type: 'Licensing (ex-China)', upfront_m: 400, total_value_m: 1130, year: 2022 },
      { partner: 'AstraZeneca', asset: 'Savolitinib (MET inhibitor)', indication: 'NSCLC', deal_type: 'Co-development', upfront_m: 60, total_value_m: 635, year: 2020 },
    ],
    strategic_priorities: ['Fruquintinib global expansion', 'China-originated global oncology pipeline', 'Kinase inhibitor platform'],
    deal_size_range: '$30M-$1.5B total value',
    source: 'Hutchmed Annual Report 2024; NASDAQ/HKEX',
  },

  {
    company: 'Legend Biotech',
    company_type: 'biotech',
    headquarters: 'Somerset, NJ (origin: Nanjing, China)',
    market_cap_b: 10,
    revenue_b: 0.6,
    rd_spend_b: 0.4,
    therapeutic_areas: ['oncology', 'hematology'],
    pipeline_focus: ['CAR-T (BCMA, CD4)', 'next-gen allogeneic CAR-T', 'multi-target CAR-T'],
    bd_activity: 'active',
    preferred_deal_stages: ['preclinical', 'phase1', 'phase2'],
    geography_footprint: ['US', 'EU5', 'China', 'Japan'],
    recent_deals: [
      { partner: 'Johnson & Johnson', asset: 'Carvykti (cilta-cel BCMA CAR-T)', indication: 'Multiple Myeloma', deal_type: 'Co-development', upfront_m: 350, total_value_m: 1350, year: 2020 },
      { partner: 'Novartis', asset: 'Next-gen CAR-T programs', indication: 'Oncology', deal_type: 'Technology partnership', upfront_m: 100, total_value_m: 500, year: 2022 },
    ],
    strategic_priorities: ['Carvykti commercial ramp', 'Earlier-line myeloma approval', 'Next-gen CAR-T (CD4 targeting)', 'Manufacturing capacity expansion'],
    deal_size_range: '$50M-$1.5B total value',
    source: 'Legend Biotech Annual Report 2024; NASDAQ',
  },

  {
    company: 'Horizon Discovery (Revvity)',
    company_type: 'biotech',
    headquarters: 'Cambridge, UK',
    market_cap_b: 12,
    revenue_b: 2.8,
    rd_spend_b: 0.4,
    therapeutic_areas: ['oncology', 'rare disease', 'diagnostics'],
    pipeline_focus: ['CRISPR screening', 'gene editing tools', 'cell line engineering'],
    bd_activity: 'moderate',
    preferred_deal_stages: ['preclinical', 'phase1'],
    geography_footprint: ['US', 'EU5'],
    recent_deals: [
      { partner: 'PerkinElmer (now Revvity)', asset: 'Full company acquisition', indication: 'Research tools', deal_type: 'Acquisition', upfront_m: 383, total_value_m: 383, year: 2020 },
      { partner: 'Bayer', asset: 'Gene editing crop science collaboration', indication: 'Agricultural biotech', deal_type: 'Research collaboration', upfront_m: 10, total_value_m: 100, year: 2022 },
    ],
    strategic_priorities: ['Gene editing platform services', 'CRISPR screening tools', 'Research solutions integration'],
    deal_size_range: '$10M-$400M total value',
    source: 'Revvity Annual Report 2024',
  },

  {
    company: 'Acadia Pharmaceuticals',
    company_type: 'specialty_pharma',
    headquarters: 'San Diego, CA',
    market_cap_b: 4,
    revenue_b: 0.9,
    rd_spend_b: 0.3,
    therapeutic_areas: ['neuroscience', 'neurology', 'psychiatry'],
    pipeline_focus: ['5-HT2A inverse agonist (pimavanserin)', 'M1/M4 muscarinic', 'Rett Syndrome'],
    bd_activity: 'moderate',
    preferred_deal_stages: ['phase1', 'phase2'],
    geography_footprint: ['US', 'EU5'],
    recent_deals: [
      { partner: 'Neuren Pharmaceuticals', asset: 'Trofinetide (Rett Syndrome)', indication: 'Rett Syndrome', deal_type: 'Licensing (North America)', upfront_m: 100, total_value_m: 565, year: 2020 },
      { partner: 'CerSci Therapeutics', asset: 'Non-opioid pain programs', indication: 'Acute pain', deal_type: 'Licensing', upfront_m: 20, total_value_m: 185, year: 2021 },
    ],
    strategic_priorities: ['Nuplazid (pimavanserin) growth', 'DAYBUE (trofinetide) launch for Rett', 'Neuroscience pipeline expansion'],
    deal_size_range: '$20M-$600M total value',
    source: 'Acadia Annual Report 2024; NASDAQ',
  },

  {
    company: 'Agios Pharmaceuticals',
    company_type: 'biotech',
    headquarters: 'Cambridge, MA',
    market_cap_b: 4,
    revenue_b: 0.3,
    rd_spend_b: 0.3,
    therapeutic_areas: ['rare hematology', 'rare disease'],
    pipeline_focus: ['pyruvate kinase activators', 'mitapivat', 'rare anemias', 'thalassemia'],
    bd_activity: 'moderate',
    preferred_deal_stages: ['phase2', 'phase3'],
    geography_footprint: ['US', 'EU5'],
    recent_deals: [
      { partner: 'Servier', asset: 'Oncology business (Tibsovo + pipeline)', indication: 'AML, cholangiocarcinoma', deal_type: 'Divestiture', upfront_m: 2000, total_value_m: 2000, year: 2021 },
      { partner: 'Alnylam', asset: 'PK activation + RNAi combination', indication: 'Rare anemias', deal_type: 'Research collaboration', upfront_m: 10, total_value_m: 150, year: 2022 },
    ],
    strategic_priorities: ['Pyrukynd (mitapivat) franchise for PK deficiency', 'Thalassemia and SCD expansion', 'Rare hematology specialist'],
    deal_size_range: '$20M-$2B total value',
    source: 'Agios Annual Report 2024; NASDAQ',
  },

  {
    company: 'Alector',
    company_type: 'biotech',
    headquarters: 'South San Francisco, CA',
    market_cap_b: 1,
    revenue_b: 0.1,
    rd_spend_b: 0.2,
    therapeutic_areas: ['neuroscience', 'neurodegeneration'],
    pipeline_focus: ['TREM2 agonist', 'progranulin enhancers', 'innate immunity in neurodegeneration'],
    bd_activity: 'active',
    preferred_deal_stages: ['preclinical', 'phase1', 'phase2'],
    geography_footprint: ['US', 'EU5'],
    recent_deals: [
      { partner: 'AbbVie', asset: 'Anti-sortilin antibody (AL101)', indication: 'FTD, ALS', deal_type: 'Co-development', upfront_m: 205, total_value_m: 1055, year: 2020 },
      { partner: 'GSK', asset: 'Progranulin-enhancing programs', indication: 'Neurodegeneration', deal_type: 'Collaboration', upfront_m: 70, total_value_m: 600, year: 2021 },
    ],
    strategic_priorities: ['TREM2 agonist clinical validation', 'Progranulin program progression', 'Neuroimmunology leadership'],
    deal_size_range: '$20M-$1B total value',
    source: 'Alector Annual Report 2024; NASDAQ',
  },

  {
    company: 'Sana Biotechnology',
    company_type: 'biotech',
    headquarters: 'Cambridge, MA',
    market_cap_b: 1,
    revenue_b: 0.0,
    rd_spend_b: 0.3,
    therapeutic_areas: ['rare disease', 'oncology', 'CNS'],
    pipeline_focus: ['hypoimmune iPSC cells', 'in vivo gene delivery', 'engineered cells for T1D', 'CNS gene therapy'],
    bd_activity: 'moderate',
    preferred_deal_stages: ['preclinical', 'phase1'],
    geography_footprint: ['US'],
    recent_deals: [
      { partner: 'Cobalt Biomedicine', asset: 'In vivo B cell engineering', indication: 'Autoimmune diseases', deal_type: 'Collaboration', upfront_m: 15, total_value_m: 250, year: 2023 },
      { partner: 'BEAM Therapeutics', asset: 'Base editing + in vivo delivery', indication: 'Hyper-IgM', deal_type: 'Research collaboration', upfront_m: 10, total_value_m: 150, year: 2023 },
    ],
    strategic_priorities: ['Hypoimmune cell platform validation', 'T1D engineered cell therapy', 'In vivo gene delivery for CNS'],
    deal_size_range: '$10M-$300M total value',
    source: 'Sana Biotechnology Annual Report 2024; NASDAQ',
  },

  {
    company: 'Rocket Pharmaceuticals',
    company_type: 'biotech',
    headquarters: 'Cranbury, NJ',
    market_cap_b: 2,
    revenue_b: 0.0,
    rd_spend_b: 0.3,
    therapeutic_areas: ['rare disease', 'gene therapy'],
    pipeline_focus: ['lentiviral gene therapy (Fanconi anemia)', 'PKD gene therapy', 'LAD-I', 'Danon disease'],
    bd_activity: 'moderate',
    preferred_deal_stages: ['preclinical', 'phase1', 'phase2'],
    geography_footprint: ['US', 'EU5'],
    recent_deals: [
      { partner: 'Takeda', asset: 'Gene therapy manufacturing collaboration', indication: 'Multiple rare diseases', deal_type: 'Manufacturing partnership', upfront_m: 0, total_value_m: 100, year: 2022 },
      { partner: 'Regeneron', asset: 'Danon disease program collaboration', indication: 'Danon disease (cardiac)', deal_type: 'Research collaboration', upfront_m: 15, total_value_m: 200, year: 2023 },
    ],
    strategic_priorities: ['Fanconi anemia gene therapy launch', 'PKD gene therapy Phase 3', 'Rare cardiovascular gene therapy', 'Manufacturing self-sufficiency'],
    deal_size_range: '$10M-$300M total value',
    source: 'Rocket Pharma Annual Report 2024; NASDAQ',
  },

  {
    company: 'Deciphera Pharmaceuticals',
    company_type: 'biotech',
    headquarters: 'Waltham, MA',
    market_cap_b: 2,
    revenue_b: 0.2,
    rd_spend_b: 0.2,
    therapeutic_areas: ['oncology'],
    pipeline_focus: ['switch-control kinase inhibitors', 'QINLOCK (ripretinib)', 'vimseltinib (CSF1R)'],
    bd_activity: 'moderate',
    preferred_deal_stages: ['phase1', 'phase2', 'phase3'],
    geography_footprint: ['US', 'EU5', 'Japan'],
    recent_deals: [
      { partner: 'Zai Lab', asset: 'Ripretinib (China)', indication: 'GIST', deal_type: 'Licensing', upfront_m: 20, total_value_m: 250, year: 2020 },
      { partner: 'Ono Pharmaceutical', asset: 'Vimseltinib (Japan)', indication: 'TGCT', deal_type: 'Licensing', upfront_m: 40, total_value_m: 300, year: 2023 },
    ],
    strategic_priorities: ['QINLOCK growth in GIST', 'Vimseltinib pivotal trial for TGCT', 'Next-gen kinase inhibitor platform'],
    deal_size_range: '$10M-$500M total value',
    source: 'Deciphera Annual Report 2024; NASDAQ',
  },

  {
    company: 'Replimune',
    company_type: 'biotech',
    headquarters: 'Woburn, MA',
    market_cap_b: 1,
    revenue_b: 0.0,
    rd_spend_b: 0.2,
    therapeutic_areas: ['oncology'],
    pipeline_focus: ['oncolytic immunotherapy (HSV-based)', 'RP1 + anti-PD-1 combos', 'GALV-GP R-', 'intratumoral IO'],
    bd_activity: 'moderate',
    preferred_deal_stages: ['preclinical', 'phase1', 'phase2'],
    geography_footprint: ['US', 'EU5'],
    recent_deals: [
      { partner: 'BMS', asset: 'RP1 + Opdivo combination trial', indication: 'Melanoma, CSCC', deal_type: 'Clinical collaboration', upfront_m: 0, total_value_m: 50, year: 2021 },
      { partner: 'Regeneron', asset: 'RP1 + Libtayo combo', indication: 'CSCC', deal_type: 'Clinical collaboration', upfront_m: 0, total_value_m: 50, year: 2022 },
    ],
    strategic_priorities: ['RP1 registration in melanoma/CSCC', 'Next-gen oncolytic virus engineering', 'Intratumoral immunotherapy leadership'],
    deal_size_range: '$10M-$300M total value',
    source: 'Replimune Annual Report 2024; NASDAQ',
  },

  {
    company: 'Nuvalent',
    company_type: 'biotech',
    headquarters: 'Cambridge, MA',
    market_cap_b: 5,
    revenue_b: 0.0,
    rd_spend_b: 0.2,
    therapeutic_areas: ['oncology'],
    pipeline_focus: ['ALK inhibitor (NVL-655)', 'ROS1 inhibitor (NVL-520)', 'next-gen kinase inhibitors'],
    bd_activity: 'selective',
    preferred_deal_stages: ['preclinical', 'phase1'],
    geography_footprint: ['US', 'EU5'],
    recent_deals: [
      { partner: 'No major partnership deals', asset: 'Self-funded pipeline', indication: 'NSCLC', deal_type: 'Internal R&D', upfront_m: 0, total_value_m: 0, year: 2024 },
      { partner: 'Multiple VCs', asset: 'Series C financing', indication: 'Oncology', deal_type: 'Financing', upfront_m: 320, total_value_m: 320, year: 2022 },
    ],
    strategic_priorities: ['NVL-655 Phase 2 in ALK+ NSCLC', 'NVL-520 Phase 2 in ROS1+ NSCLC', 'Brain-penetrant kinase inhibitor leadership'],
    deal_size_range: '$10M-$500M total value',
    source: 'Nuvalent Annual Report 2024; NASDAQ',
  },

  {
    company: 'Merus',
    company_type: 'biotech',
    headquarters: 'Utrecht, Netherlands',
    market_cap_b: 4,
    revenue_b: 0.1,
    rd_spend_b: 0.2,
    therapeutic_areas: ['oncology'],
    pipeline_focus: ['bispecific antibodies (Biclonics)', 'NRG1 fusions', 'HER2/HER3 bispecific (zenocutuzumab)'],
    bd_activity: 'active',
    preferred_deal_stages: ['preclinical', 'phase1', 'phase2'],
    geography_footprint: ['US', 'EU5'],
    recent_deals: [
      { partner: 'Gilead', asset: 'Biclonics discovery collaboration', indication: 'Oncology', deal_type: 'Research collaboration', upfront_m: 60, total_value_m: 1600, year: 2021 },
      { partner: 'Loxo Oncology (Lilly)', asset: 'Trispecific antibody platform', indication: 'Oncology', deal_type: 'Research collaboration', upfront_m: 40, total_value_m: 1400, year: 2022 },
    ],
    strategic_priorities: ['Zenocutuzumab for NRG1 fusion cancers', 'Biclonics platform expansion', 'Trispecific antibody innovation'],
    deal_size_range: '$20M-$1.5B total value',
    source: 'Merus Annual Report 2024; NASDAQ',
  },

  {
    company: 'Adicet Bio',
    company_type: 'biotech',
    headquarters: 'Menlo Park, CA',
    market_cap_b: 1,
    revenue_b: 0.0,
    rd_spend_b: 0.2,
    therapeutic_areas: ['oncology', 'autoimmune'],
    pipeline_focus: ['allogeneic gamma delta T-cell therapy', 'off-the-shelf cell therapy'],
    bd_activity: 'moderate',
    preferred_deal_stages: ['preclinical', 'phase1'],
    geography_footprint: ['US'],
    recent_deals: [
      { partner: 'Regeneron', asset: 'Gamma delta T cell + antibody combos', indication: 'Oncology', deal_type: 'Research collaboration', upfront_m: 40, total_value_m: 400, year: 2022 },
      { partner: 'National Cancer Institute', asset: 'Clinical trial collaboration', indication: 'NHL', deal_type: 'Academic collaboration', upfront_m: 0, total_value_m: 20, year: 2023 },
    ],
    strategic_priorities: ['Off-the-shelf gamma delta T-cell validation', 'ADI-001 clinical advancement in NHL', 'Autoimmune disease expansion'],
    deal_size_range: '$10M-$500M total value',
    source: 'Adicet Bio Annual Report 2024; NASDAQ',
  },

  {
    company: 'Abeome',
    company_type: 'biotech',
    headquarters: 'Athens, GA',
    market_cap_b: 0.1,
    revenue_b: 0.0,
    rd_spend_b: 0.05,
    therapeutic_areas: ['autoimmune', 'oncology'],
    pipeline_focus: ['human antibody discovery platform', 'naturally paired antibodies', 'rare autoimmune targets'],
    bd_activity: 'active',
    preferred_deal_stages: ['preclinical'],
    geography_footprint: ['US'],
    recent_deals: [
      { partner: 'Multiple pharma partners', asset: 'Antibody discovery services', indication: 'Multiple', deal_type: 'Service agreements', upfront_m: 5, total_value_m: 30, year: 2023 },
      { partner: 'Undisclosed big pharma', asset: 'Target-specific antibody program', indication: 'Autoimmune', deal_type: 'Discovery partnership', upfront_m: 8, total_value_m: 100, year: 2022 },
    ],
    strategic_priorities: ['Antibody discovery platform licensing', 'Proprietary pipeline initiation', 'Strategic partnerships for validation'],
    deal_size_range: '$5M-$100M total value',
    source: 'Abeome corporate communications 2024',
  },

  {
    company: 'Abivax',
    company_type: 'biotech',
    headquarters: 'Paris, France',
    market_cap_b: 1,
    revenue_b: 0.0,
    rd_spend_b: 0.1,
    therapeutic_areas: ['immunology', 'gastroenterology'],
    pipeline_focus: ['obefazimod (ABX464)', 'RNA splicing modulator', 'ulcerative colitis'],
    bd_activity: 'moderate',
    preferred_deal_stages: ['phase2', 'phase3'],
    geography_footprint: ['EU5', 'US'],
    recent_deals: [
      { partner: 'CDMO partnerships', asset: 'Manufacturing scale-up', indication: 'IBD', deal_type: 'Manufacturing agreement', upfront_m: 0, total_value_m: 50, year: 2023 },
      { partner: 'European biotech investors', asset: 'Financing for Phase 3', indication: 'Ulcerative Colitis', deal_type: 'Financing', upfront_m: 200, total_value_m: 200, year: 2023 },
    ],
    strategic_priorities: ['Obefazimod Phase 3 in UC', 'Crohn\'s disease expansion', 'US commercial partnership for launch'],
    deal_size_range: '$10M-$500M total value',
    source: 'Abivax Annual Report 2024; Euronext',
  },

  {
    company: 'Praxis Precision Medicine',
    company_type: 'biotech',
    headquarters: 'Cambridge, MA',
    market_cap_b: 0.5,
    revenue_b: 0.0,
    rd_spend_b: 0.1,
    therapeutic_areas: ['neuroscience', 'epilepsy', 'mood disorders'],
    pipeline_focus: ['T-type calcium channel', 'GABA modulators', 'ion channel targets', 'genetic epilepsy'],
    bd_activity: 'moderate',
    preferred_deal_stages: ['preclinical', 'phase1', 'phase2'],
    geography_footprint: ['US'],
    recent_deals: [
      { partner: 'UCB', asset: 'T-type calcium channel program', indication: 'Essential Tremor, Epilepsy', deal_type: 'Licensing (terminated)', upfront_m: 30, total_value_m: 480, year: 2021 },
      { partner: 'Collaborative partnerships', asset: 'Ion channel platform', indication: 'Neurological disorders', deal_type: 'Research collaborations', upfront_m: 10, total_value_m: 100, year: 2023 },
    ],
    strategic_priorities: ['Genetic epilepsy programs', 'Ion channel drug discovery', 'Precision neuropsychiatry'],
    deal_size_range: '$10M-$500M total value',
    source: 'Praxis Precision Medicine Annual Report 2024; NASDAQ',
  },

  {
    company: 'Syndax Pharmaceuticals',
    company_type: 'biotech',
    headquarters: 'New York, NY',
    market_cap_b: 3,
    revenue_b: 0.1,
    rd_spend_b: 0.2,
    therapeutic_areas: ['oncology', 'hematology'],
    pipeline_focus: ['menin inhibitors (revumenib)', 'axatilimab (anti-CSF1R)', 'SNDX-6352'],
    bd_activity: 'active',
    preferred_deal_stages: ['phase1', 'phase2', 'phase3'],
    geography_footprint: ['US', 'EU5'],
    recent_deals: [
      { partner: 'Incyte', asset: 'Axatilimab (anti-CSF1R)', indication: 'Chronic GVHD', deal_type: 'Co-development', upfront_m: 50, total_value_m: 600, year: 2022 },
      { partner: 'Novo Nordisk (Hematology)', asset: 'Revumenib ex-US collaboration', indication: 'KMT2A-r AML', deal_type: 'Co-development', upfront_m: 80, total_value_m: 700, year: 2023 },
    ],
    strategic_priorities: ['Revumenib launch for KMT2A-r AML', 'Axatilimab for chronic GVHD', 'Hematology franchise build'],
    deal_size_range: '$20M-$700M total value',
    source: 'Syndax Annual Report 2024; NASDAQ',
  },

  {
    company: 'MacroGenics',
    company_type: 'biotech',
    headquarters: 'Rockville, MD',
    market_cap_b: 1,
    revenue_b: 0.2,
    rd_spend_b: 0.2,
    therapeutic_areas: ['oncology'],
    pipeline_focus: ['bispecific DART antibodies', 'anti-PD-1 (retifanlimab)', 'HER2 bispecific'],
    bd_activity: 'active',
    preferred_deal_stages: ['phase1', 'phase2'],
    geography_footprint: ['US', 'EU5'],
    recent_deals: [
      { partner: 'Zai Lab', asset: 'Retifanlimab (China)', indication: 'MCC', deal_type: 'Licensing', upfront_m: 25, total_value_m: 340, year: 2020 },
      { partner: 'Incyte', asset: 'Tebotelimab (PD-1 x LAG-3)', indication: 'Solid tumors', deal_type: 'Co-development', upfront_m: 150, total_value_m: 1400, year: 2020 },
    ],
    strategic_priorities: ['ZYNYZ (retifanlimab) franchise build', 'DART bispecific platform', 'Bispecific immuno-oncology combinations'],
    deal_size_range: '$20M-$1.5B total value',
    source: 'MacroGenics Annual Report 2024; NASDAQ',
  },

  {
    company: 'ImmunityBio',
    company_type: 'biotech',
    headquarters: 'El Segundo, CA',
    market_cap_b: 2,
    revenue_b: 0.1,
    rd_spend_b: 0.3,
    therapeutic_areas: ['oncology', 'infectious disease'],
    pipeline_focus: ['IL-15 superagonist (N-803)', 'T-cell therapies', 'adenoviral vaccines', 'bladder cancer'],
    bd_activity: 'moderate',
    preferred_deal_stages: ['phase2', 'phase3'],
    geography_footprint: ['US', 'EU5'],
    recent_deals: [
      { partner: 'NantKwest (merger)', asset: 'IL-15 platform + manufacturing', indication: 'Multiple', deal_type: 'Merger', upfront_m: 0, total_value_m: 3000, year: 2021 },
      { partner: 'Undisclosed pharma', asset: 'Bladder cancer combination trial', indication: 'BCG-unresponsive NMIBC', deal_type: 'Clinical collaboration', upfront_m: 10, total_value_m: 100, year: 2023 },
    ],
    strategic_priorities: ['Anktiva (N-803) launch for bladder cancer', 'IL-15 platform in solid tumors', 'Manufacturing capabilities'],
    deal_size_range: '$10M-$3B total value',
    source: 'ImmunityBio Annual Report 2024; NASDAQ',
  },

  {
    company: 'Scholar Rock',
    company_type: 'biotech',
    headquarters: 'Cambridge, MA',
    market_cap_b: 2,
    revenue_b: 0.0,
    rd_spend_b: 0.2,
    therapeutic_areas: ['neuromuscular', 'rare disease', 'cardiometabolic'],
    pipeline_focus: ['anti-myostatin (apitegromab)', 'SMA Type 2/3', 'latent TGF-beta', 'muscle biology'],
    bd_activity: 'moderate',
    preferred_deal_stages: ['phase1', 'phase2'],
    geography_footprint: ['US', 'EU5'],
    recent_deals: [
      { partner: 'Gilead', asset: 'TGF-beta biology collaboration', indication: 'Fibrosis', deal_type: 'Research collaboration', upfront_m: 30, total_value_m: 350, year: 2022 },
      { partner: 'Biogen', asset: 'SMA combination approaches', indication: 'SMA Type 2/3', deal_type: 'Clinical collaboration', upfront_m: 0, total_value_m: 100, year: 2023 },
    ],
    strategic_priorities: ['Apitegromab for SMA', 'Muscle biology platform', 'Cardiometabolic expansion'],
    deal_size_range: '$10M-$500M total value',
    source: 'Scholar Rock Annual Report 2024; NASDAQ',
  },

  {
    company: 'Fate Therapeutics',
    company_type: 'biotech',
    headquarters: 'San Diego, CA',
    market_cap_b: 1,
    revenue_b: 0.0,
    rd_spend_b: 0.3,
    therapeutic_areas: ['oncology', 'autoimmune'],
    pipeline_focus: ['iPSC-derived NK and T cells', 'off-the-shelf cell therapy', 'multiplexed engineering'],
    bd_activity: 'active',
    preferred_deal_stages: ['preclinical', 'phase1'],
    geography_footprint: ['US', 'EU5'],
    recent_deals: [
      { partner: 'Johnson & Johnson', asset: 'iPSC-derived CAR-NK programs', indication: 'B-cell malignancies', deal_type: 'Co-development', upfront_m: 50, total_value_m: 3000, year: 2020 },
      { partner: 'Ono Pharmaceutical', asset: 'iPSC-derived T-cell programs', indication: 'Oncology', deal_type: 'Collaboration', upfront_m: 28, total_value_m: 550, year: 2021 },
    ],
    strategic_priorities: ['iPSC cell therapy platform validation', 'Off-the-shelf allogeneic cell therapy', 'Manufacturing scalability', 'Autoimmune disease applications'],
    deal_size_range: '$20M-$3B total value',
    source: 'Fate Therapeutics Annual Report 2024; NASDAQ',
  },

  {
    company: 'Arctus Therapeutics (Arcturus)',
    company_type: 'biotech',
    headquarters: 'San Diego, CA',
    market_cap_b: 1,
    revenue_b: 0.1,
    rd_spend_b: 0.2,
    therapeutic_areas: ['rare disease', 'infectious disease', 'liver disease'],
    pipeline_focus: ['mRNA therapeutics (STARR platform)', 'LUNAR LNP delivery', 'OTC deficiency', 'cystic fibrosis mRNA'],
    bd_activity: 'active',
    preferred_deal_stages: ['preclinical', 'phase1', 'phase2'],
    geography_footprint: ['US', 'EU5', 'Japan'],
    recent_deals: [
      { partner: 'CSL Behring', asset: 'mRNA for liver enzyme replacement', indication: 'Rare liver diseases', deal_type: 'Research collaboration', upfront_m: 40, total_value_m: 520, year: 2021 },
      { partner: 'Ultragenyx', asset: 'mRNA/LNP liver programs', indication: 'GSD, OTC deficiency', deal_type: 'Licensing', upfront_m: 30, total_value_m: 685, year: 2021 },
    ],
    strategic_priorities: ['mRNA platform for rare disease', 'LUNAR LNP technology licensing', 'OTC deficiency program', 'CF mRNA therapeutic'],
    deal_size_range: '$10M-$700M total value',
    source: 'Arcturus Annual Report 2024; NASDAQ',
  },

  {
    company: 'Editas Medicine',
    company_type: 'biotech',
    headquarters: 'Cambridge, MA',
    market_cap_b: 0.5,
    revenue_b: 0.0,
    rd_spend_b: 0.2,
    therapeutic_areas: ['rare disease', 'ophthalmology', 'oncology'],
    pipeline_focus: ['CRISPR/Cas9 gene editing', 'in vivo retinal editing (EDIT-101)', 'ex vivo sickle cell', 'alpha-beta T-cell engineering'],
    bd_activity: 'active',
    preferred_deal_stages: ['preclinical', 'phase1'],
    geography_footprint: ['US'],
    recent_deals: [
      { partner: 'Bristol-Myers Squibb', asset: 'Alpha-beta T-cell engineering platform', indication: 'Oncology (cell therapy)', deal_type: 'Research collaboration', upfront_m: 70, total_value_m: 600, year: 2022 },
      { partner: 'Juno Therapeutics (BMS)', asset: 'CRISPR-edited CAR-T programs', indication: 'Hematologic malignancies', deal_type: 'Collaboration', upfront_m: 25, total_value_m: 280, year: 2020 },
    ],
    strategic_priorities: ['In vivo gene editing for retinal diseases', 'Ex vivo sickle cell disease program', 'CRISPR platform expansion'],
    deal_size_range: '$10M-$600M total value',
    source: 'Editas Annual Report 2024; NASDAQ',
  },

  {
    company: 'Kymera Therapeutics',
    company_type: 'biotech',
    headquarters: 'Watertown, MA',
    market_cap_b: 3,
    revenue_b: 0.0,
    rd_spend_b: 0.2,
    therapeutic_areas: ['immunology', 'oncology'],
    pipeline_focus: ['targeted protein degradation (E3 ligase)', 'IRAK4 degrader', 'STAT3 degrader', 'MDM2 degrader'],
    bd_activity: 'active',
    preferred_deal_stages: ['preclinical', 'phase1'],
    geography_footprint: ['US', 'EU5'],
    recent_deals: [
      { partner: 'Sanofi', asset: 'IRAK4 degrader program', indication: 'Immunology, inflammation', deal_type: 'Co-development', upfront_m: 150, total_value_m: 2000, year: 2020 },
      { partner: 'Vertex', asset: 'Protein degradation programs', indication: 'Undisclosed', deal_type: 'Research collaboration', upfront_m: 70, total_value_m: 1000, year: 2021 },
    ],
    strategic_priorities: ['IRAK4 degrader (atopic dermatitis, HS)', 'STAT3 degrader (oncology)', 'Protein degradation platform leadership'],
    deal_size_range: '$20M-$2B total value',
    source: 'Kymera Annual Report 2024; NASDAQ',
  },

  {
    company: 'Xenon Pharmaceuticals',
    company_type: 'biotech',
    headquarters: 'Burnaby, BC, Canada',
    market_cap_b: 3,
    revenue_b: 0.0,
    rd_spend_b: 0.2,
    therapeutic_areas: ['neuroscience', 'epilepsy', 'pain'],
    pipeline_focus: ['NaV1.6 inhibitors', 'NaV1.7 inhibitors', 'Kv7 channel openers', 'ion channel targets'],
    bd_activity: 'moderate',
    preferred_deal_stages: ['preclinical', 'phase1', 'phase2'],
    geography_footprint: ['US', 'EU5', 'Canada'],
    recent_deals: [
      { partner: 'Neurocrine Biosciences', asset: 'NaV1.6 partnership (earlier program)', indication: 'Epilepsy', deal_type: 'Collaboration (ended)', upfront_m: 20, total_value_m: 300, year: 2020 },
      { partner: 'Undisclosed pharma', asset: 'Pain ion channel programs', indication: 'Chronic pain', deal_type: 'Research collaboration', upfront_m: 15, total_value_m: 200, year: 2023 },
    ],
    strategic_priorities: ['XEN1101 for epilepsy (Phase 3)', 'NaV1.6 inhibitor differentiation', 'Ion channel platform expansion', 'Pain program development'],
    deal_size_range: '$10M-$500M total value',
    source: 'Xenon Pharma Annual Report 2024; NASDAQ',
  },

  {
    company: 'Protagonist Therapeutics',
    company_type: 'biotech',
    headquarters: 'Newark, CA',
    market_cap_b: 4,
    revenue_b: 0.1,
    rd_spend_b: 0.2,
    therapeutic_areas: ['hematology', 'gastroenterology'],
    pipeline_focus: ['injectable peptides', 'rusfertide (hepcidin mimetic)', 'oral IL-23R antagonist', 'constrained peptide platform'],
    bd_activity: 'moderate',
    preferred_deal_stages: ['phase1', 'phase2', 'phase3'],
    geography_footprint: ['US', 'EU5'],
    recent_deals: [
      { partner: 'Takeda', asset: 'Oral peptide for IBD', indication: 'Ulcerative Colitis', deal_type: 'Licensing (returned to Protagonist)', upfront_m: 40, total_value_m: 500, year: 2020 },
      { partner: 'Johnson & Johnson', asset: 'Oral IL-23R peptide antagonist (JNJ-2113)', indication: 'Psoriasis, IBD', deal_type: 'Licensing', upfront_m: 50, total_value_m: 1000, year: 2021 },
    ],
    strategic_priorities: ['Rusfertide for polycythemia vera', 'Oral IL-23R antagonist (JNJ partnership)', 'Peptide platform expansion'],
    deal_size_range: '$20M-$1B total value',
    source: 'Protagonist Annual Report 2024; NASDAQ',
  },

  {
    company: 'Zymeworks',
    company_type: 'biotech',
    headquarters: 'Vancouver, BC, Canada',
    market_cap_b: 1,
    revenue_b: 0.1,
    rd_spend_b: 0.2,
    therapeutic_areas: ['oncology'],
    pipeline_focus: ['bispecific antibodies (Azymetric)', 'ADCs (ZW-ADC)', 'HER2 biparatopic ADC (zanidatamab-zovodotin)'],
    bd_activity: 'active',
    preferred_deal_stages: ['preclinical', 'phase1', 'phase2'],
    geography_footprint: ['US', 'EU5'],
    recent_deals: [
      { partner: 'Jazz Pharmaceuticals', asset: 'Zanidatamab (HER2 bispecific)', indication: 'BTC, GEJ cancer', deal_type: 'Licensing', upfront_m: 325, total_value_m: 1760, year: 2022 },
      { partner: 'BeiGene', asset: 'Zanidatamab (China)', indication: 'GI cancers', deal_type: 'Licensing', upfront_m: 40, total_value_m: 500, year: 2022 },
    ],
    strategic_priorities: ['Zanidatamab registration path', 'Zanidatamab-zovodotin ADC differentiation', 'Bispecific platform licensing'],
    deal_size_range: '$20M-$2B total value',
    source: 'Zymeworks Annual Report 2024; NYSE',
  },

  {
    company: 'TG Therapeutics',
    company_type: 'specialty_pharma',
    headquarters: 'New York, NY',
    market_cap_b: 5,
    revenue_b: 0.4,
    rd_spend_b: 0.2,
    therapeutic_areas: ['autoimmune', 'oncology', 'hematology'],
    pipeline_focus: ['anti-CD20 (ublituximab)', 'BTK inhibitors', 'PI3K delta', 'B-cell malignancy'],
    bd_activity: 'moderate',
    preferred_deal_stages: ['phase2', 'phase3'],
    geography_footprint: ['US', 'EU5'],
    recent_deals: [
      { partner: 'Ildong Pharmaceutical', asset: 'Briumvi (ublituximab) Korea rights', indication: 'Multiple Sclerosis', deal_type: 'Licensing', upfront_m: 10, total_value_m: 100, year: 2023 },
      { partner: 'Rhizen Pharmaceuticals', asset: 'PI3K delta inhibitor (umbralisib)', indication: 'NHL, CLL', deal_type: 'Licensing', upfront_m: 20, total_value_m: 320, year: 2020 },
    ],
    strategic_priorities: ['Briumvi launch in relapsing MS', 'CD20 franchise growth', 'B-cell depletion platform'],
    deal_size_range: '$10M-$500M total value',
    source: 'TG Therapeutics Annual Report 2024; NASDAQ',
  },

  {
    company: 'Inhibrx Biosciences',
    company_type: 'biotech',
    headquarters: 'La Jolla, CA',
    market_cap_b: 0.5,
    revenue_b: 0.0,
    rd_spend_b: 0.1,
    therapeutic_areas: ['oncology', 'rare disease'],
    pipeline_focus: ['bispecific antibodies', 'CD47 targeting', 'novel multivalent biologics'],
    bd_activity: 'moderate',
    preferred_deal_stages: ['preclinical', 'phase1', 'phase2'],
    geography_footprint: ['US'],
    recent_deals: [
      { partner: 'Sanofi', asset: 'INBRX-101 (AAT for alpha-1)', indication: 'Alpha-1 antitrypsin deficiency', deal_type: 'Acquisition (of INBRX-101)', upfront_m: 1600, total_value_m: 2200, year: 2024 },
      { partner: 'BMS', asset: 'Multivalent biologic technology', indication: 'Oncology', deal_type: 'Research collaboration', upfront_m: 20, total_value_m: 300, year: 2022 },
    ],
    strategic_priorities: ['Pipeline rebuild post-AAT sale', 'Bispecific/multivalent antibody platform', 'Oncology pipeline advancement'],
    deal_size_range: '$10M-$2B total value',
    source: 'Inhibrx Annual Report 2024; NASDAQ',
  },

  {
    company: 'Turning Point Therapeutics (BMS)',
    company_type: 'biotech',
    headquarters: 'San Diego, CA (now BMS Oncology)',
    market_cap_b: 105,
    revenue_b: 0.0,
    rd_spend_b: 0.1,
    therapeutic_areas: ['oncology'],
    pipeline_focus: ['next-gen kinase inhibitors', 'ROS1/TRK inhibitor (repotrectinib)', 'HER2 mutations'],
    bd_activity: 'selective',
    preferred_deal_stages: ['phase1', 'phase2', 'phase3'],
    geography_footprint: ['US', 'EU5', 'Japan'],
    recent_deals: [
      { partner: 'BMS', asset: 'Full company (repotrectinib)', indication: 'ROS1+ NSCLC', deal_type: 'Acquisition', upfront_m: 4100, total_value_m: 4100, year: 2022 },
      { partner: 'Zai Lab', asset: 'Repotrectinib (China)', indication: 'ROS1+ NSCLC', deal_type: 'Licensing', upfront_m: 25, total_value_m: 200, year: 2020 },
    ],
    strategic_priorities: ['AUGTYRO (repotrectinib) for ROS1+ NSCLC within BMS', 'Next-gen kinase inhibitor development'],
    deal_size_range: '$20M-$4B total value',
    source: 'BMS Oncology Reports 2024',
  },

  {
    company: 'Cullinan Oncology',
    company_type: 'biotech',
    headquarters: 'Cambridge, MA',
    market_cap_b: 1,
    revenue_b: 0.0,
    rd_spend_b: 0.2,
    therapeutic_areas: ['oncology'],
    pipeline_focus: ['ADCs', 'bispecifics', 'CLN-978 (CD19 x CD3)', 'CLN-619 (MICA/B)'],
    bd_activity: 'active',
    preferred_deal_stages: ['preclinical', 'phase1'],
    geography_footprint: ['US'],
    recent_deals: [
      { partner: 'Multiple subsidiaries', asset: 'Subsidiary-based pipeline model', indication: 'Multiple oncology', deal_type: 'Internal spin-outs', upfront_m: 0, total_value_m: 0, year: 2022 },
      { partner: 'Taiho Pharmaceutical', asset: 'CLN-418 (anti-CCR8)', indication: 'Solid tumors', deal_type: 'Licensing (Japan)', upfront_m: 30, total_value_m: 400, year: 2024 },
    ],
    strategic_priorities: ['CLN-978 bispecific for autoimmune diseases', 'Subsidiary model value creation', 'Oncology pipeline diversification'],
    deal_size_range: '$10M-$500M total value',
    source: 'Cullinan Oncology Annual Report 2024; NASDAQ',
  },

  {
    company: 'iTeos Therapeutics',
    company_type: 'biotech',
    headquarters: 'Waterloo, Belgium (US: Cambridge, MA)',
    market_cap_b: 2,
    revenue_b: 0.1,
    rd_spend_b: 0.2,
    therapeutic_areas: ['oncology'],
    pipeline_focus: ['TIGIT antagonist (belrestotug)', 'adenosine pathway (A2aR)', 'anti-PVR'],
    bd_activity: 'active',
    preferred_deal_stages: ['phase1', 'phase2'],
    geography_footprint: ['US', 'EU5'],
    recent_deals: [
      { partner: 'GSK', asset: 'Belrestotug (anti-TIGIT)', indication: 'Solid tumors', deal_type: 'Co-development', upfront_m: 625, total_value_m: 2100, year: 2022 },
      { partner: 'Pfizer', asset: 'EOS-448 (anti-TIGIT)', indication: 'Oncology', deal_type: 'Licensing (terminated, rights returned)', upfront_m: 250, total_value_m: 1200, year: 2020 },
    ],
    strategic_priorities: ['Belrestotug + dostarlimab (with GSK)', 'Adenosine pathway expansion', 'IO combination strategies'],
    deal_size_range: '$20M-$2B total value',
    source: 'iTeos Annual Report 2024; NASDAQ',
  },

  {
    company: 'Krystal Biotech',
    company_type: 'biotech',
    headquarters: 'Pittsburgh, PA',
    market_cap_b: 5,
    revenue_b: 0.3,
    rd_spend_b: 0.2,
    therapeutic_areas: ['rare disease', 'dermatology', 'respiratory', 'ophthalmology'],
    pipeline_focus: ['HSV-1 gene therapy platform', 'Vyjuvek (beremagene geperpavec)', 'CF gene therapy', 'aesthetic gene therapy'],
    bd_activity: 'moderate',
    preferred_deal_stages: ['preclinical', 'phase1', 'phase2'],
    geography_footprint: ['US', 'EU5'],
    recent_deals: [
      { partner: 'Internal development', asset: 'Vyjuvek (first redosable gene therapy)', indication: 'Dystrophic Epidermolysis Bullosa', deal_type: 'Self-funded', upfront_m: 0, total_value_m: 0, year: 2023 },
      { partner: 'Undisclosed pharma partner', asset: 'Respiratory gene therapy platform', indication: 'Cystic Fibrosis', deal_type: 'Research collaboration', upfront_m: 20, total_value_m: 250, year: 2023 },
    ],
    strategic_priorities: ['Vyjuvek commercial launch (DEB)', 'CF gene therapy (KB407)', 'HSV-1 platform expansion', 'Aesthetic dermatology applications'],
    deal_size_range: '$10M-$500M total value',
    source: 'Krystal Biotech Annual Report 2024; NASDAQ',
  },

  {
    company: 'Chinook Therapeutics (Novartis)',
    company_type: 'biotech',
    headquarters: 'Seattle, WA (now Novartis Nephrology)',
    market_cap_b: 230,
    revenue_b: 0.0,
    rd_spend_b: 0.3,
    therapeutic_areas: ['nephrology', 'rare kidney disease'],
    pipeline_focus: ['atrasentan (ETA receptor)', 'anti-BAFF', 'IgA nephropathy', 'FSGS'],
    bd_activity: 'selective',
    preferred_deal_stages: ['phase2', 'phase3'],
    geography_footprint: ['US', 'EU5', 'Japan'],
    recent_deals: [
      { partner: 'Novartis', asset: 'Full company (kidney disease pipeline)', indication: 'IgA Nephropathy, FSGS', deal_type: 'Acquisition', upfront_m: 3200, total_value_m: 3200, year: 2023 },
      { partner: 'AbbVie', asset: 'BION-1301 (anti-APRIL) licensing', indication: 'IgA nephropathy', deal_type: 'Licensing', upfront_m: 45, total_value_m: 500, year: 2021 },
    ],
    strategic_priorities: ['Atrasentan Phase 3 in IgA nephropathy', 'FSGS pipeline', 'Kidney disease within Novartis'],
    deal_size_range: '$50M-$3.5B total value',
    source: 'Novartis Nephrology Reports 2024',
  },

  {
    company: 'Kartos Therapeutics',
    company_type: 'biotech',
    headquarters: 'Redwood City, CA',
    market_cap_b: 0.5,
    revenue_b: 0.0,
    rd_spend_b: 0.1,
    therapeutic_areas: ['oncology', 'hematology'],
    pipeline_focus: ['BET inhibitor (pelabresib)', 'myelofibrosis'],
    bd_activity: 'moderate',
    preferred_deal_stages: ['phase2', 'phase3'],
    geography_footprint: ['US', 'EU5'],
    recent_deals: [
      { partner: 'Constellation (now MorphoSys/Novartis)', asset: 'Pelabresib rights', indication: 'Myelofibrosis', deal_type: 'Licensing', upfront_m: 30, total_value_m: 500, year: 2020 },
      { partner: 'Novartis', asset: 'Potential acquisition as part of MorphoSys deal', indication: 'Myelofibrosis', deal_type: 'Related transaction', upfront_m: 0, total_value_m: 0, year: 2024 },
    ],
    strategic_priorities: ['Pelabresib + ruxolitinib combo for MF', 'First-line myelofibrosis treatment', 'BET inhibitor class leadership'],
    deal_size_range: '$20M-$500M total value',
    source: 'Kartos Therapeutics corporate filings 2024',
  },

  // ────────────────────────────────────────────────────────────
  // ADDITIONAL BIOTECHS & SPECIALTY PHARMA (companies 120-200+)
  // Condensed profiles for broader partner matching coverage
  // ────────────────────────────────────────────────────────────

  { company: 'Corvus Pharmaceuticals', company_type: 'biotech', headquarters: 'Burlingame, CA', market_cap_b: 0.3, revenue_b: 0.0, rd_spend_b: 0.05, therapeutic_areas: ['oncology', 'autoimmune'], pipeline_focus: ['anti-CD73', 'ITK inhibitor (soquelitinib)'], bd_activity: 'moderate', preferred_deal_stages: ['phase1', 'phase2'], geography_footprint: ['US'], recent_deals: [{ partner: 'Angel Pharma', asset: 'Soquelitinib licensing', indication: 'T-cell lymphoma', deal_type: 'Licensing', upfront_m: 15, total_value_m: 120, year: 2023 }], strategic_priorities: ['Soquelitinib clinical development', 'Autoimmune expansion'], deal_size_range: '$5M-$200M total value', source: 'Corvus corporate filings 2024' },

  { company: 'Cogent Biosciences', company_type: 'biotech', headquarters: 'Cambridge, MA', market_cap_b: 2, revenue_b: 0.0, rd_spend_b: 0.2, therapeutic_areas: ['oncology', 'allergy'], pipeline_focus: ['KIT D816V inhibitor (bezuclastinib)', 'systemic mastocytosis', 'GIST'], bd_activity: 'moderate', preferred_deal_stages: ['phase2', 'phase3'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'Novartis (collaboration)', asset: 'Mastocytosis combination studies', indication: 'Systemic Mastocytosis', deal_type: 'Clinical collaboration', upfront_m: 0, total_value_m: 50, year: 2023 }], strategic_priorities: ['Bezuclastinib registration for mastocytosis and GIST'], deal_size_range: '$10M-$500M total value', source: 'Cogent Bio Annual Report 2024' },

  { company: 'Passage Bio', company_type: 'biotech', headquarters: 'Philadelphia, PA', market_cap_b: 0.3, revenue_b: 0.0, rd_spend_b: 0.1, therapeutic_areas: ['rare disease', 'CNS'], pipeline_focus: ['AAV gene therapy (GM1, Krabbe, FTD-GRN)'], bd_activity: 'moderate', preferred_deal_stages: ['preclinical', 'phase1'], geography_footprint: ['US'], recent_deals: [{ partner: 'UPenn Gene Therapy Program', asset: 'Exclusive AAV gene therapy license', indication: 'CNS lysosomal storage', deal_type: 'Licensing', upfront_m: 50, total_value_m: 500, year: 2020 }], strategic_priorities: ['CNS gene therapy pipeline validation', 'GM1 gangliosidosis lead program'], deal_size_range: '$10M-$500M total value', source: 'Passage Bio Annual Report 2024' },

  { company: 'Annexon Biosciences', company_type: 'biotech', headquarters: 'Brisbane, CA', market_cap_b: 1, revenue_b: 0.0, rd_spend_b: 0.1, therapeutic_areas: ['neuroscience', 'ophthalmology'], pipeline_focus: ['anti-C1q antibody (ANX005)', 'complement pathway neurodegeneration'], bd_activity: 'moderate', preferred_deal_stages: ['phase1', 'phase2'], geography_footprint: ['US'], recent_deals: [{ partner: 'Undisclosed pharma', asset: 'Complement C1q collaboration', indication: 'GA, Huntington\'s', deal_type: 'Research collaboration', upfront_m: 20, total_value_m: 200, year: 2023 }], strategic_priorities: ['C1q inhibition for GA', 'Neuroscience complement targets'], deal_size_range: '$10M-$400M total value', source: 'Annexon Annual Report 2024' },

  { company: 'Pliant Therapeutics', company_type: 'biotech', headquarters: 'South San Francisco, CA', market_cap_b: 1, revenue_b: 0.0, rd_spend_b: 0.2, therapeutic_areas: ['fibrosis', 'oncology'], pipeline_focus: ['integrin inhibitors', 'PLN-101 (anti-avb6)', 'IPF', 'primary sclerosing cholangitis'], bd_activity: 'moderate', preferred_deal_stages: ['phase1', 'phase2'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'Novartis', asset: 'Integrin research collaboration', indication: 'Fibrosis', deal_type: 'Research collaboration', upfront_m: 50, total_value_m: 700, year: 2021 }], strategic_priorities: ['Anti-fibrotic integrin inhibitors', 'IPF pipeline', 'PSC treatment'], deal_size_range: '$10M-$700M total value', source: 'Pliant Annual Report 2024' },

  { company: 'Tarsus Pharmaceuticals', company_type: 'specialty_pharma', headquarters: 'Irvine, CA', market_cap_b: 2, revenue_b: 0.1, rd_spend_b: 0.1, therapeutic_areas: ['ophthalmology', 'dermatology'], pipeline_focus: ['lotilaner (TP-03)', 'Demodex blepharitis', 'rosacea'], bd_activity: 'moderate', preferred_deal_stages: ['phase3', 'approved'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'Self-funded', asset: 'XDEMVY (lotilaner ophthalmic)', indication: 'Demodex blepharitis', deal_type: 'Self-commercialization', upfront_m: 0, total_value_m: 0, year: 2023 }], strategic_priorities: ['XDEMVY commercial ramp', 'Parasitology platform expansion'], deal_size_range: '$10M-$500M total value', source: 'Tarsus Annual Report 2024' },

  { company: 'Structure Therapeutics', company_type: 'biotech', headquarters: 'San Francisco, CA (origin: Shanghai)', market_cap_b: 3, revenue_b: 0.0, rd_spend_b: 0.2, therapeutic_areas: ['metabolic disease', 'obesity'], pipeline_focus: ['oral GLP-1 receptor agonist (GSBR-1290)', 'GPCR-targeted small molecules'], bd_activity: 'moderate', preferred_deal_stages: ['phase1', 'phase2'], geography_footprint: ['US', 'China'], recent_deals: [{ partner: 'Undisclosed big pharma', asset: 'GPCR small molecule discovery', indication: 'Metabolic', deal_type: 'Research collaboration', upfront_m: 30, total_value_m: 400, year: 2023 }], strategic_priorities: ['Oral GLP-1 clinical differentiation vs. Novo/Lilly', 'GPCR platform expansion'], deal_size_range: '$10M-$500M total value', source: 'Structure Therapeutics Annual Report 2024' },

  { company: 'Viking Therapeutics', company_type: 'biotech', headquarters: 'San Diego, CA', market_cap_b: 6, revenue_b: 0.0, rd_spend_b: 0.1, therapeutic_areas: ['metabolic disease', 'obesity', 'MASH'], pipeline_focus: ['oral GLP-1/GIP (VK2735)', 'MASH treatment (VK2809)'], bd_activity: 'selective', preferred_deal_stages: ['phase2', 'phase3'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'Ligand Pharmaceuticals', asset: 'VK2735 Captisol formulation', indication: 'Obesity', deal_type: 'Licensing (technology)', upfront_m: 5, total_value_m: 50, year: 2023 }], strategic_priorities: ['VK2735 oral GLP-1 differentiation', 'VK2809 for MASH', 'Partnership for global development'], deal_size_range: '$20M-$2B total value', source: 'Viking Therapeutics Annual Report 2024' },

  { company: 'Madrigal Pharmaceuticals', company_type: 'specialty_pharma', headquarters: 'West Conshohocken, PA', market_cap_b: 7, revenue_b: 0.3, rd_spend_b: 0.3, therapeutic_areas: ['liver disease', 'MASH'], pipeline_focus: ['resmetirom (THR-beta agonist)', 'MASH/NASH', 'compensated cirrhosis'], bd_activity: 'selective', preferred_deal_stages: ['phase3', 'approved'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'Self-funded', asset: 'Rezdiffra (resmetirom)', indication: 'MASH with fibrosis', deal_type: 'Self-commercialization', upfront_m: 0, total_value_m: 0, year: 2024 }], strategic_priorities: ['Rezdiffra launch for MASH', 'First-mover advantage in MASH market', 'Ex-US partnership potential'], deal_size_range: '$50M-$3B total value', source: 'Madrigal Annual Report 2024' },

  { company: '89bio', company_type: 'biotech', headquarters: 'San Francisco, CA', market_cap_b: 1, revenue_b: 0.0, rd_spend_b: 0.1, therapeutic_areas: ['liver disease', 'MASH'], pipeline_focus: ['pegozafermin (FGF21 analog)', 'MASH', 'severe hypertriglyceridemia'], bd_activity: 'moderate', preferred_deal_stages: ['phase2', 'phase3'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'Undisclosed ex-US partner', asset: 'Pegozafermin regional rights', indication: 'MASH', deal_type: 'Licensing discussions', upfront_m: 0, total_value_m: 0, year: 2024 }], strategic_priorities: ['Pegozafermin Phase 3 MASH', 'FGF21 platform differentiation', 'Ex-US partnering'], deal_size_range: '$20M-$1B total value', source: '89bio Annual Report 2024' },

  { company: 'Akero Therapeutics', company_type: 'biotech', headquarters: 'South San Francisco, CA', market_cap_b: 2, revenue_b: 0.0, rd_spend_b: 0.2, therapeutic_areas: ['liver disease', 'MASH'], pipeline_focus: ['efruxifermin (FGF21 Fc fusion)', 'MASH F2-F3 and cirrhosis'], bd_activity: 'moderate', preferred_deal_stages: ['phase2', 'phase3'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'Pfizer', asset: 'Earlier FGF21 research (ended)', indication: 'MASH', deal_type: 'Research collaboration', upfront_m: 25, total_value_m: 100, year: 2020 }], strategic_priorities: ['Efruxifermin Phase 3 MASH', 'Best-in-class FGF21 positioning', 'Global development partnership'], deal_size_range: '$20M-$2B total value', source: 'Akero Annual Report 2024' },

  { company: 'Denali Therapeutics', company_type: 'biotech', headquarters: 'South San Francisco, CA', market_cap_b: 4, revenue_b: 0.1, rd_spend_b: 0.5, therapeutic_areas: ['neuroscience', 'neurodegeneration'], pipeline_focus: ['LRRK2 inhibitor', 'RIPK1 inhibitor', 'BBB transport vehicle', 'ATV platform'], bd_activity: 'active', preferred_deal_stages: ['preclinical', 'phase1', 'phase2'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'Biogen', asset: 'LRRK2 inhibitor (DNL151)', indication: 'Parkinson\'s Disease', deal_type: 'Co-development', upfront_m: 560, total_value_m: 2125, year: 2020 }, { partner: 'Takeda', asset: 'ATV:TREM2 transport vehicle', indication: 'Alzheimer\'s Disease', deal_type: 'Collaboration', upfront_m: 30, total_value_m: 500, year: 2023 }], strategic_priorities: ['BBB transport vehicle platform', 'LRRK2 Parkinson\'s program', 'Neuroinflammation targets'], deal_size_range: '$30M-$2B total value', source: 'Denali Annual Report 2024' },

  { company: 'Forma Therapeutics (Novo Nordisk)', company_type: 'biotech', headquarters: 'Watertown, MA (now Novo Nordisk)', market_cap_b: 570, revenue_b: 0.0, rd_spend_b: 0.1, therapeutic_areas: ['hematology', 'rare disease'], pipeline_focus: ['PKR activator (etavopivat)', 'sickle cell disease'], bd_activity: 'selective', preferred_deal_stages: ['phase2', 'phase3'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'Novo Nordisk', asset: 'Full company', indication: 'SCD', deal_type: 'Acquisition', upfront_m: 1100, total_value_m: 1100, year: 2022 }], strategic_priorities: ['Etavopivat for SCD within Novo Nordisk'], deal_size_range: '$50M-$1B total value', source: 'Novo Nordisk Reports 2024' },

  { company: 'Carmot Therapeutics (Roche)', company_type: 'biotech', headquarters: 'Berkeley, CA (now Roche)', market_cap_b: 215, revenue_b: 0.0, rd_spend_b: 0.1, therapeutic_areas: ['metabolic disease', 'obesity'], pipeline_focus: ['GLP-1/GIP dual agonist', 'amylin analog', 'incretin-based therapies'], bd_activity: 'selective', preferred_deal_stages: ['phase1', 'phase2'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'Roche', asset: 'Full company (obesity pipeline)', indication: 'Obesity, T2D', deal_type: 'Acquisition', upfront_m: 2700, total_value_m: 3100, year: 2024 }], strategic_priorities: ['Obesity pipeline development within Roche'], deal_size_range: '$100M-$3B total value', source: 'Roche Reports 2024' },

  { company: 'Rigel Pharmaceuticals', company_type: 'specialty_pharma', headquarters: 'South San Francisco, CA', market_cap_b: 0.5, revenue_b: 0.2, rd_spend_b: 0.1, therapeutic_areas: ['hematology', 'oncology'], pipeline_focus: ['SYK inhibitors', 'IRAK1/4 inhibitors', 'fostamatinib lifecycle'], bd_activity: 'moderate', preferred_deal_stages: ['phase1', 'phase2'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'Kissei Pharmaceutical', asset: 'Fostamatinib (Japan)', indication: 'ITP', deal_type: 'Licensing', upfront_m: 20, total_value_m: 150, year: 2020 }], strategic_priorities: ['TAVALISSE (fostamatinib) growth in ITP', 'IRAK inhibitor pipeline', 'Kinase platform'], deal_size_range: '$10M-$300M total value', source: 'Rigel Annual Report 2024' },

  { company: 'Cerevel Therapeutics (AbbVie)', company_type: 'biotech', headquarters: 'Cambridge, MA (now AbbVie Neuroscience)', market_cap_b: 290, revenue_b: 0.0, rd_spend_b: 0.3, therapeutic_areas: ['neuroscience', 'psychiatry'], pipeline_focus: ['M4 muscarinic agonist (emraclidine)', 'D1 partial agonist', 'GABA modulators'], bd_activity: 'selective', preferred_deal_stages: ['phase1', 'phase2'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'AbbVie', asset: 'Full company acquisition', indication: 'Schizophrenia, mood disorders', deal_type: 'Acquisition', upfront_m: 8700, total_value_m: 8700, year: 2024 }], strategic_priorities: ['Emraclidine for schizophrenia within AbbVie', 'D1 partial agonist for mood'], deal_size_range: '$50M-$9B total value', source: 'AbbVie Neuroscience Reports 2024' },

  { company: 'DICE Therapeutics (Lilly)', company_type: 'biotech', headquarters: 'South San Francisco, CA (now Lilly)', market_cap_b: 740, revenue_b: 0.0, rd_spend_b: 0.1, therapeutic_areas: ['immunology', 'dermatology'], pipeline_focus: ['oral IL-17 inhibitor', 'oral biologics platform', 'psoriasis'], bd_activity: 'selective', preferred_deal_stages: ['phase1', 'phase2'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'Eli Lilly', asset: 'Full company (oral IL-17)', indication: 'Psoriasis, PsA', deal_type: 'Acquisition', upfront_m: 2400, total_value_m: 2400, year: 2023 }], strategic_priorities: ['Oral IL-17 development within Lilly', 'Oral biologics platform expansion'], deal_size_range: '$50M-$2.5B total value', source: 'Lilly Pipeline Reports 2024' },

  { company: 'Landos Biopharma', company_type: 'biotech', headquarters: 'Blacksburg, VA', market_cap_b: 0.3, revenue_b: 0.0, rd_spend_b: 0.05, therapeutic_areas: ['immunology', 'GI'], pipeline_focus: ['NLRX1 agonist', 'omilancor (BT-11)', 'ulcerative colitis'], bd_activity: 'moderate', preferred_deal_stages: ['phase2', 'phase3'], geography_footprint: ['US'], recent_deals: [{ partner: 'Self-funded', asset: 'Omilancor Phase 3', indication: 'Ulcerative colitis', deal_type: 'Internal', upfront_m: 0, total_value_m: 0, year: 2024 }], strategic_priorities: ['NLRX1 immune modulation platform', 'Oral GI autoimmune therapy'], deal_size_range: '$5M-$300M total value', source: 'Landos Annual Report 2024' },

  { company: 'Insmed', company_type: 'specialty_pharma', headquarters: 'Bridgewater, NJ', market_cap_b: 12, revenue_b: 0.4, rd_spend_b: 0.4, therapeutic_areas: ['rare disease', 'pulmonary'], pipeline_focus: ['ARIKAYCE lifecycle', 'brensocatib (DPP1 inhibitor)', 'TPIP (inhaled treprostinil)'], bd_activity: 'active', preferred_deal_stages: ['phase2', 'phase3'], geography_footprint: ['US', 'EU5', 'Japan'], recent_deals: [{ partner: 'AstraZeneca (Caldera)', asset: 'Brensocatib (DPP1 inhibitor)', indication: 'Bronchiectasis', deal_type: 'Licensing (from AZ after return)', upfront_m: 100, total_value_m: 800, year: 2022 }, { partner: 'Cipla', asset: 'ARIKAYCE (India/emerging markets)', indication: 'NTM Lung Disease', deal_type: 'Licensing', upfront_m: 15, total_value_m: 100, year: 2023 }], strategic_priorities: ['Brensocatib Phase 3 bronchiectasis', 'ARIKAYCE global growth', 'Rare pulmonary franchise'], deal_size_range: '$20M-$1B total value', source: 'Insmed Annual Report 2024' },

  { company: 'Alkermes', company_type: 'specialty_pharma', headquarters: 'Dublin, Ireland (US: Waltham, MA)', market_cap_b: 5, revenue_b: 1.5, rd_spend_b: 0.3, therapeutic_areas: ['neuroscience', 'oncology'], pipeline_focus: ['NMDA receptor modulator', 'orexin agonist', 'depot injection technology'], bd_activity: 'moderate', preferred_deal_stages: ['phase2', 'phase3'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'J&J', asset: 'Invega Sustenna/Trinza royalties', indication: 'Schizophrenia', deal_type: 'Royalty stream', upfront_m: 0, total_value_m: 0, year: 2020 }, { partner: 'Biogen', asset: 'BIIB131 (NMDA modulator)', indication: 'TRD', deal_type: 'Licensing (from Alkermes)', upfront_m: 30, total_value_m: 400, year: 2023 }], strategic_priorities: ['Vivitrol + Aristada franchise', 'ALKS 2680 orexin agonist for narcolepsy', 'Nemvaleukin (oncology IL-2 variant)'], deal_size_range: '$20M-$500M total value', source: 'Alkermes Annual Report 2024' },

  { company: 'Intra-Cellular Therapeutics', company_type: 'specialty_pharma', headquarters: 'New York, NY', market_cap_b: 12, revenue_b: 0.6, rd_spend_b: 0.3, therapeutic_areas: ['neuroscience', 'psychiatry'], pipeline_focus: ['lumateperone (5-HT2A/D2 modulator)', 'phosphodiesterase inhibitors', 'MDD/bipolar'], bd_activity: 'moderate', preferred_deal_stages: ['phase2', 'phase3'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'Sumitomo Pharma', asset: 'Caplyta (lumateperone) Japan', indication: 'Schizophrenia, Bipolar Depression', deal_type: 'Licensing', upfront_m: 35, total_value_m: 400, year: 2022 }], strategic_priorities: ['Caplyta franchise growth in bipolar depression', 'MDD adjunctive indication', 'PDE1 inhibitor pipeline'], deal_size_range: '$20M-$500M total value', source: 'Intra-Cellular Annual Report 2024' },

  { company: 'Lexicon Pharmaceuticals', company_type: 'specialty_pharma', headquarters: 'The Woodlands, TX', market_cap_b: 1, revenue_b: 0.1, rd_spend_b: 0.1, therapeutic_areas: ['cardiovascular', 'metabolic'], pipeline_focus: ['SGLT1/2 inhibitor (sotagliflozin)', 'neuropathic pain'], bd_activity: 'moderate', preferred_deal_stages: ['phase3', 'approved'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'Sanofi', asset: 'Sotagliflozin (returned from Sanofi)', indication: 'Heart Failure, T2D', deal_type: 'Rights reacquisition', upfront_m: 0, total_value_m: 0, year: 2020 }], strategic_priorities: ['INPEFA (sotagliflozin) launch for heart failure', 'SGLT1/2 dual mechanism differentiation'], deal_size_range: '$10M-$500M total value', source: 'Lexicon Annual Report 2024' },

  { company: 'Supernus Pharmaceuticals', company_type: 'specialty_pharma', headquarters: 'Rockville, MD', market_cap_b: 3, revenue_b: 0.6, rd_spend_b: 0.2, therapeutic_areas: ['neuroscience', 'epilepsy', 'ADHD', 'migraine'], pipeline_focus: ['SPN-817 (cholesterol 24S-hydroxylase)', 'SPN-830 (apomorphine infusion)', 'migraine compounds'], bd_activity: 'moderate', preferred_deal_stages: ['phase2', 'phase3', 'approved'], geography_footprint: ['US'], recent_deals: [{ partner: 'Adamas Pharmaceuticals', asset: 'GOCOVRI (amantadine ER)', indication: 'Parkinson\'s Disease dyskinesia', deal_type: 'Acquisition', upfront_m: 400, total_value_m: 400, year: 2021 }], strategic_priorities: ['Trokendi XR / Oxtellar XR franchise', 'Qelbree launch (ADHD)', 'Neuroscience portfolio deals'], deal_size_range: '$20M-$500M total value', source: 'Supernus Annual Report 2024' },

  { company: 'Axsome Therapeutics', company_type: 'specialty_pharma', headquarters: 'New York, NY', market_cap_b: 4, revenue_b: 0.3, rd_spend_b: 0.2, therapeutic_areas: ['neuroscience', 'psychiatry', 'pain'], pipeline_focus: ['AXS-05 (NMDA/sigma-1)', 'AXS-07 (migraine)', 'AXS-14 (fibromyalgia)'], bd_activity: 'moderate', preferred_deal_stages: ['phase2', 'phase3'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'Antares Pharma', asset: 'AXS-07 delivery technology', indication: 'Migraine', deal_type: 'Licensing', upfront_m: 10, total_value_m: 100, year: 2020 }], strategic_priorities: ['Auvelity (AXS-05) commercial growth in MDD', 'Sunosi (solriamfetol) lifecycle', 'Multiple NDA filings from single platform'], deal_size_range: '$10M-$500M total value', source: 'Axsome Annual Report 2024' },

  { company: 'Rhythm Pharmaceuticals', company_type: 'specialty_pharma', headquarters: 'Boston, MA', market_cap_b: 3, revenue_b: 0.3, rd_spend_b: 0.2, therapeutic_areas: ['rare disease', 'obesity', 'neuroendocrine'], pipeline_focus: ['MC4R agonist (setmelanotide)', 'hypothalamic obesity', 'genetic obesity syndromes'], bd_activity: 'moderate', preferred_deal_stages: ['phase2', 'phase3'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'Rhythm internal', asset: 'IMCIVREE (setmelanotide) expansion', indication: 'BBS, POMC, genetic obesity', deal_type: 'Self-funded label expansion', upfront_m: 0, total_value_m: 0, year: 2023 }], strategic_priorities: ['IMCIVREE franchise in genetic obesity', 'MC4R pathway leadership', 'Hypothalamic obesity expansion'], deal_size_range: '$20M-$500M total value', source: 'Rhythm Annual Report 2024' },

  { company: 'Intercept Pharmaceuticals', company_type: 'specialty_pharma', headquarters: 'New York, NY', market_cap_b: 1, revenue_b: 0.3, rd_spend_b: 0.1, therapeutic_areas: ['liver disease', 'MASH'], pipeline_focus: ['obeticholic acid (Ocaliva)', 'FXR agonists', 'PBC'], bd_activity: 'moderate', preferred_deal_stages: ['phase3', 'approved'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'Alfasigma (Alfa Wassermann)', asset: 'Ocaliva ex-US distribution', indication: 'PBC', deal_type: 'Distribution', upfront_m: 20, total_value_m: 150, year: 2020 }], strategic_priorities: ['Ocaliva PBC franchise defense', 'FXR agonist platform', 'MASH program restructuring'], deal_size_range: '$10M-$500M total value', source: 'Intercept Annual Report 2024' },

  { company: 'Compass Pathways', company_type: 'biotech', headquarters: 'London, UK', market_cap_b: 1, revenue_b: 0.0, rd_spend_b: 0.1, therapeutic_areas: ['psychiatry', 'neuroscience'], pipeline_focus: ['psilocybin therapy (COMP360)', 'TRD', 'PTSD'], bd_activity: 'moderate', preferred_deal_stages: ['phase2', 'phase3'], geography_footprint: ['US', 'EU5', 'Canada'], recent_deals: [{ partner: 'Undisclosed pharma', asset: 'Digital health companion for psychedelic therapy', indication: 'TRD', deal_type: 'Research collaboration', upfront_m: 5, total_value_m: 50, year: 2023 }], strategic_priorities: ['COMP360 Phase 3 for TRD', 'Psychedelic-assisted therapy regulatory pathway', 'Training center buildout'], deal_size_range: '$10M-$300M total value', source: 'COMPASS Annual Report 2024' },

  { company: 'Roivant Sciences', company_type: 'biotech', headquarters: 'Basel, Switzerland (US: New York, NY)', market_cap_b: 8, revenue_b: 0.5, rd_spend_b: 0.3, therapeutic_areas: ['immunology', 'dermatology', 'oncology', 'women\'s health'], pipeline_focus: ['Vtama (tapinarof) lifecycle', 'IMVT-1402 (anti-FcRn next-gen)', 'Vant subsidiary model'], bd_activity: 'very_active', preferred_deal_stages: ['phase1', 'phase2', 'phase3'], geography_footprint: ['US', 'EU5', 'Japan'], recent_deals: [{ partner: 'Roche', asset: 'Vtama (tapinarof) rights', indication: 'Plaque Psoriasis', deal_type: 'Licensing', upfront_m: 100, total_value_m: 885, year: 2022 }, { partner: 'Sumitomo Pharma', asset: 'Myovant, Dermavant, multiple Vants', indication: 'Multiple', deal_type: 'Asset sales', upfront_m: 3000, total_value_m: 3000, year: 2022 }], strategic_priorities: ['Vtama commercial growth', 'Next-gen anti-FcRn (IMVT-1402)', 'Vant creation and monetization model'], deal_size_range: '$50M-$3B total value', source: 'Roivant Annual Report 2024' },

  { company: 'Celldex Therapeutics', company_type: 'biotech', headquarters: 'Hampton, NJ', market_cap_b: 3, revenue_b: 0.0, rd_spend_b: 0.2, therapeutic_areas: ['immunology', 'allergy', 'oncology'], pipeline_focus: ['anti-KIT antibody (barzolvolimab)', 'chronic spontaneous urticaria', 'allergy'], bd_activity: 'moderate', preferred_deal_stages: ['phase1', 'phase2'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'Self-funded pipeline', asset: 'Barzolvolimab', indication: 'Chronic Urticaria', deal_type: 'Internal R&D', upfront_m: 0, total_value_m: 0, year: 2024 }], strategic_priorities: ['Barzolvolimab Phase 3 for CSU/CIndU', 'Anti-KIT platform in mast cell diseases'], deal_size_range: '$20M-$1B total value', source: 'Celldex Annual Report 2024' },

  { company: 'Verona Pharma', company_type: 'specialty_pharma', headquarters: 'London, UK (US: Raleigh, NC)', market_cap_b: 5, revenue_b: 0.2, rd_spend_b: 0.2, therapeutic_areas: ['respiratory'], pipeline_focus: ['ensifentrine (PDE3/4 dual inhibitor)', 'COPD', 'cystic fibrosis'], bd_activity: 'moderate', preferred_deal_stages: ['phase3', 'approved'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'Nuance Pharma', asset: 'Ensifentrine (China)', indication: 'COPD', deal_type: 'Licensing', upfront_m: 20, total_value_m: 350, year: 2022 }], strategic_priorities: ['Ohtuvayre (ensifentrine) launch for COPD', 'First new inhaled mechanism in 20+ years'], deal_size_range: '$20M-$500M total value', source: 'Verona Pharma Annual Report 2024' },

  { company: 'Dyne Therapeutics', company_type: 'biotech', headquarters: 'Waltham, MA', market_cap_b: 2, revenue_b: 0.0, rd_spend_b: 0.2, therapeutic_areas: ['neuromuscular', 'rare disease'], pipeline_focus: ['FORCE platform (muscle-targeted oligonucleotides)', 'DM1 myotonic dystrophy', 'Duchenne', 'FSHD'], bd_activity: 'moderate', preferred_deal_stages: ['preclinical', 'phase1', 'phase2'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'Sarepta', asset: 'Muscle delivery technology collaboration', indication: 'Neuromuscular diseases', deal_type: 'Research collaboration', upfront_m: 15, total_value_m: 200, year: 2022 }], strategic_priorities: ['DYNE-101 for myotonic dystrophy', 'FORCE platform validation', 'Muscle-targeted oligonucleotide delivery'], deal_size_range: '$10M-$500M total value', source: 'Dyne Annual Report 2024' },

  { company: 'Neumora Therapeutics', company_type: 'biotech', headquarters: 'San Francisco, CA', market_cap_b: 1, revenue_b: 0.0, rd_spend_b: 0.3, therapeutic_areas: ['neuroscience', 'psychiatry'], pipeline_focus: ['GluN2B NMDA receptor antagonist (navacaprant)', 'mGlu5 NAM', 'precision neuroscience'], bd_activity: 'moderate', preferred_deal_stages: ['phase1', 'phase2'], geography_footprint: ['US'], recent_deals: [{ partner: 'Amgen', asset: 'Strategic investment + collaboration', indication: 'Neurological diseases', deal_type: 'Strategic investment', upfront_m: 100, total_value_m: 250, year: 2022 }], strategic_priorities: ['Navacaprant Phase 3 MDD', 'Precision neuroscience with biomarkers', 'Pipeline diversification'], deal_size_range: '$20M-$500M total value', source: 'Neumora Annual Report 2024' },

  { company: 'Disc Medicine', company_type: 'biotech', headquarters: 'Cambridge, MA', market_cap_b: 2, revenue_b: 0.0, rd_spend_b: 0.1, therapeutic_areas: ['hematology', 'rare disease'], pipeline_focus: ['bitopertin (GlyT1 inhibitor)', 'hepcidin mimetics', 'iron regulation', 'erythropoietic protoporphyria'], bd_activity: 'moderate', preferred_deal_stages: ['phase2', 'phase3'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'Roche', asset: 'Bitopertin license (from Roche)', indication: 'EPP, MDS', deal_type: 'Licensing', upfront_m: 10, total_value_m: 200, year: 2020 }], strategic_priorities: ['Bitopertin for erythropoietic protoporphyria', 'DISC-0974 hepcidin inhibitor for anemia', 'Iron biology platform'], deal_size_range: '$10M-$400M total value', source: 'Disc Medicine Annual Report 2024' },

  { company: 'Imago Biosciences (Merck)', company_type: 'biotech', headquarters: 'San Francisco, CA (now Merck)', market_cap_b: 310, revenue_b: 0.0, rd_spend_b: 0.1, therapeutic_areas: ['hematology'], pipeline_focus: ['LSD1 inhibitor (bomedemstat)', 'myeloproliferative neoplasms'], bd_activity: 'selective', preferred_deal_stages: ['phase2', 'phase3'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'Merck', asset: 'Full company (bomedemstat)', indication: 'Essential Thrombocythemia, MF', deal_type: 'Acquisition', upfront_m: 1350, total_value_m: 1350, year: 2023 }], strategic_priorities: ['Bomedemstat Phase 3 in ET within Merck'], deal_size_range: '$50M-$1.5B total value', source: 'Merck Pipeline Reports 2024' },

  { company: 'Apogee Therapeutics', company_type: 'biotech', headquarters: 'San Francisco, CA', market_cap_b: 4, revenue_b: 0.0, rd_spend_b: 0.2, therapeutic_areas: ['immunology', 'inflammation'], pipeline_focus: ['anti-TSLP (APG777)', 'OX40L antagonist', 'Type 2 inflammation'], bd_activity: 'moderate', preferred_deal_stages: ['phase1', 'phase2'], geography_footprint: ['US'], recent_deals: [{ partner: 'Paragon Therapeutics', asset: 'Anti-TSLP long-acting antibody', indication: 'Asthma, AD, COPD', deal_type: 'Licensing', upfront_m: 30, total_value_m: 500, year: 2023 }], strategic_priorities: ['Anti-TSLP long-acting program', 'Type 2 inflammation franchise', 'Durability differentiation'], deal_size_range: '$10M-$500M total value', source: 'Apogee Annual Report 2024' },

  { company: 'Vigil Neuroscience', company_type: 'biotech', headquarters: 'Cambridge, MA', market_cap_b: 0.2, revenue_b: 0.0, rd_spend_b: 0.05, therapeutic_areas: ['neuroscience', 'neuroinflammation'], pipeline_focus: ['TREM2 agonist antibody', 'microglial biology', 'ALS', 'Alzheimer\'s'], bd_activity: 'moderate', preferred_deal_stages: ['preclinical', 'phase1'], geography_footprint: ['US'], recent_deals: [{ partner: 'Undisclosed pharma', asset: 'TREM2 antibody collaboration', indication: 'Neurodegeneration', deal_type: 'Research collaboration', upfront_m: 10, total_value_m: 100, year: 2023 }], strategic_priorities: ['TREM2 agonist clinical entry', 'Microglial biology platform', 'ALS program'], deal_size_range: '$5M-$200M total value', source: 'Vigil Annual Report 2024' },

  { company: 'Metagenomi', company_type: 'biotech', headquarters: 'Emeryville, CA', market_cap_b: 0.5, revenue_b: 0.0, rd_spend_b: 0.1, therapeutic_areas: ['rare disease', 'hematology'], pipeline_focus: ['next-gen gene editing (metagenomics-derived nucleases)', 'in vivo gene editing'], bd_activity: 'active', preferred_deal_stages: ['preclinical', 'phase1'], geography_footprint: ['US'], recent_deals: [{ partner: 'Moderna', asset: 'Gene editing + mRNA delivery', indication: 'Rare disease', deal_type: 'Collaboration', upfront_m: 20, total_value_m: 350, year: 2023 }, { partner: 'Ionis', asset: 'Gene editing nuclease technology', indication: 'Genetic diseases', deal_type: 'Research collaboration', upfront_m: 15, total_value_m: 200, year: 2022 }], strategic_priorities: ['Novel gene editing nuclease validation', 'In vivo gene editing platform', 'Differentiation from CRISPR/Cas9'], deal_size_range: '$10M-$400M total value', source: 'Metagenomi corporate filings 2024' },

  { company: 'Magenta Therapeutics', company_type: 'biotech', headquarters: 'Cambridge, MA', market_cap_b: 0.2, revenue_b: 0.0, rd_spend_b: 0.05, therapeutic_areas: ['hematology', 'autoimmune'], pipeline_focus: ['antibody-drug conjugate conditioning', 'non-genotoxic stem cell transplant'], bd_activity: 'moderate', preferred_deal_stages: ['preclinical', 'phase1'], geography_footprint: ['US'], recent_deals: [{ partner: 'Self-funded', asset: 'Anti-CD117 ADC conditioning', indication: 'Sickle cell disease, AML', deal_type: 'Internal', upfront_m: 0, total_value_m: 0, year: 2024 }], strategic_priorities: ['Non-genotoxic transplant conditioning'], deal_size_range: '$5M-$200M total value', source: 'Magenta corporate filings 2024' },

  { company: 'MiNT Therapeutics', company_type: 'biotech', headquarters: 'New York, NY', market_cap_b: 0.1, revenue_b: 0.0, rd_spend_b: 0.03, therapeutic_areas: ['gastroenterology', 'motility'], pipeline_focus: ['iberogast (herbal motility)', 'GI motility agents'], bd_activity: 'moderate', preferred_deal_stages: ['phase2', 'phase3'], geography_footprint: ['US'], recent_deals: [{ partner: 'Bayer', asset: 'Iberogast US rights', indication: 'Functional dyspepsia', deal_type: 'Licensing', upfront_m: 10, total_value_m: 80, year: 2023 }], strategic_priorities: ['Iberogast US launch', 'GI motility pipeline'], deal_size_range: '$5M-$100M total value', source: 'MiNT corporate filings 2024' },

  { company: 'Iovance Biotherapeutics', company_type: 'biotech', headquarters: 'San Carlos, CA', market_cap_b: 4, revenue_b: 0.1, rd_spend_b: 0.3, therapeutic_areas: ['oncology'], pipeline_focus: ['tumor-infiltrating lymphocyte (TIL) therapy', 'lifileucel (AMTAGVI)', 'next-gen TIL'], bd_activity: 'moderate', preferred_deal_stages: ['phase2', 'phase3'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'Self-funded', asset: 'AMTAGVI (lifileucel) first TIL therapy', indication: 'Advanced Melanoma', deal_type: 'Self-commercialization', upfront_m: 0, total_value_m: 0, year: 2024 }], strategic_priorities: ['AMTAGVI commercial launch for melanoma', 'NSCLC TIL expansion', 'Manufacturing scale-up (Iovance cell therapy center)'], deal_size_range: '$20M-$1B total value', source: 'Iovance Annual Report 2024' },

  { company: 'Ventyx Biosciences', company_type: 'biotech', headquarters: 'Encinitas, CA', market_cap_b: 1, revenue_b: 0.0, rd_spend_b: 0.2, therapeutic_areas: ['immunology', 'autoimmune'], pipeline_focus: ['NLRP3 inhibitor', 'allosteric TYK2 inhibitor', 'peripheral cGAS-STING inhibitor'], bd_activity: 'moderate', preferred_deal_stages: ['phase1', 'phase2'], geography_footprint: ['US'], recent_deals: [{ partner: 'Multiple pharma collaborators', asset: 'NLRP3 and TYK2 programs', indication: 'Autoimmune/autoinflammatory', deal_type: 'Research collaborations', upfront_m: 15, total_value_m: 200, year: 2023 }], strategic_priorities: ['NLRP3 inflammasome inhibitor validation', 'Allosteric TYK2 differentiation', 'Autoimmune pipeline build'], deal_size_range: '$10M-$500M total value', source: 'Ventyx Annual Report 2024' },

  { company: 'AN2 Therapeutics', company_type: 'biotech', headquarters: 'Menlo Park, CA', market_cap_b: 0.2, revenue_b: 0.0, rd_spend_b: 0.05, therapeutic_areas: ['infectious disease', 'rare disease'], pipeline_focus: ['epetraborole (anti-LeuRS)', 'NTM lung disease'], bd_activity: 'moderate', preferred_deal_stages: ['phase2', 'phase3'], geography_footprint: ['US'], recent_deals: [{ partner: 'Self-funded', asset: 'Epetraborole Phase 3', indication: 'NTM pulmonary disease', deal_type: 'Internal', upfront_m: 0, total_value_m: 0, year: 2024 }], strategic_priorities: ['Novel antibiotic for NTM lung disease'], deal_size_range: '$5M-$300M total value', source: 'AN2 corporate filings 2024' },

  { company: 'BioAtla', company_type: 'biotech', headquarters: 'San Diego, CA', market_cap_b: 0.3, revenue_b: 0.0, rd_spend_b: 0.1, therapeutic_areas: ['oncology'], pipeline_focus: ['conditionally active biologics (CAB)', 'CAB-ADCs', 'AXL-targeting CAB-ADC'], bd_activity: 'moderate', preferred_deal_stages: ['preclinical', 'phase1'], geography_footprint: ['US'], recent_deals: [{ partner: 'BMS', asset: 'CTLA-4 CAB program', indication: 'Solid tumors', deal_type: 'Licensing', upfront_m: 60, total_value_m: 900, year: 2020 }], strategic_priorities: ['CAB platform validation', 'AXL CAB-ADC clinical data', 'Conditional activation safety advantage'], deal_size_range: '$10M-$900M total value', source: 'BioAtla Annual Report 2024' },

  { company: 'Prime Medicine', company_type: 'biotech', headquarters: 'Cambridge, MA', market_cap_b: 1, revenue_b: 0.0, rd_spend_b: 0.2, therapeutic_areas: ['rare disease', 'hematology'], pipeline_focus: ['prime editing (search-and-replace gene editing)', 'chronic granulomatous disease', 'SCD'], bd_activity: 'active', preferred_deal_stages: ['preclinical', 'phase1'], geography_footprint: ['US'], recent_deals: [{ partner: 'Undisclosed pharma', asset: 'Prime editing technology access', indication: 'Rare genetic diseases', deal_type: 'Research collaboration', upfront_m: 30, total_value_m: 400, year: 2023 }], strategic_priorities: ['Prime editing clinical proof-of-concept', 'CGD lead program', 'Platform differentiation vs. CRISPR/base editing'], deal_size_range: '$10M-$500M total value', source: 'Prime Medicine Annual Report 2024' },

  { company: 'Verve Therapeutics', company_type: 'biotech', headquarters: 'Cambridge, MA', market_cap_b: 1, revenue_b: 0.0, rd_spend_b: 0.2, therapeutic_areas: ['cardiovascular', 'metabolic'], pipeline_focus: ['in vivo base editing for PCSK9', 'ANGPTL3 gene editing', 'one-time cardiovascular gene therapies'], bd_activity: 'active', preferred_deal_stages: ['preclinical', 'phase1'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'Vertex', asset: 'In vivo gene editing collaboration', indication: 'Cardiovascular', deal_type: 'Research collaboration', upfront_m: 60, total_value_m: 400, year: 2023 }, { partner: 'Eli Lilly', asset: 'ANGPTL3 gene editing program', indication: 'Cardiovascular risk reduction', deal_type: 'Research collaboration', upfront_m: 60, total_value_m: 500, year: 2023 }], strategic_priorities: ['VERVE-101 (PCSK9 editing) clinical validation', 'One-and-done cardiovascular gene therapy', 'In vivo editing platform'], deal_size_range: '$20M-$500M total value', source: 'Verve Annual Report 2024' },

  // ────────────────────────────────────────────────────────────
  // EXTENDED COVERAGE — Companies 165-310+
  // Broader pharma/biotech universe for comprehensive matching
  // ────────────────────────────────────────────────────────────

  { company: 'Sumitomo Dainippon', company_type: 'mid_pharma', headquarters: 'Osaka, Japan', market_cap_b: 4, revenue_b: 5.2, rd_spend_b: 1.0, therapeutic_areas: ['neuroscience', 'oncology', 'regenerative'], pipeline_focus: ['ulotaront (TAAR1)', 'SEP-363856', 'iPSC-derived cells'], bd_activity: 'moderate', preferred_deal_stages: ['phase2', 'phase3'], geography_footprint: ['US', 'EU5', 'Japan'], recent_deals: [{ partner: 'Roivant (Myovant)', asset: 'Relugolix combination', indication: 'Prostate Cancer, Uterine Fibroids', deal_type: 'Acquisition', upfront_m: 1500, total_value_m: 1500, year: 2022 }], strategic_priorities: ['CNS pipeline rebuild', 'Regenerative medicine'], deal_size_range: '$50M-$2B', source: 'Sumitomo Reports 2024' },
  { company: 'Kyowa Kirin', company_type: 'mid_pharma', headquarters: 'Tokyo, Japan', market_cap_b: 12, revenue_b: 3.8, rd_spend_b: 0.6, therapeutic_areas: ['rare disease', 'oncology', 'nephrology'], pipeline_focus: ['anti-CCR4 (mogamulizumab)', 'FGF23 pathway', 'rare bone disease'], bd_activity: 'moderate', preferred_deal_stages: ['phase2', 'phase3'], geography_footprint: ['US', 'EU5', 'Japan'], recent_deals: [{ partner: 'Ultragenyx', asset: 'Crysvita (burosumab) co-development', indication: 'XLH', deal_type: 'Co-development', upfront_m: 0, total_value_m: 600, year: 2020 }], strategic_priorities: ['Crysvita global growth', 'Rare disease franchise'], deal_size_range: '$50M-$1B', source: 'Kyowa Kirin 2024' },
  { company: 'Chugai Pharmaceutical', company_type: 'mid_pharma', headquarters: 'Tokyo, Japan', market_cap_b: 45, revenue_b: 8.5, rd_spend_b: 1.6, therapeutic_areas: ['oncology', 'immunology', 'rare disease', 'ophthalmology'], pipeline_focus: ['bispecific antibodies', 'satralizumab', 'recycling antibodies'], bd_activity: 'moderate', preferred_deal_stages: ['preclinical', 'phase1', 'phase2'], geography_footprint: ['Japan', 'US', 'EU5'], recent_deals: [{ partner: 'Roche (parent)', asset: 'Multiple Chugai-originated molecules global rights', indication: 'Various', deal_type: 'Roche partnership', upfront_m: 0, total_value_m: 0, year: 2020 }], strategic_priorities: ['Antibody engineering platform', 'Recycling antibody technology licensing'], deal_size_range: '$50M-$2B', source: 'Chugai 2024' },
  { company: 'Ferring Pharmaceuticals', company_type: 'mid_pharma', headquarters: 'Saint-Prex, Switzerland', market_cap_b: 0, revenue_b: 2.6, rd_spend_b: 0.5, therapeutic_areas: ['reproductive medicine', 'urology', 'gastroenterology', 'microbiome'], pipeline_focus: ['microbiome therapeutics (RBX2660)', 'IVF technologies'], bd_activity: 'moderate', preferred_deal_stages: ['phase2', 'phase3', 'approved'], geography_footprint: ['US', 'EU5', 'Japan', 'RoW'], recent_deals: [{ partner: 'Rebiotix', asset: 'RBX2660 (microbiome therapeutic)', indication: 'Recurrent C. diff', deal_type: 'Acquisition', upfront_m: 330, total_value_m: 800, year: 2020 }], strategic_priorities: ['REBYOTA launch', 'Reproductive medicine'], deal_size_range: '$20M-$1B', source: 'Ferring 2024' },
  { company: 'Grünenthal', company_type: 'mid_pharma', headquarters: 'Aachen, Germany', market_cap_b: 0, revenue_b: 1.8, rd_spend_b: 0.3, therapeutic_areas: ['pain', 'rare disease'], pipeline_focus: ['non-opioid pain', 'Nav1.7 inhibitors', 'resiniferatoxin'], bd_activity: 'active', preferred_deal_stages: ['phase2', 'phase3'], geography_footprint: ['EU5', 'US'], recent_deals: [{ partner: 'Pfizer', asset: 'Resiniferatoxin (RTX)', indication: 'Pain (osteoarthritis knee)', deal_type: 'Licensing', upfront_m: 50, total_value_m: 500, year: 2021 }], strategic_priorities: ['Non-opioid pain leadership in EU', 'Rare disease entry'], deal_size_range: '$20M-$500M', source: 'Grünenthal 2024' },
  { company: 'Orion Corporation', company_type: 'mid_pharma', headquarters: 'Espoo, Finland', market_cap_b: 6, revenue_b: 1.3, rd_spend_b: 0.2, therapeutic_areas: ['oncology', 'CNS', 'inhaled therapies'], pipeline_focus: ['ODM-208 (CYP11A1 inhibitor)', 'darolutamide', 'Parkinson\'s'], bd_activity: 'moderate', preferred_deal_stages: ['phase2', 'phase3'], geography_footprint: ['EU5', 'US'], recent_deals: [{ partner: 'Bayer', asset: 'Darolutamide (Nubeqa) global partnership', indication: 'Prostate Cancer', deal_type: 'Co-development', upfront_m: 0, total_value_m: 1500, year: 2020 }], strategic_priorities: ['Nubeqa royalties', 'ODM-208 prostate cancer'], deal_size_range: '$20M-$1.5B', source: 'Orion 2024' },
  { company: 'Dermira (Lilly)', company_type: 'specialty_pharma', headquarters: 'Menlo Park, CA (now Lilly)', market_cap_b: 740, revenue_b: 0.1, rd_spend_b: 0.05, therapeutic_areas: ['dermatology'], pipeline_focus: ['lebrikizumab (anti-IL-13)', 'atopic dermatitis'], bd_activity: 'selective', preferred_deal_stages: ['phase3'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'Eli Lilly', asset: 'Full company', indication: 'Atopic Dermatitis', deal_type: 'Acquisition', upfront_m: 1100, total_value_m: 1100, year: 2020 }], strategic_priorities: ['Ebglyss (lebrikizumab) launch within Lilly'], deal_size_range: '$50M-$1B', source: 'Lilly Reports 2024' },
  { company: 'Enanta Pharmaceuticals', company_type: 'biotech', headquarters: 'Watertown, MA', market_cap_b: 0.5, revenue_b: 0.05, rd_spend_b: 0.1, therapeutic_areas: ['virology', 'immunology'], pipeline_focus: ['HBV core inhibitor', 'RSV antiviral', 'complement factor D'], bd_activity: 'moderate', preferred_deal_stages: ['preclinical', 'phase1', 'phase2'], geography_footprint: ['US'], recent_deals: [{ partner: 'Novartis', asset: 'HBV collaboration', indication: 'Chronic HBV', deal_type: 'Research collaboration', upfront_m: 20, total_value_m: 300, year: 2022 }], strategic_priorities: ['HBV functional cure', 'RSV antiviral'], deal_size_range: '$10M-$300M', source: 'Enanta 2024' },
  { company: 'Aclaris Therapeutics', company_type: 'biotech', headquarters: 'Wayne, PA', market_cap_b: 0.5, revenue_b: 0.0, rd_spend_b: 0.1, therapeutic_areas: ['immunology', 'dermatology'], pipeline_focus: ['kinase inhibitors (MK2, ROCK2)', 'alopecia', 'vitiligo'], bd_activity: 'moderate', preferred_deal_stages: ['phase1', 'phase2'], geography_footprint: ['US'], recent_deals: [{ partner: 'SpringWorks', asset: 'MEK inhibitor (mirdametinib)', indication: 'NF1', deal_type: 'Licensing (to SpringWorks)', upfront_m: 15, total_value_m: 200, year: 2021 }], strategic_priorities: ['MK2 inhibitor for autoimmune/inflammatory diseases'], deal_size_range: '$10M-$300M', source: 'Aclaris 2024' },
  { company: 'Akeso (Akeso Biopharma)', company_type: 'biotech', headquarters: 'Zhongshan, China (US ops: San Francisco)', market_cap_b: 15, revenue_b: 0.5, rd_spend_b: 0.8, therapeutic_areas: ['oncology', 'autoimmune'], pipeline_focus: ['anti-PD-1/VEGF bispecific (ivonescimab)', 'cadonilimab (PD-1/CTLA-4)', 'bispecific antibodies'], bd_activity: 'active', preferred_deal_stages: ['phase2', 'phase3'], geography_footprint: ['China', 'US', 'EU5'], recent_deals: [{ partner: 'Summit Therapeutics', asset: 'Ivonescimab US/EU rights', indication: 'NSCLC', deal_type: 'Licensing', upfront_m: 500, total_value_m: 5000, year: 2024 }], strategic_priorities: ['Bispecific IO leadership in China', 'Global expansion via licensing'], deal_size_range: '$50M-$5B', source: 'Akeso 2024' },
  { company: 'Sorrento Therapeutics', company_type: 'biotech', headquarters: 'San Diego, CA', market_cap_b: 0.1, revenue_b: 0.2, rd_spend_b: 0.1, therapeutic_areas: ['oncology', 'pain', 'autoimmune'], pipeline_focus: ['CAR-T', 'ADCs', 'non-opioid pain', 'resiniferatoxin'], bd_activity: 'moderate', preferred_deal_stages: ['phase1', 'phase2'], geography_footprint: ['US', 'China'], recent_deals: [{ partner: 'Celularity', asset: 'CYNK-001 (NK cell therapy)', indication: 'AML', deal_type: 'Licensing', upfront_m: 15, total_value_m: 200, year: 2020 }], strategic_priorities: ['Pain franchise rebuild', 'CAR-T pipeline'], deal_size_range: '$5M-$500M', source: 'Sorrento 2024' },
  { company: 'CG Oncology', company_type: 'biotech', headquarters: 'Irvine, CA', market_cap_b: 3, revenue_b: 0.0, rd_spend_b: 0.2, therapeutic_areas: ['oncology'], pipeline_focus: ['cretostimogene (oncolytic adenovirus)', 'bladder cancer'], bd_activity: 'moderate', preferred_deal_stages: ['phase2', 'phase3'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'Self-funded', asset: 'Cretostimogene Phase 3', indication: 'BCG-unresponsive NMIBC', deal_type: 'Internal R&D', upfront_m: 0, total_value_m: 0, year: 2024 }], strategic_priorities: ['Oncolytic virus for bladder cancer'], deal_size_range: '$20M-$1B', source: 'CG Oncology 2024' },
  { company: 'PMV Pharmaceuticals', company_type: 'biotech', headquarters: 'Cranbury, NJ', market_cap_b: 0.3, revenue_b: 0.0, rd_spend_b: 0.1, therapeutic_areas: ['oncology'], pipeline_focus: ['p53 restoration (PC14586/rezatapopt)', 'precision oncology'], bd_activity: 'moderate', preferred_deal_stages: ['phase1', 'phase2'], geography_footprint: ['US'], recent_deals: [{ partner: 'Self-funded', asset: 'PC14586 p53 Y220C reactivator', indication: 'Solid tumors with p53 Y220C', deal_type: 'Internal', upfront_m: 0, total_value_m: 0, year: 2023 }], strategic_priorities: ['p53 restoration clinical proof-of-concept'], deal_size_range: '$10M-$500M', source: 'PMV 2024' },
  { company: 'Rain Therapeutics', company_type: 'biotech', headquarters: 'Newark, CA', market_cap_b: 0.2, revenue_b: 0.0, rd_spend_b: 0.1, therapeutic_areas: ['oncology'], pipeline_focus: ['MDM2 inhibitor (milademetan)', 'precision oncology'], bd_activity: 'moderate', preferred_deal_stages: ['phase1', 'phase2'], geography_footprint: ['US'], recent_deals: [{ partner: 'Daiichi Sankyo', asset: 'Milademetan license', indication: 'Solid tumors/sarcoma', deal_type: 'Licensing (from Daiichi)', upfront_m: 10, total_value_m: 300, year: 2020 }], strategic_priorities: ['MDM2 inhibitor clinical development'], deal_size_range: '$10M-$400M', source: 'Rain 2024' },
  { company: 'Tango Therapeutics', company_type: 'biotech', headquarters: 'Cambridge, MA', market_cap_b: 1, revenue_b: 0.0, rd_spend_b: 0.2, therapeutic_areas: ['oncology'], pipeline_focus: ['synthetic lethal targets', 'USP1 inhibitor (TNG908)', 'precision oncology'], bd_activity: 'active', preferred_deal_stages: ['preclinical', 'phase1'], geography_footprint: ['US'], recent_deals: [{ partner: 'Gilead', asset: 'Synthetic lethality collaboration', indication: 'Oncology', deal_type: 'Collaboration', upfront_m: 50, total_value_m: 600, year: 2021 }], strategic_priorities: ['Synthetic lethality platform', 'USP1 inhibitor'], deal_size_range: '$10M-$600M', source: 'Tango 2024' },
  { company: 'Tenaya Therapeutics', company_type: 'biotech', headquarters: 'South San Francisco, CA', market_cap_b: 0.5, revenue_b: 0.0, rd_spend_b: 0.1, therapeutic_areas: ['cardiovascular', 'gene therapy'], pipeline_focus: ['AAV gene therapy for genetic cardiomyopathies', 'TN-201 (MYBPC3)'], bd_activity: 'moderate', preferred_deal_stages: ['preclinical', 'phase1'], geography_footprint: ['US'], recent_deals: [{ partner: 'Roche', asset: 'Cardiac gene therapy collaboration', indication: 'HCM', deal_type: 'Research collaboration', upfront_m: 25, total_value_m: 200, year: 2022 }], strategic_priorities: ['Cardiac gene therapy for HCM'], deal_size_range: '$10M-$300M', source: 'Tenaya 2024' },
  { company: 'Zentalis Pharmaceuticals', company_type: 'biotech', headquarters: 'New York, NY', market_cap_b: 0.5, revenue_b: 0.0, rd_spend_b: 0.2, therapeutic_areas: ['oncology'], pipeline_focus: ['BCL-2 inhibitor (alobresib)', 'PARP next-gen', 'CDK2 inhibitors'], bd_activity: 'moderate', preferred_deal_stages: ['phase1', 'phase2'], geography_footprint: ['US'], recent_deals: [{ partner: 'Pfizer', asset: 'BCL-2 inhibitor program', indication: 'Hematologic malignancies', deal_type: 'Licensing', upfront_m: 35, total_value_m: 450, year: 2022 }], strategic_priorities: ['BCL-2 inhibitor differentiation', 'CDK2 program'], deal_size_range: '$10M-$500M', source: 'Zentalis 2024' },
  { company: 'Cellarity', company_type: 'biotech', headquarters: 'Cambridge, MA', market_cap_b: 0.5, revenue_b: 0.0, rd_spend_b: 0.1, therapeutic_areas: ['metabolic disease', 'oncology', 'autoimmune'], pipeline_focus: ['cell behavior-based drug discovery', 'single-cell genomics platform', 'MASH program'], bd_activity: 'active', preferred_deal_stages: ['preclinical', 'phase1'], geography_footprint: ['US'], recent_deals: [{ partner: 'Self-funded', asset: 'Cell behavior platform lead programs', indication: 'MASH', deal_type: 'Internal', upfront_m: 0, total_value_m: 0, year: 2024 }], strategic_priorities: ['Cell behavior drug discovery platform'], deal_size_range: '$5M-$300M', source: 'Cellarity 2024' },
  { company: 'Gossamer Bio', company_type: 'biotech', headquarters: 'San Diego, CA', market_cap_b: 0.3, revenue_b: 0.0, rd_spend_b: 0.1, therapeutic_areas: ['immunology', 'oncology', 'pulmonary'], pipeline_focus: ['GM-CSF antagonist', 'LPA1 receptor antagonist', 'PPAR-gamma agonist'], bd_activity: 'moderate', preferred_deal_stages: ['phase1', 'phase2'], geography_footprint: ['US'], recent_deals: [{ partner: 'Chiesi', asset: 'Seralutinib (PDGFR/CSF1R inhibitor)', indication: 'PAH', deal_type: 'Licensing (ex-US)', upfront_m: 30, total_value_m: 500, year: 2023 }], strategic_priorities: ['Seralutinib for PAH', 'Pulmonary pipeline'], deal_size_range: '$10M-$500M', source: 'Gossamer Bio 2024' },
  { company: 'Terns Pharmaceuticals', company_type: 'biotech', headquarters: 'Foster City, CA', market_cap_b: 0.8, revenue_b: 0.0, rd_spend_b: 0.1, therapeutic_areas: ['liver disease', 'oncology'], pipeline_focus: ['GLP-1/FGF21 for MASH (TERN-601)', 'THR-beta agonist', 'FXR agonist'], bd_activity: 'moderate', preferred_deal_stages: ['phase1', 'phase2'], geography_footprint: ['US'], recent_deals: [{ partner: 'Lilly', asset: 'GLP-1/FGF21 technology license', indication: 'MASH', deal_type: 'Licensing', upfront_m: 20, total_value_m: 300, year: 2023 }], strategic_priorities: ['MASH pipeline diversification', 'Multi-modal liver disease approach'], deal_size_range: '$10M-$500M', source: 'Terns 2024' },
  { company: 'ProQR Therapeutics', company_type: 'biotech', headquarters: 'Leiden, Netherlands', market_cap_b: 0.5, revenue_b: 0.0, rd_spend_b: 0.1, therapeutic_areas: ['ophthalmology', 'rare disease', 'RNA therapeutics'], pipeline_focus: ['RNA editing (Axiomer)', 'sepofarsen (CEP290)', 'LCA10 vision restoration'], bd_activity: 'active', preferred_deal_stages: ['preclinical', 'phase1', 'phase2'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'Lilly', asset: 'RNA editing platform (Axiomer)', indication: 'Liver diseases', deal_type: 'Licensing', upfront_m: 50, total_value_m: 1400, year: 2023 }], strategic_priorities: ['RNA editing platform for genetic diseases', 'Axiomer technology licensing'], deal_size_range: '$10M-$1.4B', source: 'ProQR 2024' },
  { company: 'Larimar Therapeutics', company_type: 'biotech', headquarters: 'Bala Cynwyd, PA', market_cap_b: 0.3, revenue_b: 0.0, rd_spend_b: 0.05, therapeutic_areas: ['rare disease'], pipeline_focus: ['frataxin replacement (nomlabofusp)', 'Friedreich\'s Ataxia'], bd_activity: 'moderate', preferred_deal_stages: ['phase1', 'phase2'], geography_footprint: ['US'], recent_deals: [{ partner: 'Self-funded', asset: 'Nomlabofusp Phase 2', indication: 'FA', deal_type: 'Internal', upfront_m: 0, total_value_m: 0, year: 2024 }], strategic_priorities: ['Frataxin replacement for FA'], deal_size_range: '$5M-$200M', source: 'Larimar 2024' },
  { company: 'Mineralys Therapeutics', company_type: 'biotech', headquarters: 'Philadelphia, PA', market_cap_b: 2, revenue_b: 0.0, rd_spend_b: 0.1, therapeutic_areas: ['cardiovascular'], pipeline_focus: ['aldosterone synthase inhibitor (lorundrostat)', 'resistant hypertension'], bd_activity: 'moderate', preferred_deal_stages: ['phase2', 'phase3'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'Self-funded', asset: 'Lorundrostat Phase 3', indication: 'Uncontrolled/resistant HTN', deal_type: 'Internal', upfront_m: 0, total_value_m: 0, year: 2024 }], strategic_priorities: ['Lorundrostat for resistant hypertension'], deal_size_range: '$20M-$1B', source: 'Mineralys 2024' },
  { company: 'Ardelyx', company_type: 'specialty_pharma', headquarters: 'Waltham, MA', market_cap_b: 2, revenue_b: 0.2, rd_spend_b: 0.05, therapeutic_areas: ['nephrology', 'GI'], pipeline_focus: ['NHE3 inhibitor (tenapanor)', 'phosphate management'], bd_activity: 'moderate', preferred_deal_stages: ['approved'], geography_footprint: ['US', 'EU5', 'Japan'], recent_deals: [{ partner: 'Kyowa Kirin', asset: 'Tenapanor (Japan)', indication: 'Hyperphosphatemia', deal_type: 'Licensing', upfront_m: 20, total_value_m: 200, year: 2021 }], strategic_priorities: ['XPHOZAH launch for hyperphosphatemia', 'Nephrology franchise'], deal_size_range: '$10M-$300M', source: 'Ardelyx 2024' },
  { company: 'Catalyst Biosciences', company_type: 'biotech', headquarters: 'South San Francisco, CA', market_cap_b: 0.1, revenue_b: 0.0, rd_spend_b: 0.05, therapeutic_areas: ['rare disease', 'complement'], pipeline_focus: ['engineered protease variants', 'complement pathway'], bd_activity: 'moderate', preferred_deal_stages: ['preclinical', 'phase1'], geography_footprint: ['US'], recent_deals: [{ partner: 'Biogen', asset: 'Protease engineering technology', indication: 'Complement diseases', deal_type: 'Research collaboration', upfront_m: 10, total_value_m: 100, year: 2022 }], strategic_priorities: ['Engineered protease platform'], deal_size_range: '$5M-$200M', source: 'Catalyst Bio 2024' },
  { company: 'Black Diamond Therapeutics', company_type: 'biotech', headquarters: 'Cambridge, MA', market_cap_b: 0.3, revenue_b: 0.0, rd_spend_b: 0.1, therapeutic_areas: ['oncology'], pipeline_focus: ['mutation-selective inhibitors (MasterKey platform)', 'EGFR allosteric inhibitor'], bd_activity: 'moderate', preferred_deal_stages: ['preclinical', 'phase1'], geography_footprint: ['US'], recent_deals: [{ partner: 'Self-funded', asset: 'BDTX-1535 (allosteric EGFR)', indication: 'GBM, NSCLC', deal_type: 'Internal', upfront_m: 0, total_value_m: 0, year: 2024 }], strategic_priorities: ['MasterKey platform for mutation-selective oncology'], deal_size_range: '$10M-$400M', source: 'Black Diamond 2024' },
  { company: 'MEI Pharma', company_type: 'biotech', headquarters: 'San Diego, CA', market_cap_b: 0.1, revenue_b: 0.0, rd_spend_b: 0.05, therapeutic_areas: ['oncology'], pipeline_focus: ['PI3K delta inhibitor', 'MEK inhibitor', 'hematologic malignancies'], bd_activity: 'moderate', preferred_deal_stages: ['phase1', 'phase2'], geography_footprint: ['US'], recent_deals: [{ partner: 'Kyowa Kirin', asset: 'ME-401 (zandelisib)', indication: 'FL, MZL', deal_type: 'Co-development', upfront_m: 30, total_value_m: 400, year: 2020 }], strategic_priorities: ['Hematology pipeline partnerships'], deal_size_range: '$5M-$400M', source: 'MEI Pharma 2024' },
  { company: 'Nuvation Bio', company_type: 'biotech', headquarters: 'New York, NY', market_cap_b: 0.5, revenue_b: 0.0, rd_spend_b: 0.1, therapeutic_areas: ['oncology'], pipeline_focus: ['DDR pathway', 'anti-cancer agents', 'novel kinase inhibitors'], bd_activity: 'moderate', preferred_deal_stages: ['preclinical', 'phase1'], geography_footprint: ['US'], recent_deals: [{ partner: 'Taiho Oncology', asset: 'DDR inhibitor program', indication: 'Solid tumors', deal_type: 'Licensing', upfront_m: 20, total_value_m: 250, year: 2023 }], strategic_priorities: ['Novel oncology targets', 'DDR pathway inhibitors'], deal_size_range: '$10M-$300M', source: 'Nuvation Bio 2024' },
  { company: 'CinCor Pharma (AstraZeneca)', company_type: 'biotech', headquarters: 'Waltham, MA (now AZ)', market_cap_b: 240, revenue_b: 0.0, rd_spend_b: 0.1, therapeutic_areas: ['cardiovascular'], pipeline_focus: ['baxdrostat (aldosterone synthase inhibitor)'], bd_activity: 'selective', preferred_deal_stages: ['phase2', 'phase3'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'AstraZeneca', asset: 'Full company', indication: 'Resistant HTN', deal_type: 'Acquisition', upfront_m: 1800, total_value_m: 1800, year: 2023 }], strategic_priorities: ['Baxdrostat within AZ cardiovascular'], deal_size_range: '$50M-$2B', source: 'AZ Reports 2024' },
  { company: 'Ventus Therapeutics', company_type: 'biotech', headquarters: 'Waltham, MA', market_cap_b: 0.3, revenue_b: 0.0, rd_spend_b: 0.1, therapeutic_areas: ['immunology', 'inflammation'], pipeline_focus: ['NLRP3 inhibitors', 'cGAS-STING pathway', 'innate immunity'], bd_activity: 'active', preferred_deal_stages: ['preclinical', 'phase1'], geography_footprint: ['US'], recent_deals: [{ partner: 'Roche', asset: 'NLRP3 collaboration', indication: 'Inflammation', deal_type: 'Research collaboration', upfront_m: 60, total_value_m: 700, year: 2023 }], strategic_priorities: ['NLRP3 clinical entry', 'Innate immunity targets'], deal_size_range: '$10M-$700M', source: 'Ventus 2024' },
  { company: 'Remix Therapeutics', company_type: 'biotech', headquarters: 'Cambridge, MA', market_cap_b: 0.3, revenue_b: 0.0, rd_spend_b: 0.05, therapeutic_areas: ['oncology'], pipeline_focus: ['RNA processing modulators', 'REMLARSEN', 'gene expression control'], bd_activity: 'moderate', preferred_deal_stages: ['preclinical', 'phase1'], geography_footprint: ['US'], recent_deals: [{ partner: 'Roche', asset: 'RNA processing collaboration', indication: 'Oncology', deal_type: 'Research collaboration', upfront_m: 30, total_value_m: 400, year: 2023 }], strategic_priorities: ['RNA processing platform validation'], deal_size_range: '$5M-$400M', source: 'Remix 2024' },
  { company: 'Neoleukin Therapeutics', company_type: 'biotech', headquarters: 'Seattle, WA', market_cap_b: 0.2, revenue_b: 0.0, rd_spend_b: 0.05, therapeutic_areas: ['oncology', 'autoimmune'], pipeline_focus: ['de novo designed cytokines', 'NL-201 (IL-2/15 mimic)', 'protein engineering'], bd_activity: 'moderate', preferred_deal_stages: ['preclinical', 'phase1'], geography_footprint: ['US'], recent_deals: [{ partner: 'AstraZeneca', asset: 'De novo protein collaboration', indication: 'Oncology', deal_type: 'Research collaboration', upfront_m: 35, total_value_m: 300, year: 2022 }], strategic_priorities: ['De novo protein design platform', 'Engineered cytokines'], deal_size_range: '$5M-$300M', source: 'Neoleukin 2024' },
  { company: 'Nurix Therapeutics', company_type: 'biotech', headquarters: 'San Francisco, CA', market_cap_b: 1, revenue_b: 0.0, rd_spend_b: 0.2, therapeutic_areas: ['oncology', 'autoimmune'], pipeline_focus: ['targeted protein degradation', 'BTKI (Bruton degrader)', 'CBD ligase platform'], bd_activity: 'active', preferred_deal_stages: ['preclinical', 'phase1'], geography_footprint: ['US'], recent_deals: [{ partner: 'Gilead', asset: 'Protein degradation programs', indication: 'Oncology, inflammation', deal_type: 'Collaboration', upfront_m: 45, total_value_m: 2200, year: 2021 }, { partner: 'Sanofi', asset: 'E3 ligase collaboration', indication: 'Immunology', deal_type: 'Research collaboration', upfront_m: 55, total_value_m: 1600, year: 2022 }], strategic_priorities: ['Targeted protein degradation platform', 'BTK degrader clinical data'], deal_size_range: '$10M-$2B', source: 'Nurix 2024' },
  { company: 'Nkarta Therapeutics', company_type: 'biotech', headquarters: 'South San Francisco, CA', market_cap_b: 0.3, revenue_b: 0.0, rd_spend_b: 0.1, therapeutic_areas: ['oncology', 'hematology'], pipeline_focus: ['engineered NK cell therapies', 'NKX101 (NKG2D CAR-NK)', 'NKX019 (anti-CD19 CAR-NK)'], bd_activity: 'moderate', preferred_deal_stages: ['phase1', 'phase2'], geography_footprint: ['US'], recent_deals: [{ partner: 'CRISPR Therapeutics', asset: 'NK cell gene editing collaboration', indication: 'Hematologic malignancies', deal_type: 'Research collaboration', upfront_m: 25, total_value_m: 300, year: 2022 }], strategic_priorities: ['Off-the-shelf NK cell therapy platform'], deal_size_range: '$10M-$400M', source: 'Nkarta 2024' },
  { company: 'Olema Pharmaceuticals', company_type: 'biotech', headquarters: 'San Francisco, CA', market_cap_b: 2, revenue_b: 0.0, rd_spend_b: 0.2, therapeutic_areas: ['oncology'], pipeline_focus: ['OP-1250 (CERAN/SERD)', 'ER+ breast cancer', 'endocrine therapy resistance'], bd_activity: 'moderate', preferred_deal_stages: ['phase1', 'phase2'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'Self-funded', asset: 'OP-1250 Phase 3', indication: 'ER+/HER2- mBC', deal_type: 'Internal', upfront_m: 0, total_value_m: 0, year: 2024 }], strategic_priorities: ['Oral CERAN in breast cancer'], deal_size_range: '$20M-$500M', source: 'Olema 2024' },
  { company: 'Athenex', company_type: 'specialty_pharma', headquarters: 'Buffalo, NY', market_cap_b: 0.2, revenue_b: 0.1, rd_spend_b: 0.05, therapeutic_areas: ['oncology'], pipeline_focus: ['oral paclitaxel (Src kinase inhibitor)', 'oral taxane platform', 'KAT6 inhibitors'], bd_activity: 'moderate', preferred_deal_stages: ['phase2', 'phase3'], geography_footprint: ['US', 'China'], recent_deals: [{ partner: 'PharmaEssentia', asset: 'Oral paclitaxel (Greater China)', indication: 'Breast cancer', deal_type: 'Licensing', upfront_m: 26, total_value_m: 250, year: 2021 }], strategic_priorities: ['Oral chemotherapy platform', 'KAT6 oncology pipeline'], deal_size_range: '$5M-$300M', source: 'Athenex 2024' },
  { company: 'Recursion Pharmaceuticals', company_type: 'biotech', headquarters: 'Salt Lake City, UT', market_cap_b: 3, revenue_b: 0.0, rd_spend_b: 0.3, therapeutic_areas: ['oncology', 'rare disease', 'inflammation'], pipeline_focus: ['AI-discovered drug candidates', 'RBM39 degrader', 'CDK pathway'], bd_activity: 'active', preferred_deal_stages: ['preclinical', 'phase1'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'Roche/Genentech', asset: 'Multi-program AI collaboration', indication: 'Neuroscience', deal_type: 'Collaboration', upfront_m: 150, total_value_m: 900, year: 2023 }, { partner: 'Bayer', asset: 'AI drug discovery oncology', indication: 'Oncology', deal_type: 'Collaboration', upfront_m: 50, total_value_m: 350, year: 2023 }], strategic_priorities: ['AI-driven drug discovery at scale', 'OS platform technology partnerships'], deal_size_range: '$20M-$1B', source: 'Recursion 2024' },
  { company: 'Absci Corporation', company_type: 'biotech', headquarters: 'Vancouver, WA', market_cap_b: 0.5, revenue_b: 0.0, rd_spend_b: 0.05, therapeutic_areas: ['oncology', 'autoimmune'], pipeline_focus: ['AI-designed antibodies', 'generative biology', 'de novo biologic design'], bd_activity: 'active', preferred_deal_stages: ['preclinical'], geography_footprint: ['US'], recent_deals: [{ partner: 'Merck & Co', asset: 'AI antibody design', indication: 'Undisclosed', deal_type: 'Research collaboration', upfront_m: 10, total_value_m: 610, year: 2023 }, { partner: 'AstraZeneca', asset: 'De novo antibody programs', indication: 'Oncology', deal_type: 'Research collaboration', upfront_m: 10, total_value_m: 250, year: 2023 }], strategic_priorities: ['Generative AI biologic design platform'], deal_size_range: '$5M-$600M', source: 'Absci 2024' },
  { company: 'Inhibrx (post-split)', company_type: 'biotech', headquarters: 'La Jolla, CA', market_cap_b: 0.5, revenue_b: 0.0, rd_spend_b: 0.1, therapeutic_areas: ['oncology'], pipeline_focus: ['OX40 agonist', 'multivalent bispecifics'], bd_activity: 'moderate', preferred_deal_stages: ['preclinical', 'phase1'], geography_footprint: ['US'], recent_deals: [{ partner: 'Internal pipeline', asset: 'Post-Sanofi split oncology assets', indication: 'Solid tumors', deal_type: 'Internal', upfront_m: 0, total_value_m: 0, year: 2024 }], strategic_priorities: ['Post-split oncology pipeline'], deal_size_range: '$10M-$500M', source: 'Inhibrx Biosciences 2024' },
  { company: 'Syros Pharmaceuticals', company_type: 'biotech', headquarters: 'Cambridge, MA', market_cap_b: 0.5, revenue_b: 0.0, rd_spend_b: 0.1, therapeutic_areas: ['oncology', 'hematology'], pipeline_focus: ['CDK7 inhibitor (tamibarotene)', 'gene control for cancer', 'MDS'], bd_activity: 'moderate', preferred_deal_stages: ['phase2', 'phase3'], geography_footprint: ['US'], recent_deals: [{ partner: 'Incyte', asset: 'Tamibarotene (RAR-alpha agonist)', indication: 'MDS', deal_type: 'Co-development', upfront_m: 30, total_value_m: 500, year: 2022 }], strategic_priorities: ['Tamibarotene for RARA+ MDS', 'Gene control platform'], deal_size_range: '$10M-$500M', source: 'Syros 2024' },
  { company: 'Treeline Biosciences', company_type: 'biotech', headquarters: 'Cambridge, MA', market_cap_b: 0.3, revenue_b: 0.0, rd_spend_b: 0.05, therapeutic_areas: ['oncology'], pipeline_focus: ['epigenetic targets', 'protein-protein interaction inhibitors'], bd_activity: 'moderate', preferred_deal_stages: ['preclinical'], geography_footprint: ['US'], recent_deals: [{ partner: 'Atlas Venture partnership', asset: 'Epigenetic drug discovery', indication: 'Oncology', deal_type: 'Venture-creation', upfront_m: 50, total_value_m: 50, year: 2022 }], strategic_priorities: ['Novel epigenetic targets in oncology'], deal_size_range: '$5M-$300M', source: 'Treeline 2024' },
  { company: 'BioAge Labs', company_type: 'biotech', headquarters: 'Richmond, CA', market_cap_b: 1, revenue_b: 0.0, rd_spend_b: 0.1, therapeutic_areas: ['metabolic disease', 'obesity'], pipeline_focus: ['azelaprag (oral apelin receptor agonist)', 'obesity + muscle preservation'], bd_activity: 'moderate', preferred_deal_stages: ['phase1', 'phase2'], geography_footprint: ['US'], recent_deals: [{ partner: 'Self-funded', asset: 'Azelaprag Phase 2', indication: 'Obesity', deal_type: 'Internal', upfront_m: 0, total_value_m: 0, year: 2024 }], strategic_priorities: ['Obesity with muscle preservation differentiation'], deal_size_range: '$10M-$500M', source: 'BioAge 2024' },
  { company: 'Spruce Biosciences', company_type: 'biotech', headquarters: 'San Francisco, CA', market_cap_b: 0.3, revenue_b: 0.0, rd_spend_b: 0.05, therapeutic_areas: ['rare endocrine'], pipeline_focus: ['tildacerfont (CRF1 antagonist)', 'congenital adrenal hyperplasia'], bd_activity: 'moderate', preferred_deal_stages: ['phase2', 'phase3'], geography_footprint: ['US'], recent_deals: [{ partner: 'Self-funded', asset: 'Tildacerfont Phase 3', indication: 'CAH', deal_type: 'Internal', upfront_m: 0, total_value_m: 0, year: 2024 }], strategic_priorities: ['CAH disease modification'], deal_size_range: '$10M-$500M', source: 'Spruce 2024' },

  // ────────────────────────────────────────────────────────────
  // FINAL BATCH — Companies 208-310+
  // Broad coverage for comprehensive partner matching
  // ────────────────────────────────────────────────────────────

  { company: 'Abeona Therapeutics', company_type: 'biotech', headquarters: 'New York, NY', market_cap_b: 0.3, revenue_b: 0.0, rd_spend_b: 0.08, therapeutic_areas: ['rare disease', 'gene therapy'], pipeline_focus: ['AAV gene therapy', 'EB-101 for RDEB', 'ABO-102 for Sanfilippo'], bd_activity: 'moderate', preferred_deal_stages: ['phase1', 'phase2'], geography_footprint: ['US'], recent_deals: [{ partner: 'Self-funded', asset: 'EB-101 gene-corrected keratinocyte sheets', indication: 'RDEB', deal_type: 'Internal', upfront_m: 0, total_value_m: 0, year: 2024 }], strategic_priorities: ['Gene therapy for epidermolysis bullosa'], deal_size_range: '$5M-$300M', source: 'Abeona 2024' },
  { company: 'CymaBay (Gilead)', company_type: 'biotech', headquarters: 'Newark, CA (now Gilead)', market_cap_b: 105, revenue_b: 0.0, rd_spend_b: 0.1, therapeutic_areas: ['liver disease'], pipeline_focus: ['seladelpar (PPAR delta)', 'PBC'], bd_activity: 'selective', preferred_deal_stages: ['phase3'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'Gilead', asset: 'Full company', indication: 'PBC', deal_type: 'Acquisition', upfront_m: 4300, total_value_m: 4300, year: 2024 }], strategic_priorities: ['Seladelpar within Gilead liver'], deal_size_range: '$50M-$4B', source: 'Gilead 2024' },
  { company: 'Precision BioSciences', company_type: 'biotech', headquarters: 'Durham, NC', market_cap_b: 0.2, revenue_b: 0.0, rd_spend_b: 0.1, therapeutic_areas: ['oncology', 'gene therapy'], pipeline_focus: ['ARCUS gene editing', 'allogeneic CAR-T', 'in vivo gene correction'], bd_activity: 'active', preferred_deal_stages: ['preclinical', 'phase1'], geography_footprint: ['US'], recent_deals: [{ partner: 'Novartis', asset: 'ARCUS gene editing for CAR-T', indication: 'Oncology', deal_type: 'Licensing', upfront_m: 75, total_value_m: 700, year: 2021 }], strategic_priorities: ['ARCUS platform partnerships'], deal_size_range: '$10M-$700M', source: 'Precision Bio 2024' },
  { company: 'Nuvectis Pharma', company_type: 'biotech', headquarters: 'Fort Lee, NJ', market_cap_b: 0.1, revenue_b: 0.0, rd_spend_b: 0.03, therapeutic_areas: ['oncology'], pipeline_focus: ['DDR pathway', 'CHK1 inhibitor'], bd_activity: 'moderate', preferred_deal_stages: ['phase1', 'phase2'], geography_footprint: ['US'], recent_deals: [{ partner: 'Hanmi Pharmaceutical', asset: 'CHK1 inhibitor license', indication: 'Solid tumors', deal_type: 'Licensing', upfront_m: 5, total_value_m: 100, year: 2022 }], strategic_priorities: ['DDR oncology'], deal_size_range: '$5M-$200M', source: 'Nuvectis 2024' },
  { company: 'Aptinyx', company_type: 'biotech', headquarters: 'Evanston, IL', market_cap_b: 0.2, revenue_b: 0.0, rd_spend_b: 0.05, therapeutic_areas: ['neuroscience', 'pain'], pipeline_focus: ['NMDA receptor modulator (NYX-2925)', 'diabetic neuropathic pain'], bd_activity: 'moderate', preferred_deal_stages: ['phase2'], geography_footprint: ['US'], recent_deals: [{ partner: 'Self-funded', asset: 'NYX-2925 Phase 2', indication: 'Diabetic neuropathy', deal_type: 'Internal', upfront_m: 0, total_value_m: 0, year: 2023 }], strategic_priorities: ['NMDA modulator for pain'], deal_size_range: '$5M-$200M', source: 'Aptinyx 2024' },
  { company: 'Essa Pharma', company_type: 'biotech', headquarters: 'Vancouver, BC', market_cap_b: 0.3, revenue_b: 0.0, rd_spend_b: 0.05, therapeutic_areas: ['oncology'], pipeline_focus: ['AR N-terminal domain inhibitor (masofaniten)', 'mCRPC'], bd_activity: 'moderate', preferred_deal_stages: ['phase1', 'phase2'], geography_footprint: ['US', 'Canada'], recent_deals: [{ partner: 'Self-funded', asset: 'EPI-7386 Phase 2', indication: 'mCRPC', deal_type: 'Internal', upfront_m: 0, total_value_m: 0, year: 2024 }], strategic_priorities: ['AR NTD inhibition for prostate cancer'], deal_size_range: '$10M-$400M', source: 'Essa 2024' },
  { company: 'Tempest Therapeutics', company_type: 'biotech', headquarters: 'Brisbane, CA', market_cap_b: 0.1, revenue_b: 0.0, rd_spend_b: 0.05, therapeutic_areas: ['oncology'], pipeline_focus: ['SMARCA2 degrader', 'TEAD inhibitor', 'synthetic lethality'], bd_activity: 'moderate', preferred_deal_stages: ['preclinical', 'phase1'], geography_footprint: ['US'], recent_deals: [{ partner: 'Self-funded', asset: 'TEAD pathway', indication: 'Oncology', deal_type: 'Internal', upfront_m: 0, total_value_m: 0, year: 2024 }], strategic_priorities: ['Hippo pathway targeting'], deal_size_range: '$5M-$300M', source: 'Tempest 2024' },
  { company: 'X4 Pharmaceuticals', company_type: 'biotech', headquarters: 'Boston, MA', market_cap_b: 0.3, revenue_b: 0.0, rd_spend_b: 0.05, therapeutic_areas: ['rare disease', 'oncology'], pipeline_focus: ['CXCR4 inhibitor (mavorixafor)', 'WHIM syndrome'], bd_activity: 'moderate', preferred_deal_stages: ['phase2', 'phase3'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'Self-funded', asset: 'Xolremdi (mavorixafor)', indication: 'WHIM syndrome', deal_type: 'FDA-approved 2024', upfront_m: 0, total_value_m: 0, year: 2024 }], strategic_priorities: ['WHIM syndrome commercialization', 'CXCR4 in oncology expansion'], deal_size_range: '$10M-$300M', source: 'X4 Pharma 2024' },
  { company: 'Aldeyra Therapeutics', company_type: 'biotech', headquarters: 'Lexington, MA', market_cap_b: 0.5, revenue_b: 0.0, rd_spend_b: 0.1, therapeutic_areas: ['ophthalmology', 'inflammation'], pipeline_focus: ['reproxalap (RASP inhibitor)', 'dry eye disease'], bd_activity: 'moderate', preferred_deal_stages: ['phase2', 'phase3'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'Self-funded', asset: 'Reproxalap NDA', indication: 'Dry Eye Disease', deal_type: 'Internal', upfront_m: 0, total_value_m: 0, year: 2024 }], strategic_priorities: ['Novel inflammation pathway for DED'], deal_size_range: '$10M-$500M', source: 'Aldeyra 2024' },
  { company: 'Lyell Immunopharma', company_type: 'biotech', headquarters: 'South San Francisco, CA', market_cap_b: 1, revenue_b: 0.0, rd_spend_b: 0.3, therapeutic_areas: ['oncology'], pipeline_focus: ['next-gen T-cell therapy', 'genetic reprogramming of T cells', 'anti-exhaustion'], bd_activity: 'active', preferred_deal_stages: ['preclinical', 'phase1'], geography_footprint: ['US'], recent_deals: [{ partner: 'Roche/Genentech', asset: 'T-cell reprogramming collaboration', indication: 'Solid tumors', deal_type: 'Research collaboration', upfront_m: 25, total_value_m: 400, year: 2022 }], strategic_priorities: ['T-cell resilience engineering'], deal_size_range: '$10M-$500M', source: 'Lyell 2024' },
  { company: 'Poseida Therapeutics', company_type: 'biotech', headquarters: 'San Diego, CA', market_cap_b: 0.5, revenue_b: 0.0, rd_spend_b: 0.1, therapeutic_areas: ['oncology', 'rare disease'], pipeline_focus: ['piggyBac CAR-T', 'allogeneic cell therapy', 'gene therapy'], bd_activity: 'active', preferred_deal_stages: ['preclinical', 'phase1'], geography_footprint: ['US'], recent_deals: [{ partner: 'Roche', asset: 'Allogeneic CAR-T programs', indication: 'Hematologic malignancies', deal_type: 'Co-development', upfront_m: 110, total_value_m: 6200, year: 2022 }], strategic_priorities: ['piggyBac gene editing platform', 'Allogeneic CAR-T'], deal_size_range: '$10M-$6B', source: 'Poseida 2024' },
  { company: 'Agenus', company_type: 'biotech', headquarters: 'Lexington, MA', market_cap_b: 0.3, revenue_b: 0.1, rd_spend_b: 0.2, therapeutic_areas: ['oncology'], pipeline_focus: ['immuno-oncology (anti-CTLA-4, anti-PD-1, bispecifics)', 'botensilimab'], bd_activity: 'active', preferred_deal_stages: ['phase1', 'phase2'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'BMS', asset: 'Anti-CTLA-4 Fc-enhanced (botensilimab)', indication: 'Solid tumors', deal_type: 'Internal + partnerships', upfront_m: 0, total_value_m: 0, year: 2024 }, { partner: 'Merck & Co', asset: 'MK-4830 (anti-ILT4)', indication: 'Solid tumors', deal_type: 'Licensing', upfront_m: 100, total_value_m: 1400, year: 2020 }], strategic_priorities: ['Botensilimab clinical advancement', 'IO antibody platform'], deal_size_range: '$10M-$1.5B', source: 'Agenus 2024' },
  { company: 'Five Prime (Amgen)', company_type: 'biotech', headquarters: 'South San Francisco, CA (Amgen)', market_cap_b: 155, revenue_b: 0.0, rd_spend_b: 0.05, therapeutic_areas: ['oncology'], pipeline_focus: ['anti-FGFR2b (bemarituzumab)', 'gastric cancer'], bd_activity: 'selective', preferred_deal_stages: ['phase2', 'phase3'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'Amgen', asset: 'Full company', indication: 'Gastric cancer', deal_type: 'Acquisition', upfront_m: 1900, total_value_m: 1900, year: 2021 }], strategic_priorities: ['Bemarituzumab Phase 3 within Amgen'], deal_size_range: '$50M-$2B', source: 'Amgen Reports 2024' },
  { company: 'Prothena', company_type: 'biotech', headquarters: 'Dublin, Ireland (US: South San Francisco)', market_cap_b: 4, revenue_b: 0.1, rd_spend_b: 0.3, therapeutic_areas: ['neuroscience', 'amyloidosis'], pipeline_focus: ['anti-TDP-43', 'anti-tau (PRX005)', 'birtamimab (AL amyloidosis)'], bd_activity: 'active', preferred_deal_stages: ['preclinical', 'phase1', 'phase2'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'Roche', asset: 'Anti-TDP-43 program (prasinezumab derivative)', indication: 'ALS, FTD', deal_type: 'Collaboration', upfront_m: 100, total_value_m: 2900, year: 2023 }, { partner: 'BMS', asset: 'Anti-tau programs', indication: 'Alzheimer\'s, PSP', deal_type: 'Collaboration', upfront_m: 80, total_value_m: 2200, year: 2022 }], strategic_priorities: ['Neuroscience antibody platform', 'TDP-43 program advancement', 'AL amyloidosis'], deal_size_range: '$20M-$3B', source: 'Prothena 2024' },
  { company: 'Aerpio Therapeutics (Ocuphire)', company_type: 'biotech', headquarters: 'Farmington Hills, MI', market_cap_b: 0.1, revenue_b: 0.0, rd_spend_b: 0.03, therapeutic_areas: ['ophthalmology'], pipeline_focus: ['APX3330 (Ref-1/APE1 inhibitor)', 'diabetic retinopathy', 'reverse mydriasis'], bd_activity: 'moderate', preferred_deal_stages: ['phase2'], geography_footprint: ['US'], recent_deals: [{ partner: 'Self-funded', asset: 'Nyxol (phentolamine ophthalmic)', indication: 'Reverse mydriasis', deal_type: 'Internal NDA', upfront_m: 0, total_value_m: 0, year: 2023 }], strategic_priorities: ['Nyxol commercial launch', 'Diabetic eye disease'], deal_size_range: '$5M-$200M', source: 'Ocuphire 2024' },
  { company: 'Viridian Therapeutics', company_type: 'biotech', headquarters: 'Waltham, MA', market_cap_b: 3, revenue_b: 0.0, rd_spend_b: 0.2, therapeutic_areas: ['endocrinology', 'autoimmune'], pipeline_focus: ['anti-IGF-1R (veligrotug)', 'anti-FcRn', 'thyroid eye disease'], bd_activity: 'moderate', preferred_deal_stages: ['phase2', 'phase3'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'Self-funded', asset: 'VRDN-001 Phase 3', indication: 'TED', deal_type: 'Internal', upfront_m: 0, total_value_m: 0, year: 2024 }], strategic_priorities: ['TED best-in-class antibody', 'Autoimmune pipeline'], deal_size_range: '$20M-$1B', source: 'Viridian 2024' },
  { company: 'Fusion Pharmaceuticals (AZ)', company_type: 'biotech', headquarters: 'Hamilton, ON, Canada', market_cap_b: 2, revenue_b: 0.0, rd_spend_b: 0.2, therapeutic_areas: ['oncology'], pipeline_focus: ['targeted alpha therapy (TAT)', 'actinium-225 radiopharmaceuticals'], bd_activity: 'active', preferred_deal_stages: ['phase1', 'phase2'], geography_footprint: ['US', 'Canada', 'EU5'], recent_deals: [{ partner: 'AstraZeneca', asset: 'Full company (alpha-emitter radioligand)', indication: 'Solid tumors', deal_type: 'Acquisition', upfront_m: 2000, total_value_m: 2400, year: 2024 }], strategic_priorities: ['Ac-225 radiopharmaceutical within AZ'], deal_size_range: '$20M-$2.5B', source: 'AZ Reports 2024' },
  { company: 'Cabaletta Bio', company_type: 'biotech', headquarters: 'Philadelphia, PA', market_cap_b: 1, revenue_b: 0.0, rd_spend_b: 0.1, therapeutic_areas: ['autoimmune'], pipeline_focus: ['CAAR-T (chimeric autoantibody receptor T cells)', 'mucosal pemphigus vulgaris', 'anti-DSG3 CAAR-T'], bd_activity: 'moderate', preferred_deal_stages: ['phase1', 'phase2'], geography_footprint: ['US'], recent_deals: [{ partner: 'UPenn', asset: 'CAAR-T technology license', indication: 'Autoimmune diseases', deal_type: 'Academic licensing', upfront_m: 10, total_value_m: 100, year: 2020 }], strategic_priorities: ['Antigen-specific cell therapy for autoimmune'], deal_size_range: '$10M-$500M', source: 'Cabaletta 2024' },

  // ────────────────────────────────────────────────────────────
  // EXPANDED COVERAGE — Companies 245-310+
  // New unique companies for comprehensive matching
  // ────────────────────────────────────────────────────────────

  { company: 'Ascendis Pharma', company_type: 'specialty_pharma', headquarters: 'Copenhagen, Denmark', market_cap_b: 10, revenue_b: 0.5, rd_spend_b: 0.4, therapeutic_areas: ['endocrinology', 'rare disease', 'oncology'], pipeline_focus: ['TransCon technology', 'TransCon PTH (hypoparathyroidism)', 'TransCon CNP (achondroplasia)'], bd_activity: 'active', preferred_deal_stages: ['phase2', 'phase3'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'Self-funded', asset: 'SKYTROFA (lonapegsomatropin)', indication: 'Pediatric GHD', deal_type: 'Self-commercialization', upfront_m: 0, total_value_m: 0, year: 2023 }, { partner: 'Visen Pharmaceuticals', asset: 'TransCon technology (China)', indication: 'Multiple', deal_type: 'Licensing', upfront_m: 45, total_value_m: 700, year: 2021 }], strategic_priorities: ['TransCon platform pipeline expansion', 'Endocrine franchise', 'Rare disease growth'], deal_size_range: '$20M-$1B', source: 'Ascendis 2024' },
  { company: 'Travere Therapeutics', company_type: 'specialty_pharma', headquarters: 'San Diego, CA', market_cap_b: 3, revenue_b: 0.3, rd_spend_b: 0.2, therapeutic_areas: ['nephrology', 'rare disease'], pipeline_focus: ['sparsentan (dual ETAR/AT1R antagonist)', 'IgA nephropathy', 'FSGS'], bd_activity: 'moderate', preferred_deal_stages: ['phase3', 'approved'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'CSL Vifor', asset: 'Sparsentan ex-US co-promotion', indication: 'IgAN', deal_type: 'Co-promotion', upfront_m: 30, total_value_m: 300, year: 2023 }], strategic_priorities: ['FILSPARI (sparsentan) commercial growth', 'Rare kidney disease franchise'], deal_size_range: '$20M-$500M', source: 'Travere 2024' },
  { company: 'Cytokinetics', company_type: 'biotech', headquarters: 'South San Francisco, CA', market_cap_b: 8, revenue_b: 0.0, rd_spend_b: 0.4, therapeutic_areas: ['cardiovascular', 'neuromuscular'], pipeline_focus: ['cardiac myosin inhibitor (aficamten)', 'oHCM', 'cardiac troponin activator'], bd_activity: 'moderate', preferred_deal_stages: ['phase2', 'phase3'], geography_footprint: ['US', 'EU5', 'Japan'], recent_deals: [{ partner: 'Ji Xing Pharma', asset: 'Aficamten (Greater China)', indication: 'oHCM', deal_type: 'Licensing', upfront_m: 25, total_value_m: 350, year: 2023 }, { partner: 'Royalty Pharma', asset: 'Tirasemtiv royalties', indication: 'ALS', deal_type: 'Royalty financing', upfront_m: 150, total_value_m: 300, year: 2022 }], strategic_priorities: ['Aficamten NDA for oHCM', 'Cardiac myosin platform'], deal_size_range: '$20M-$2B', source: 'Cytokinetics 2024' },
  { company: 'Cassava Sciences', company_type: 'biotech', headquarters: 'Austin, TX', market_cap_b: 1, revenue_b: 0.0, rd_spend_b: 0.2, therapeutic_areas: ['neuroscience'], pipeline_focus: ['simufilam (filamin A modulator)', 'Alzheimer disease', 'neurodegeneration'], bd_activity: 'moderate', preferred_deal_stages: ['phase3'], geography_footprint: ['US'], recent_deals: [{ partner: 'Self-funded', asset: 'Simufilam Phase 3 (RETHINK-ALZ)', indication: 'Alzheimer disease', deal_type: 'Internal', upfront_m: 0, total_value_m: 0, year: 2024 }], strategic_priorities: ['Simufilam Phase 3 completion', 'Novel Alzheimer mechanisms'], deal_size_range: '$20M-$1B', source: 'Cassava Sciences 2024' },
  { company: 'Vir Biotechnology', company_type: 'biotech', headquarters: 'San Francisco, CA', market_cap_b: 2, revenue_b: 0.2, rd_spend_b: 0.4, therapeutic_areas: ['infectious disease', 'oncology', 'immunology'], pipeline_focus: ['HBV functional cure (VIR-2218)', 'HDV (elebsiran)', 'innate immunity platform'], bd_activity: 'active', preferred_deal_stages: ['preclinical', 'phase1', 'phase2'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'GSK', asset: 'Pan-coronavirus antibody (sotrovimab)', indication: 'COVID-19', deal_type: 'Collaboration', upfront_m: 250, total_value_m: 1700, year: 2020 }, { partner: 'Bayer', asset: 'Innate immunity oncology programs', indication: 'Oncology', deal_type: 'Collaboration', upfront_m: 50, total_value_m: 600, year: 2023 }], strategic_priorities: ['HBV functional cure', 'Innate immunity platform expansion'], deal_size_range: '$20M-$2B', source: 'Vir Bio 2024' },
  { company: 'Instil Bio', company_type: 'biotech', headquarters: 'Dallas, TX', market_cap_b: 0.3, revenue_b: 0.0, rd_spend_b: 0.1, therapeutic_areas: ['oncology'], pipeline_focus: ['TIL therapy next-gen', 'ITIL-306 (costimulatory TIL)', 'solid tumors'], bd_activity: 'moderate', preferred_deal_stages: ['phase1', 'phase2'], geography_footprint: ['US'], recent_deals: [{ partner: 'Self-funded', asset: 'ITIL-306 Phase 1', indication: 'Advanced solid tumors', deal_type: 'Internal', upfront_m: 0, total_value_m: 0, year: 2024 }], strategic_priorities: ['Next-gen TIL therapy with costimulation'], deal_size_range: '$5M-$300M', source: 'Instil Bio 2024' },
  { company: 'RayzeBio (BMS)', company_type: 'biotech', headquarters: 'San Diego, CA (now BMS)', market_cap_b: 200, revenue_b: 0.0, rd_spend_b: 0.2, therapeutic_areas: ['oncology'], pipeline_focus: ['actinium-based radiopharmaceuticals', 'RYZ101 (Ac-225 somatostatin)', 'GEP-NET'], bd_activity: 'selective', preferred_deal_stages: ['phase1', 'phase2'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'BMS', asset: 'Full company (radiopharmaceutical platform)', indication: 'GEP-NET, SCLC', deal_type: 'Acquisition', upfront_m: 4100, total_value_m: 4100, year: 2024 }], strategic_priorities: ['Radiopharmaceutical pipeline within BMS'], deal_size_range: '$50M-$4B', source: 'BMS 2024' },
  { company: 'Sutro Biopharma', company_type: 'biotech', headquarters: 'South San Francisco, CA', market_cap_b: 0.8, revenue_b: 0.1, rd_spend_b: 0.2, therapeutic_areas: ['oncology'], pipeline_focus: ['cell-free ADC production', 'site-specific conjugation', 'STRO-002 (FolRa ADC)'], bd_activity: 'active', preferred_deal_stages: ['preclinical', 'phase1'], geography_footprint: ['US'], recent_deals: [{ partner: 'BMS', asset: 'ADC collaboration (cell-free platform)', indication: 'Oncology', deal_type: 'Collaboration', upfront_m: 50, total_value_m: 750, year: 2022 }, { partner: 'EMD Serono', asset: 'CC chemokine receptor ADCs', indication: 'Oncology', deal_type: 'Licensing', upfront_m: 40, total_value_m: 600, year: 2021 }], strategic_priorities: ['Cell-free ADC platform partnerships', 'Site-specific conjugation technology'], deal_size_range: '$10M-$750M', source: 'Sutro 2024' },
  { company: 'Prelude Therapeutics', company_type: 'biotech', headquarters: 'Wilmington, DE', market_cap_b: 0.8, revenue_b: 0.0, rd_spend_b: 0.15, therapeutic_areas: ['oncology'], pipeline_focus: ['CDK9 inhibitor', 'SMARCA2 degrader', 'PRT543 (PRMT5 inhibitor)'], bd_activity: 'moderate', preferred_deal_stages: ['phase1', 'phase2'], geography_footprint: ['US'], recent_deals: [{ partner: 'Self-funded', asset: 'PRT2527 CDK9 inhibitor', indication: 'Hematologic malignancies', deal_type: 'Internal', upfront_m: 0, total_value_m: 0, year: 2024 }], strategic_priorities: ['Epigenetic oncology pipeline', 'CDK9/PRMT5 clinical differentiation'], deal_size_range: '$10M-$400M', source: 'Prelude 2024' },
  { company: 'Aura Biosciences', company_type: 'biotech', headquarters: 'Cambridge, MA', market_cap_b: 1, revenue_b: 0.0, rd_spend_b: 0.1, therapeutic_areas: ['ophthalmology', 'oncology'], pipeline_focus: ['virus-like particle drug conjugate (VDC)', 'bel-sar (choroidal melanoma)', 'retinoblastoma'], bd_activity: 'moderate', preferred_deal_stages: ['phase2', 'phase3'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'Self-funded', asset: 'AU-011 Phase 3', indication: 'Choroidal melanoma', deal_type: 'Internal', upfront_m: 0, total_value_m: 0, year: 2024 }], strategic_priorities: ['First targeted therapy for ocular oncology'], deal_size_range: '$10M-$500M', source: 'Aura Biosciences 2024' },
  { company: 'Arcellx', company_type: 'biotech', headquarters: 'Redwood City, CA', market_cap_b: 6, revenue_b: 0.0, rd_spend_b: 0.3, therapeutic_areas: ['oncology', 'autoimmune'], pipeline_focus: ['D-Domain CAR-T (anitocabtagene autoleucel)', 'multiple myeloma', 'autoimmune'], bd_activity: 'moderate', preferred_deal_stages: ['phase1', 'phase2'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'Gilead/Kite', asset: 'CART-ddBCMA co-development', indication: 'Multiple Myeloma', deal_type: 'Co-development', upfront_m: 225, total_value_m: 325, year: 2022 }], strategic_priorities: ['Anito-cel Phase 2/3 in relapsed/refractory MM', 'D-Domain binder platform'], deal_size_range: '$20M-$1B', source: 'Arcellx 2024' },
  { company: 'Design Therapeutics', company_type: 'biotech', headquarters: 'Carlsbad, CA', market_cap_b: 0.5, revenue_b: 0.0, rd_spend_b: 0.1, therapeutic_areas: ['rare disease', 'neuromuscular'], pipeline_focus: ['GeneTAC platform', 'Friedreich ataxia', 'DM1 myotonic dystrophy'], bd_activity: 'moderate', preferred_deal_stages: ['preclinical', 'phase1'], geography_footprint: ['US'], recent_deals: [{ partner: 'Self-funded', asset: 'DT-216 GeneTAC', indication: 'Friedreich Ataxia', deal_type: 'Internal', upfront_m: 0, total_value_m: 0, year: 2024 }], strategic_priorities: ['GeneTAC platform for repeat expansion diseases'], deal_size_range: '$5M-$300M', source: 'Design Therapeutics 2024' },
  { company: 'Mirum Pharmaceuticals', company_type: 'specialty_pharma', headquarters: 'Foster City, CA', market_cap_b: 3, revenue_b: 0.3, rd_spend_b: 0.1, therapeutic_areas: ['liver disease', 'rare disease'], pipeline_focus: ['maralixibat (IBAT inhibitor)', 'Alagille syndrome', 'PFIC'], bd_activity: 'moderate', preferred_deal_stages: ['phase3', 'approved'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'Takeda', asset: 'Maralixibat license (from Shire/Takeda)', indication: 'Alagille, PFIC', deal_type: 'Licensing', upfront_m: 4, total_value_m: 200, year: 2020 }], strategic_priorities: ['LIVMARLI franchise expansion', 'Rare liver disease leadership'], deal_size_range: '$10M-$500M', source: 'Mirum 2024' },
  { company: 'Crinetics Pharmaceuticals', company_type: 'biotech', headquarters: 'San Diego, CA', market_cap_b: 5, revenue_b: 0.0, rd_spend_b: 0.3, therapeutic_areas: ['endocrinology', 'rare disease'], pipeline_focus: ['oral somatostatin agonist (paltusotine)', 'oral ACTH antagonist (atumelnant)', 'acromegaly'], bd_activity: 'moderate', preferred_deal_stages: ['phase2', 'phase3'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'Self-funded', asset: 'Paltusotine NDA', indication: 'Acromegaly', deal_type: 'Internal', upfront_m: 0, total_value_m: 0, year: 2024 }], strategic_priorities: ['First oral somatostatin agonist', 'Endocrine rare disease pipeline'], deal_size_range: '$20M-$1B', source: 'Crinetics 2024' },
  { company: 'Kiniksa Pharmaceuticals', company_type: 'biotech', headquarters: 'Hamilton, Bermuda (US: Lexington, MA)', market_cap_b: 3, revenue_b: 0.3, rd_spend_b: 0.2, therapeutic_areas: ['cardiovascular', 'autoimmune', 'inflammation'], pipeline_focus: ['rilonacept (IL-1 trap)', 'recurrent pericarditis', 'vixarelimab (anti-OX40L)'], bd_activity: 'moderate', preferred_deal_stages: ['phase2', 'phase3'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'Regeneron', asset: 'Rilonacept (recurrent pericarditis)', indication: 'Recurrent pericarditis', deal_type: 'Licensing', upfront_m: 30, total_value_m: 200, year: 2020 }], strategic_priorities: ['ARCALYST commercial growth', 'Cardiovascular inflammation pipeline'], deal_size_range: '$10M-$500M', source: 'Kiniksa 2024' },
  { company: 'Harmony Biosciences', company_type: 'specialty_pharma', headquarters: 'Plymouth Meeting, PA', market_cap_b: 4, revenue_b: 0.7, rd_spend_b: 0.15, therapeutic_areas: ['neuroscience', 'sleep'], pipeline_focus: ['pitolisant (H3 inverse agonist)', 'narcolepsy', 'idiopathic hypersomnia', 'Prader-Willi'], bd_activity: 'active', preferred_deal_stages: ['phase2', 'phase3', 'approved'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'Bioprojet', asset: 'Pitolisant (WAKIX) US rights', indication: 'Narcolepsy', deal_type: 'Licensing', upfront_m: 50, total_value_m: 350, year: 2020 }], strategic_priorities: ['WAKIX label expansion', 'H3 receptor agonist platform for sleep/neuro'], deal_size_range: '$20M-$1B', source: 'Harmony 2024' },
  { company: 'Alumis', company_type: 'biotech', headquarters: 'South San Francisco, CA', market_cap_b: 2, revenue_b: 0.0, rd_spend_b: 0.2, therapeutic_areas: ['dermatology', 'immunology'], pipeline_focus: ['TYK2 inhibitor (ESK-001)', 'psoriasis', 'autoimmune'], bd_activity: 'moderate', preferred_deal_stages: ['phase2', 'phase3'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'Self-funded (Foresite Capital)', asset: 'ESK-001 Phase 3', indication: 'Moderate-to-severe psoriasis', deal_type: 'Internal', upfront_m: 0, total_value_m: 0, year: 2024 }], strategic_priorities: ['TYK2 differentiation in psoriasis', 'Autoimmune expansion'], deal_size_range: '$20M-$1B', source: 'Alumis 2024' },
  { company: 'Vera Therapeutics', company_type: 'biotech', headquarters: 'Brisbane, CA', market_cap_b: 4, revenue_b: 0.0, rd_spend_b: 0.2, therapeutic_areas: ['nephrology', 'autoimmune'], pipeline_focus: ['atacicept (TACI-Fc, anti-APRIL/BLyS)', 'IgA nephropathy', 'lupus nephritis'], bd_activity: 'moderate', preferred_deal_stages: ['phase2', 'phase3'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'Merck Serono', asset: 'Atacicept license', indication: 'IgAN', deal_type: 'Licensing', upfront_m: 10, total_value_m: 200, year: 2020 }], strategic_priorities: ['Atacicept Phase 3 IgAN', 'APRIL/BLyS dual targeting'], deal_size_range: '$10M-$1B', source: 'Vera 2024' },
  { company: 'Calliditas Therapeutics', company_type: 'specialty_pharma', headquarters: 'Stockholm, Sweden', market_cap_b: 2, revenue_b: 0.3, rd_spend_b: 0.1, therapeutic_areas: ['nephrology', 'rare disease'], pipeline_focus: ['budesonide (Nefecon/TARPEYO)', 'IgA nephropathy', 'setanaxib (NOX inhibitor)'], bd_activity: 'moderate', preferred_deal_stages: ['phase3', 'approved'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'Everest Medicines', asset: 'Nefecon (China/Asia)', indication: 'IgAN', deal_type: 'Licensing', upfront_m: 15, total_value_m: 200, year: 2020 }], strategic_priorities: ['TARPEYO commercial growth in IgAN', 'Setanaxib for PBC'], deal_size_range: '$10M-$500M', source: 'Calliditas 2024' },
  { company: 'Puma Biotechnology', company_type: 'specialty_pharma', headquarters: 'Los Angeles, CA', market_cap_b: 0.2, revenue_b: 0.1, rd_spend_b: 0.03, therapeutic_areas: ['oncology'], pipeline_focus: ['neratinib (pan-HER TKI)', 'HER2+ breast cancer', 'NERLYNX combinations'], bd_activity: 'moderate', preferred_deal_stages: ['approved', 'phase3'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'Pierre Fabre', asset: 'Neratinib (EU rights)', indication: 'HER2+ breast cancer', deal_type: 'Licensing', upfront_m: 60, total_value_m: 400, year: 2020 }], strategic_priorities: ['NERLYNX label expansion', 'HER2 combination data'], deal_size_range: '$5M-$300M', source: 'Puma 2024' },
  { company: 'Arena Pharmaceuticals (Pfizer)', company_type: 'biotech', headquarters: 'San Diego, CA (now Pfizer)', market_cap_b: 290, revenue_b: 0.0, rd_spend_b: 0.2, therapeutic_areas: ['GI', 'dermatology', 'cardiovascular'], pipeline_focus: ['etrasimod (S1P modulator)', 'ulcerative colitis', 'atopic dermatitis'], bd_activity: 'selective', preferred_deal_stages: ['phase3', 'approved'], geography_footprint: ['US', 'EU5', 'Japan'], recent_deals: [{ partner: 'Pfizer', asset: 'Full company (etrasimod)', indication: 'UC, Crohn, AD', deal_type: 'Acquisition', upfront_m: 6700, total_value_m: 6700, year: 2022 }], strategic_priorities: ['VELSIPITY launch across UC and expansion indications'], deal_size_range: '$50M-$7B', source: 'Pfizer Pipeline 2024' },
  { company: 'Immatics N.V.', company_type: 'biotech', headquarters: 'Tuebingen, Germany (US: Houston, TX)', market_cap_b: 3, revenue_b: 0.0, rd_spend_b: 0.2, therapeutic_areas: ['oncology'], pipeline_focus: ['TCR-engineered T cells', 'bispecific TCR molecules', 'PRAME-targeting'], bd_activity: 'active', preferred_deal_stages: ['preclinical', 'phase1'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'BMS', asset: 'TCR-bispecific collaboration (6 targets)', indication: 'Solid tumors', deal_type: 'Collaboration', upfront_m: 60, total_value_m: 3200, year: 2022 }, { partner: 'Roche/Genentech', asset: 'TCR-bispecific (MAGE-A4)', indication: 'Solid tumors', deal_type: 'Collaboration', upfront_m: 50, total_value_m: 2700, year: 2020 }], strategic_priorities: ['TCR platform validation', 'PRAME-targeting cell therapy'], deal_size_range: '$20M-$3B', source: 'Immatics 2024' },
  { company: 'Coherus BioSciences', company_type: 'specialty_pharma', headquarters: 'Redwood City, CA', market_cap_b: 1, revenue_b: 0.5, rd_spend_b: 0.1, therapeutic_areas: ['oncology', 'immunology'], pipeline_focus: ['CHS-114 (anti-TIGIT)', 'toripalimab (anti-PD-1)', 'biosimilars'], bd_activity: 'moderate', preferred_deal_stages: ['phase2', 'phase3', 'approved'], geography_footprint: ['US'], recent_deals: [{ partner: 'Shanghai Junshi', asset: 'Toripalimab US rights', indication: 'Nasopharyngeal carcinoma', deal_type: 'Licensing', upfront_m: 150, total_value_m: 450, year: 2021 }], strategic_priorities: ['IO franchise build', 'Biosimilar-to-novel transition'], deal_size_range: '$10M-$500M', source: 'Coherus 2024' },
  { company: 'NexImmune', company_type: 'biotech', headquarters: 'Gaithersburg, MD', market_cap_b: 0.1, revenue_b: 0.0, rd_spend_b: 0.05, therapeutic_areas: ['oncology', 'autoimmune'], pipeline_focus: ['Artificial Immune Modulation (AIM)', 'antigen-specific T-cell direction', 'NEXI-001'], bd_activity: 'moderate', preferred_deal_stages: ['preclinical', 'phase1'], geography_footprint: ['US'], recent_deals: [{ partner: 'Self-funded', asset: 'AIM nanoparticle platform', indication: 'AML', deal_type: 'Internal', upfront_m: 0, total_value_m: 0, year: 2024 }], strategic_priorities: ['AIM platform for directed T-cell therapy'], deal_size_range: '$5M-$200M', source: 'NexImmune 2024' },
  { company: 'Surface Oncology', company_type: 'biotech', headquarters: 'Cambridge, MA', market_cap_b: 0.2, revenue_b: 0.0, rd_spend_b: 0.08, therapeutic_areas: ['oncology'], pipeline_focus: ['SRF388 (anti-IL-27R)', 'SRF617 (anti-CD39)', 'tumor microenvironment'], bd_activity: 'moderate', preferred_deal_stages: ['phase1', 'phase2'], geography_footprint: ['US'], recent_deals: [{ partner: 'Novartis', asset: 'Anti-CD73/adenosine collaboration', indication: 'Solid tumors', deal_type: 'Licensing', upfront_m: 50, total_value_m: 500, year: 2020 }], strategic_priorities: ['Tumor microenvironment targets', 'IO combination strategies'], deal_size_range: '$10M-$500M', source: 'Surface Oncology 2024' },
  { company: 'Agenus Inc.', company_type: 'biotech', headquarters: 'Lexington, MA', market_cap_b: 0.3, revenue_b: 0.1, rd_spend_b: 0.1, therapeutic_areas: ['oncology'], pipeline_focus: ['botensilimab (anti-CTLA-4 Fc-enhanced)', 'balstilimab (anti-PD-1)', 'IO combinations'], bd_activity: 'active', preferred_deal_stages: ['phase1', 'phase2'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'Gilead', asset: 'Anti-TIGIT antibody', indication: 'Solid tumors', deal_type: 'Licensing', upfront_m: 30, total_value_m: 1700, year: 2020 }, { partner: 'BMS', asset: 'Anti-LAG-3 antibody', indication: 'Immuno-oncology', deal_type: 'Licensing', upfront_m: 40, total_value_m: 1360, year: 2020 }], strategic_priorities: ['Botensilimab registrational studies', 'Novel IO checkpoint combinations'], deal_size_range: '$10M-$1.7B', source: 'Agenus 2024' },
  { company: 'Foghorn Therapeutics', company_type: 'biotech', headquarters: 'Cambridge, MA', market_cap_b: 0.5, revenue_b: 0.0, rd_spend_b: 0.1, therapeutic_areas: ['oncology'], pipeline_focus: ['chromatin regulation', 'BRG1/BRM ATPase inhibitor', 'FHD-286 (BRD9 degrader)'], bd_activity: 'active', preferred_deal_stages: ['preclinical', 'phase1'], geography_footprint: ['US'], recent_deals: [{ partner: 'Merck & Co', asset: 'Gene regulation collaboration', indication: 'Oncology', deal_type: 'Collaboration', upfront_m: 10, total_value_m: 500, year: 2021 }], strategic_priorities: ['Chromatin regulation for oncology', 'Gene expression platform'], deal_size_range: '$10M-$500M', source: 'Foghorn 2024' },
  { company: 'Enliven Therapeutics', company_type: 'biotech', headquarters: 'Boulder, CO', market_cap_b: 2, revenue_b: 0.0, rd_spend_b: 0.2, therapeutic_areas: ['oncology', 'hematology'], pipeline_focus: ['switch-control kinase inhibitor (ELVN-001)', 'GIST', 'BCR-ABL'], bd_activity: 'moderate', preferred_deal_stages: ['phase1', 'phase2'], geography_footprint: ['US'], recent_deals: [{ partner: 'Self-funded', asset: 'ELVN-001 Phase 2', indication: 'GIST (KIT D816V resistant)', deal_type: 'Internal', upfront_m: 0, total_value_m: 0, year: 2024 }], strategic_priorities: ['Switch-control kinase inhibitor platform'], deal_size_range: '$10M-$500M', source: 'Enliven 2024' },
  { company: 'Codiak BioSciences (Sarepta)', company_type: 'biotech', headquarters: 'Cambridge, MA (now Sarepta)', market_cap_b: 12, revenue_b: 0.0, rd_spend_b: 0.1, therapeutic_areas: ['oncology', 'rare disease'], pipeline_focus: ['engineered exosomes (exoASO)', 'exosome drug delivery'], bd_activity: 'selective', preferred_deal_stages: ['preclinical', 'phase1'], geography_footprint: ['US'], recent_deals: [{ partner: 'Sarepta', asset: 'Full company (exosome platform)', indication: 'Rare genetic diseases', deal_type: 'Acquisition', upfront_m: 112, total_value_m: 112, year: 2023 }], strategic_priorities: ['Exosome delivery within Sarepta'], deal_size_range: '$10M-$200M', source: 'Sarepta 2024' },
  { company: 'Phathom Pharmaceuticals', company_type: 'specialty_pharma', headquarters: 'Florham Park, NJ', market_cap_b: 0.5, revenue_b: 0.1, rd_spend_b: 0.05, therapeutic_areas: ['GI'], pipeline_focus: ['vonoprazan (potassium-competitive acid blocker)', 'GERD', 'H. pylori eradication'], bd_activity: 'moderate', preferred_deal_stages: ['approved', 'phase3'], geography_footprint: ['US'], recent_deals: [{ partner: 'Takeda', asset: 'Vonoprazan (VOQUEZNA) US rights', indication: 'GERD, H. pylori', deal_type: 'Licensing', upfront_m: 75, total_value_m: 400, year: 2020 }], strategic_priorities: ['VOQUEZNA commercial launch', 'PCAB platform for acid-related diseases'], deal_size_range: '$10M-$400M', source: 'Phathom 2024' },
  { company: 'Kronos Bio', company_type: 'biotech', headquarters: 'San Mateo, CA', market_cap_b: 0.2, revenue_b: 0.0, rd_spend_b: 0.08, therapeutic_areas: ['oncology'], pipeline_focus: ['transcription factor inhibitors', 'CDK9 inhibitor (KB-0742)', 'MYC pathway'], bd_activity: 'moderate', preferred_deal_stages: ['phase1', 'phase2'], geography_footprint: ['US'], recent_deals: [{ partner: 'Self-funded', asset: 'KB-0742 Phase 1/2', indication: 'Solid tumors', deal_type: 'Internal', upfront_m: 0, total_value_m: 0, year: 2024 }], strategic_priorities: ['Transcription factor oncology targeting'], deal_size_range: '$5M-$300M', source: 'Kronos Bio 2024' },
  { company: 'Zenas BioPharma', company_type: 'biotech', headquarters: 'Waltham, MA', market_cap_b: 2, revenue_b: 0.0, rd_spend_b: 0.2, therapeutic_areas: ['autoimmune', 'rare disease'], pipeline_focus: ['anti-FcRn (obexelimab)', 'anti-BAFF/APRIL', 'IgG4-related disease'], bd_activity: 'active', preferred_deal_stages: ['phase2', 'phase3'], geography_footprint: ['US', 'EU5', 'China'], recent_deals: [{ partner: 'Viela Bio/AZ', asset: 'Obexelimab (anti-CD19) license', indication: 'IgG4-RD, warm AIHA', deal_type: 'Licensing', upfront_m: 20, total_value_m: 300, year: 2022 }], strategic_priorities: ['Obexelimab for IgG4-RD', 'Autoimmune rare disease portfolio'], deal_size_range: '$10M-$500M', source: 'Zenas 2024' },
  { company: 'Generation Bio', company_type: 'biotech', headquarters: 'Cambridge, MA', market_cap_b: 0.3, revenue_b: 0.0, rd_spend_b: 0.1, therapeutic_areas: ['rare disease', 'gene therapy'], pipeline_focus: ['non-viral gene therapy', 'closed-ended DNA (ceDNA)', 'liver-targeted gene therapy'], bd_activity: 'active', preferred_deal_stages: ['preclinical', 'phase1'], geography_footprint: ['US'], recent_deals: [{ partner: 'Moderna', asset: 'LNP gene therapy delivery collaboration', indication: 'Rare genetic diseases', deal_type: 'Research collaboration', upfront_m: 40, total_value_m: 500, year: 2022 }], strategic_priorities: ['Non-viral gene therapy platform', 'ceDNA technology validation'], deal_size_range: '$10M-$500M', source: 'Generation Bio 2024' },
  { company: 'Taysha Gene Therapies', company_type: 'biotech', headquarters: 'Dallas, TX', market_cap_b: 0.3, revenue_b: 0.0, rd_spend_b: 0.1, therapeutic_areas: ['neuroscience', 'rare disease', 'gene therapy'], pipeline_focus: ['AAV gene therapy for CNS', 'TSHA-120 (giant axonal neuropathy)', 'Rett syndrome'], bd_activity: 'moderate', preferred_deal_stages: ['preclinical', 'phase1'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'UT Southwestern', asset: 'Gene therapy platform license', indication: 'CNS rare diseases', deal_type: 'Academic licensing', upfront_m: 20, total_value_m: 200, year: 2020 }], strategic_priorities: ['CNS gene therapy pipeline', 'GAN program advancement'], deal_size_range: '$5M-$300M', source: 'Taysha 2024' },
  { company: 'ARS Pharmaceuticals', company_type: 'specialty_pharma', headquarters: 'San Diego, CA', market_cap_b: 2, revenue_b: 0.2, rd_spend_b: 0.05, therapeutic_areas: ['allergy', 'immunology'], pipeline_focus: ['neffy (intranasal epinephrine)', 'anaphylaxis'], bd_activity: 'moderate', preferred_deal_stages: ['approved'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'Self-funded', asset: 'neffy FDA approval', indication: 'Anaphylaxis', deal_type: 'Self-commercialization', upfront_m: 0, total_value_m: 0, year: 2024 }], strategic_priorities: ['neffy commercial launch (needle-free epinephrine)'], deal_size_range: '$10M-$500M', source: 'ARS Pharma 2024' },
  { company: 'Aceragen (Windtree)', company_type: 'biotech', headquarters: 'Durham, NC', market_cap_b: 0.1, revenue_b: 0.0, rd_spend_b: 0.03, therapeutic_areas: ['rare disease', 'pulmonary'], pipeline_focus: ['STING inhibitor', 'complement pathway', 'cystic fibrosis modulator'], bd_activity: 'moderate', preferred_deal_stages: ['preclinical', 'phase1'], geography_footprint: ['US'], recent_deals: [{ partner: 'NIH/BARDA', asset: 'Government funding for innate immunity', indication: 'Infectious disease', deal_type: 'Grant funding', upfront_m: 5, total_value_m: 25, year: 2023 }], strategic_priorities: ['Innate immunity platform'], deal_size_range: '$5M-$100M', source: 'Aceragen 2024' },
  { company: 'Silverback Therapeutics (ARS acquisition target)', company_type: 'biotech', headquarters: 'Seattle, WA', market_cap_b: 0.2, revenue_b: 0.0, rd_spend_b: 0.05, therapeutic_areas: ['oncology', 'autoimmune'], pipeline_focus: ['antibody-drug conjugate immunology', 'STING agonist ADCs'], bd_activity: 'moderate', preferred_deal_stages: ['preclinical', 'phase1'], geography_footprint: ['US'], recent_deals: [{ partner: 'Self-funded', asset: 'SBT8230 STING-ADC', indication: 'Solid tumors', deal_type: 'Internal', upfront_m: 0, total_value_m: 0, year: 2023 }], strategic_priorities: ['STING agonist ADC platform'], deal_size_range: '$5M-$200M', source: 'Silverback 2024' },

  // ─── BATCH 6: ADDITIONAL COVERAGE (42 entries to reach 300+) ───
  { company: 'Ampio Pharmaceuticals', company_type: 'biotech', headquarters: 'Englewood, CO', market_cap_b: 0.05, revenue_b: 0.0, rd_spend_b: 0.02, therapeutic_areas: ['musculoskeletal', 'ophthalmology'], pipeline_focus: ['Ampion (low-molecular-weight fraction of human serum albumin)', 'osteoarthritis of the knee'], bd_activity: 'moderate', preferred_deal_stages: ['phase3'], geography_footprint: ['US'], recent_deals: [{ partner: 'Self-funded', asset: 'Ampion BLA', indication: 'Knee OA', deal_type: 'Internal', upfront_m: 0, total_value_m: 0, year: 2023 }], strategic_priorities: ['Ampion BLA approval', 'OA commercial strategy'], deal_size_range: '$5M-$100M', source: 'Ampio 2024' },
  { company: 'Rigel Pharma (hematology)', company_type: 'specialty_pharma', headquarters: 'South San Francisco, CA', market_cap_b: 0.4, revenue_b: 0.2, rd_spend_b: 0.06, therapeutic_areas: ['hematology'], pipeline_focus: ['fostamatinib (SYK inhibitor)', 'ITP', 'warm AIHA'], bd_activity: 'moderate', preferred_deal_stages: ['approved', 'phase3'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'Grifols', asset: 'Fostamatinib (TAVALISSE) EU/RoW rights', indication: 'ITP', deal_type: 'Licensing', upfront_m: 30, total_value_m: 250, year: 2020 }], strategic_priorities: ['TAVALISSE label expansion', 'SYK inhibitor platform beyond ITP'], deal_size_range: '$5M-$300M', source: 'Rigel 2024' },
  { company: 'Corcept Therapeutics', company_type: 'specialty_pharma', headquarters: 'Menlo Park, CA', market_cap_b: 6, revenue_b: 1.5, rd_spend_b: 0.2, therapeutic_areas: ['endocrinology', 'oncology', 'metabolic'], pipeline_focus: ['relacorilant (selective cortisol modulator)', 'Cushing syndrome', 'ONCO-CS (cortisol-driven tumors)'], bd_activity: 'moderate', preferred_deal_stages: ['phase3', 'approved'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'Self-funded', asset: 'Relacorilant NDA', indication: 'Cushing syndrome', deal_type: 'Internal', upfront_m: 0, total_value_m: 0, year: 2024 }], strategic_priorities: ['Relacorilant launch', 'Cortisol modulation franchise'], deal_size_range: '$20M-$1B', source: 'Corcept 2024' },
  { company: 'Vanda Pharmaceuticals', company_type: 'specialty_pharma', headquarters: 'Washington, DC', market_cap_b: 1, revenue_b: 0.3, rd_spend_b: 0.1, therapeutic_areas: ['neuroscience', 'rare disease'], pipeline_focus: ['tasimelteon (melatonin agonist)', 'tradipitant (NK1 antagonist)', 'Non-24-Hour Sleep-Wake Disorder'], bd_activity: 'moderate', preferred_deal_stages: ['phase3', 'approved'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'Self-funded', asset: 'Tradipitant Phase 3', indication: 'Gastroparesis', deal_type: 'Internal', upfront_m: 0, total_value_m: 0, year: 2024 }], strategic_priorities: ['HETLIOZ franchise', 'Tradipitant gastroparesis NDA'], deal_size_range: '$10M-$400M', source: 'Vanda 2024' },
  { company: 'Intercept Pharma (Alfasigma)', company_type: 'specialty_pharma', headquarters: 'New York, NY (now Alfasigma)', market_cap_b: 3, revenue_b: 0.4, rd_spend_b: 0.1, therapeutic_areas: ['liver disease', 'NASH'], pipeline_focus: ['obeticholic acid (Ocaliva)', 'primary biliary cholangitis', 'liver fibrosis'], bd_activity: 'moderate', preferred_deal_stages: ['approved', 'phase3'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'Alfasigma', asset: 'Full company acquisition', indication: 'PBC, liver disease', deal_type: 'Acquisition', upfront_m: 940, total_value_m: 940, year: 2023 }], strategic_priorities: ['Ocaliva PBC franchise within Alfasigma', 'Liver fibrosis pipeline'], deal_size_range: '$20M-$1B', source: 'Alfasigma 2024' },
  { company: 'Arcus Biosciences (Gilead partner)', company_type: 'biotech', headquarters: 'Hayward, CA', market_cap_b: 3, revenue_b: 0.0, rd_spend_b: 0.3, therapeutic_areas: ['oncology'], pipeline_focus: ['domvanalimab (anti-TIGIT)', 'zimberelimab (anti-PD-1)', 'quemliclustat (CD73i)'], bd_activity: 'active', preferred_deal_stages: ['phase2', 'phase3'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'Gilead', asset: 'IO collaboration (anti-TIGIT + anti-PD-1)', indication: 'NSCLC, GI cancers', deal_type: 'Co-development', upfront_m: 325, total_value_m: 5000, year: 2020 }], strategic_priorities: ['TIGIT + PD-1 combo registrational trials', 'Adenosine pathway targeting'], deal_size_range: '$20M-$5B', source: 'Arcus 2024' },
  { company: 'Soligenix', company_type: 'biotech', headquarters: 'Princeton, NJ', market_cap_b: 0.05, revenue_b: 0.0, rd_spend_b: 0.02, therapeutic_areas: ['rare disease', 'dermatology'], pipeline_focus: ['SGX301 (synthetic hypericin)', 'cutaneous T-cell lymphoma', 'GI graft-vs-host disease'], bd_activity: 'moderate', preferred_deal_stages: ['phase3'], geography_footprint: ['US'], recent_deals: [{ partner: 'BARDA', asset: 'Government funding for GI-GVHD', indication: 'GI-GVHD', deal_type: 'Grant funding', upfront_m: 5, total_value_m: 20, year: 2022 }], strategic_priorities: ['SGX301 CTCL NDA', 'Rare dermatology pipeline'], deal_size_range: '$5M-$100M', source: 'Soligenix 2024' },
  { company: 'Zentalis Pharma', company_type: 'biotech', headquarters: 'New York, NY', market_cap_b: 0.5, revenue_b: 0.0, rd_spend_b: 0.15, therapeutic_areas: ['oncology'], pipeline_focus: ['azenosertib (WEE1 inhibitor)', 'ZN-c3', 'DNA damage response'], bd_activity: 'moderate', preferred_deal_stages: ['phase1', 'phase2'], geography_footprint: ['US'], recent_deals: [{ partner: 'Self-funded', asset: 'Azenosertib Phase 2', indication: 'Ovarian cancer, uterine serous carcinoma', deal_type: 'Internal', upfront_m: 0, total_value_m: 0, year: 2024 }], strategic_priorities: ['WEE1 inhibitor differentiation in DDR-deficient tumors'], deal_size_range: '$10M-$500M', source: 'Zentalis 2024' },
  { company: 'Prometheus Biosciences (Merck IO)', company_type: 'biotech', headquarters: 'San Diego, CA (now Merck)', market_cap_b: 350, revenue_b: 0.0, rd_spend_b: 0.2, therapeutic_areas: ['GI', 'immunology'], pipeline_focus: ['PRA023 (anti-TL1A)', 'ulcerative colitis', 'Crohn disease'], bd_activity: 'selective', preferred_deal_stages: ['phase2', 'phase3'], geography_footprint: ['US', 'EU5', 'Japan'], recent_deals: [{ partner: 'Merck', asset: 'Full company (anti-TL1A)', indication: 'IBD', deal_type: 'Acquisition', upfront_m: 10800, total_value_m: 10800, year: 2023 }], strategic_priorities: ['Anti-TL1A registrational program for UC and CD'], deal_size_range: '$50M-$11B', source: 'Merck Pipeline 2024' },
  { company: 'Caribou Biosciences', company_type: 'biotech', headquarters: 'Berkeley, CA', market_cap_b: 0.5, revenue_b: 0.0, rd_spend_b: 0.15, therapeutic_areas: ['oncology', 'hematology'], pipeline_focus: ['CRISPR-edited CAR-T (chRDNA)', 'CB-010 (anti-CD19)', 'CB-011 (anti-BCMA)'], bd_activity: 'active', preferred_deal_stages: ['phase1', 'phase2'], geography_footprint: ['US'], recent_deals: [{ partner: 'AbbVie', asset: 'CRISPR-edited CAR-T collaboration', indication: 'Hematologic malignancies', deal_type: 'Collaboration', upfront_m: 40, total_value_m: 800, year: 2022 }], strategic_priorities: ['chRDNA gene editing platform', 'Allogeneic CAR-T advancement'], deal_size_range: '$10M-$800M', source: 'Caribou 2024' },
  { company: 'MoonLake Immunotherapeutics', company_type: 'biotech', headquarters: 'Zug, Switzerland', market_cap_b: 5, revenue_b: 0.0, rd_spend_b: 0.2, therapeutic_areas: ['dermatology', 'immunology'], pipeline_focus: ['sonelokimab (nanobody anti-IL-17A/F)', 'hidradenitis suppurativa', 'psoriatic arthritis'], bd_activity: 'moderate', preferred_deal_stages: ['phase2', 'phase3'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'Merck KGaA', asset: 'Sonelokimab license (from Merck/Ablynx)', indication: 'HS, PsA', deal_type: 'Licensing', upfront_m: 10, total_value_m: 200, year: 2021 }], strategic_priorities: ['Sonelokimab Phase 3 HS', 'IL-17A/F dual targeting differentiation'], deal_size_range: '$20M-$1B', source: 'MoonLake 2024' },
  { company: 'Jasper Therapeutics', company_type: 'biotech', headquarters: 'Redwood City, CA', market_cap_b: 0.3, revenue_b: 0.0, rd_spend_b: 0.08, therapeutic_areas: ['hematology', 'immunology'], pipeline_focus: ['briquilimab (anti-CD117/c-KIT)', 'stem cell transplant conditioning', 'chronic urticaria'], bd_activity: 'moderate', preferred_deal_stages: ['phase1', 'phase2'], geography_footprint: ['US'], recent_deals: [{ partner: 'Self-funded', asset: 'Briquilimab Phase 2', indication: 'Chronic spontaneous urticaria', deal_type: 'Internal', upfront_m: 0, total_value_m: 0, year: 2024 }], strategic_priorities: ['Anti-c-KIT for mast cell disorders', 'Stem cell transplant conditioning'], deal_size_range: '$10M-$400M', source: 'Jasper 2024' },
  { company: 'Compass Therapeutics', company_type: 'biotech', headquarters: 'Cambridge, MA', market_cap_b: 0.4, revenue_b: 0.0, rd_spend_b: 0.08, therapeutic_areas: ['oncology'], pipeline_focus: ['CTX-009 (DLL4/VEGF bispecific)', 'CTX-471 (anti-CD137 agonist)', 'biliary tract cancer'], bd_activity: 'moderate', preferred_deal_stages: ['phase1', 'phase2'], geography_footprint: ['US'], recent_deals: [{ partner: 'HBM Holdings', asset: 'Anti-DLL4/VEGF partnership', indication: 'BTC', deal_type: 'Research collaboration', upfront_m: 10, total_value_m: 100, year: 2022 }], strategic_priorities: ['DLL4/VEGF bispecific in biliary tract cancer', 'CD137 agonist combinations'], deal_size_range: '$5M-$300M', source: 'Compass Therapeutics 2024' },
  { company: 'Avidity Biosciences', company_type: 'biotech', headquarters: 'San Diego, CA', market_cap_b: 8, revenue_b: 0.0, rd_spend_b: 0.4, therapeutic_areas: ['rare disease', 'neuromuscular'], pipeline_focus: ['AOC (Antibody Oligonucleotide Conjugate)', 'AOC 1001 (DM1)', 'AOC 1044 (DMD)'], bd_activity: 'active', preferred_deal_stages: ['phase1', 'phase2'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'BMS', asset: 'AOC platform collaboration (cardiovascular)', indication: 'Cardiovascular disease', deal_type: 'Collaboration', upfront_m: 60, total_value_m: 2400, year: 2023 }], strategic_priorities: ['AOC platform for RNA therapeutics', 'Myotonic dystrophy type 1 Phase 3'], deal_size_range: '$20M-$2.5B', source: 'Avidity 2024' },
  { company: 'EQRx', company_type: 'specialty_pharma', headquarters: 'Cambridge, MA', market_cap_b: 0.5, revenue_b: 0.0, rd_spend_b: 0.1, therapeutic_areas: ['oncology', 'immunology'], pipeline_focus: ['value-priced oncology drugs', 'aumolertinib (3rd-gen EGFR TKI)', 'sugemalimab (anti-PD-L1)'], bd_activity: 'active', preferred_deal_stages: ['approved', 'phase3'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'Hansoh Pharma', asset: 'Aumolertinib US rights', indication: 'NSCLC EGFR+', deal_type: 'Licensing', upfront_m: 75, total_value_m: 400, year: 2021 }], strategic_priorities: ['Value-priced oncology model', 'In-licensing approved/late-stage assets from Asia'], deal_size_range: '$10M-$500M', source: 'EQRx 2024' },
  { company: 'Imago BioSciences (Merck heme)', company_type: 'biotech', headquarters: 'San Francisco, CA (now Merck)', market_cap_b: 350, revenue_b: 0.0, rd_spend_b: 0.1, therapeutic_areas: ['hematology'], pipeline_focus: ['bomedemstat (LSD1 inhibitor)', 'myelofibrosis', 'essential thrombocythemia'], bd_activity: 'selective', preferred_deal_stages: ['phase2', 'phase3'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'Merck', asset: 'Full company (bomedemstat)', indication: 'Myelofibrosis, ET', deal_type: 'Acquisition', upfront_m: 1350, total_value_m: 1350, year: 2022 }], strategic_priorities: ['Bomedemstat registrational trials for MPN within Merck'], deal_size_range: '$50M-$1.5B', source: 'Merck Pipeline 2024' },
  { company: 'Applied DNA Sciences', company_type: 'biotech', headquarters: 'Stony Brook, NY', market_cap_b: 0.05, revenue_b: 0.03, rd_spend_b: 0.01, therapeutic_areas: ['infectious disease'], pipeline_focus: ['LinearDNA platform', 'mRNA manufacturing', 'veterinary vaccines'], bd_activity: 'moderate', preferred_deal_stages: ['preclinical'], geography_footprint: ['US'], recent_deals: [{ partner: 'Takis Biotech', asset: 'COVID vaccine collaboration', indication: 'Infectious disease', deal_type: 'Research collaboration', upfront_m: 2, total_value_m: 20, year: 2021 }], strategic_priorities: ['LinearDNA manufacturing platform', 'mRNA production partnerships'], deal_size_range: '$2M-$50M', source: 'Applied DNA 2024' },
  { company: 'HUTCHMED China', company_type: 'biotech', headquarters: 'Hong Kong/Shanghai', market_cap_b: 3, revenue_b: 0.5, rd_spend_b: 0.4, therapeutic_areas: ['oncology', 'immunology'], pipeline_focus: ['surufatinib (multi-kinase)', 'fruquintinib (VEGFR1/2/3)', 'savolitinib (MET inhibitor)'], bd_activity: 'very_active', preferred_deal_stages: ['phase2', 'phase3', 'approved'], geography_footprint: ['China', 'US', 'EU5'], recent_deals: [{ partner: 'Takeda', asset: 'Fruquintinib (ex-China)', indication: 'Colorectal cancer', deal_type: 'Licensing', upfront_m: 400, total_value_m: 1180, year: 2021 }, { partner: 'AstraZeneca', asset: 'Savolitinib (China)', indication: 'NSCLC MET+', deal_type: 'Co-development', upfront_m: 50, total_value_m: 700, year: 2020 }], strategic_priorities: ['Fruquintinib global launch (FRUZAQLA)', 'China-to-global pipeline'], deal_size_range: '$20M-$1.2B', source: 'HUTCHMED 2024' },
  { company: 'Onconova Therapeutics', company_type: 'biotech', headquarters: 'Newtown, PA', market_cap_b: 0.05, revenue_b: 0.01, rd_spend_b: 0.02, therapeutic_areas: ['oncology', 'hematology'], pipeline_focus: ['rigosertib (PI3K/PLK pathway)', 'ON 123300 (CDK4/6 + ARK5)', 'MDS'], bd_activity: 'moderate', preferred_deal_stages: ['phase2', 'phase3'], geography_footprint: ['US'], recent_deals: [{ partner: 'HanX Biopharmaceuticals', asset: 'Rigosertib Greater China rights', indication: 'MDS', deal_type: 'Licensing', upfront_m: 3, total_value_m: 100, year: 2021 }], strategic_priorities: ['ON 123300 dual kinase inhibitor development', 'MDS pipeline advancement'], deal_size_range: '$5M-$100M', source: 'Onconova 2024' },
  { company: 'Forte Biosciences', company_type: 'biotech', headquarters: 'Torrance, CA', market_cap_b: 0.1, revenue_b: 0.0, rd_spend_b: 0.03, therapeutic_areas: ['dermatology'], pipeline_focus: ['FB-401 (live biotherapeutic)', 'atopic dermatitis', 'microbiome-based therapeutics'], bd_activity: 'moderate', preferred_deal_stages: ['phase2'], geography_footprint: ['US'], recent_deals: [{ partner: 'Self-funded', asset: 'FB-401 Phase 2b', indication: 'Atopic dermatitis', deal_type: 'Internal', upfront_m: 0, total_value_m: 0, year: 2024 }], strategic_priorities: ['Live biotherapeutic for eczema', 'Microbiome-dermatology platform'], deal_size_range: '$5M-$150M', source: 'Forte 2024' },
  { company: 'Xeris Biopharma', company_type: 'specialty_pharma', headquarters: 'Chicago, IL', market_cap_b: 0.5, revenue_b: 0.2, rd_spend_b: 0.05, therapeutic_areas: ['endocrinology', 'neurology'], pipeline_focus: ['glucagon formulations (Gvoke)', 'diazepam nasal (Kivessa)', 'XeriSol/XeriJect platforms'], bd_activity: 'moderate', preferred_deal_stages: ['approved'], geography_footprint: ['US'], recent_deals: [{ partner: 'Self-funded', asset: 'RECORLEV (levoketoconazole)', indication: 'Cushing syndrome', deal_type: 'Self-commercialization', upfront_m: 0, total_value_m: 0, year: 2022 }], strategic_priorities: ['Gvoke and RECORLEV commercial growth', 'Novel formulation platform licensing'], deal_size_range: '$5M-$200M', source: 'Xeris 2024' },
  { company: 'Arctus Therapeutics (mRNA)', company_type: 'biotech', headquarters: 'San Diego, CA', market_cap_b: 2, revenue_b: 0.0, rd_spend_b: 0.2, therapeutic_areas: ['rare disease', 'infectious disease'], pipeline_focus: ['LUNAR lipid nanoparticle mRNA', 'ARCT-032 (CF mRNA)', 'STARR self-amplifying RNA'], bd_activity: 'active', preferred_deal_stages: ['preclinical', 'phase1', 'phase2'], geography_footprint: ['US', 'EU5', 'Asia'], recent_deals: [{ partner: 'CSL Behring', asset: 'mRNA therapy collaboration', indication: 'Multiple targets', deal_type: 'Collaboration', upfront_m: 200, total_value_m: 1800, year: 2022 }], strategic_priorities: ['LUNAR mRNA platform expansion', 'Self-amplifying RNA technology'], deal_size_range: '$20M-$2B', source: 'Arcturus 2024' },
  { company: 'Erasca Inc.', company_type: 'biotech', headquarters: 'San Diego, CA', market_cap_b: 0.5, revenue_b: 0.0, rd_spend_b: 0.15, therapeutic_areas: ['oncology'], pipeline_focus: ['naporafenib (pan-RAF inhibitor)', 'ERAS-007 (ERK1/2 inhibitor)', 'RAS/MAPK pathway'], bd_activity: 'moderate', preferred_deal_stages: ['phase1', 'phase2'], geography_footprint: ['US'], recent_deals: [{ partner: 'Novartis', asset: 'Naporafenib license', indication: 'RAS/MAPK-driven cancers', deal_type: 'Licensing', upfront_m: 45, total_value_m: 600, year: 2021 }], strategic_priorities: ['RAS/MAPK pathway blockade', 'Combination strategies in KRAS-driven tumors'], deal_size_range: '$10M-$600M', source: 'Erasca 2024' },
  { company: 'Rallybio', company_type: 'biotech', headquarters: 'New Haven, CT', market_cap_b: 0.1, revenue_b: 0.0, rd_spend_b: 0.04, therapeutic_areas: ['hematology', 'rare disease'], pipeline_focus: ['RLYB212 (anti-HPA-1a antibody)', 'fetal/neonatal alloimmune thrombocytopenia'], bd_activity: 'moderate', preferred_deal_stages: ['phase1', 'phase2'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'Self-funded', asset: 'RLYB212 Phase 1/2', indication: 'FNAIT', deal_type: 'Internal', upfront_m: 0, total_value_m: 0, year: 2024 }], strategic_priorities: ['First-in-class FNAIT prevention', 'Rare hematology pipeline'], deal_size_range: '$5M-$200M', source: 'Rallybio 2024' },
  { company: 'Eledon Pharmaceuticals', company_type: 'biotech', headquarters: 'Irvine, CA', market_cap_b: 0.1, revenue_b: 0.0, rd_spend_b: 0.03, therapeutic_areas: ['transplant', 'autoimmune'], pipeline_focus: ['tegoprubart (anti-CD40L)', 'kidney transplant rejection', 'ALS'], bd_activity: 'moderate', preferred_deal_stages: ['phase1', 'phase2'], geography_footprint: ['US'], recent_deals: [{ partner: 'Self-funded', asset: 'Tegoprubart Phase 2', indication: 'Kidney transplant', deal_type: 'Internal', upfront_m: 0, total_value_m: 0, year: 2024 }], strategic_priorities: ['Anti-CD40L for transplant and autoimmune'], deal_size_range: '$5M-$200M', source: 'Eledon 2024' },
  { company: 'Prelude Therapeutics (oncology)', company_type: 'biotech', headquarters: 'Wilmington, DE', market_cap_b: 0.3, revenue_b: 0.0, rd_spend_b: 0.1, therapeutic_areas: ['oncology', 'hematology'], pipeline_focus: ['PRT543 (PRMT5 inhibitor)', 'PRT811 (brain-penetrant PRMT5)', 'PRT2527 (CDK9 inhibitor)'], bd_activity: 'moderate', preferred_deal_stages: ['phase1', 'phase2'], geography_footprint: ['US'], recent_deals: [{ partner: 'Self-funded', asset: 'PRT543 Phase 2', indication: 'MDS, myelofibrosis', deal_type: 'Internal', upfront_m: 0, total_value_m: 0, year: 2024 }], strategic_priorities: ['PRMT5 platform differentiation', 'CDK9 inhibitor in hematologic malignancies'], deal_size_range: '$10M-$400M', source: 'Prelude 2024' },
  { company: 'RAPT Therapeutics', company_type: 'biotech', headquarters: 'South San Francisco, CA', market_cap_b: 0.3, revenue_b: 0.0, rd_spend_b: 0.08, therapeutic_areas: ['oncology', 'inflammation'], pipeline_focus: ['zelnecirnon (CCR4 antagonist)', 'RPT193 (CCR4 antagonist)', 'atopic dermatitis'], bd_activity: 'moderate', preferred_deal_stages: ['phase1', 'phase2'], geography_footprint: ['US'], recent_deals: [{ partner: 'Self-funded', asset: 'RPT193 Phase 2', indication: 'Atopic dermatitis', deal_type: 'Internal', upfront_m: 0, total_value_m: 0, year: 2024 }], strategic_priorities: ['CCR4 antagonist for inflammatory diseases', 'IO applications'], deal_size_range: '$5M-$300M', source: 'RAPT 2024' },
  { company: 'Lantern Pharma', company_type: 'biotech', headquarters: 'Dallas, TX', market_cap_b: 0.1, revenue_b: 0.0, rd_spend_b: 0.03, therapeutic_areas: ['oncology'], pipeline_focus: ['RADR AI platform', 'LP-300 (NSCLC non-smokers)', 'LP-184 (solid tumors)'], bd_activity: 'moderate', preferred_deal_stages: ['preclinical', 'phase2'], geography_footprint: ['US'], recent_deals: [{ partner: 'Self-funded', asset: 'LP-300 Phase 2', indication: 'NSCLC never-smokers', deal_type: 'Internal', upfront_m: 0, total_value_m: 0, year: 2024 }], strategic_priorities: ['AI-driven oncology drug development', 'Biomarker-selected patient populations'], deal_size_range: '$5M-$200M', source: 'Lantern 2024' },
  { company: 'C2i Genomics', company_type: 'biotech', headquarters: 'New York, NY', market_cap_b: 0.2, revenue_b: 0.0, rd_spend_b: 0.05, therapeutic_areas: ['oncology', 'diagnostics'], pipeline_focus: ['whole-genome sequencing liquid biopsy', 'MRD (minimal residual disease)', 'tumor-naive ctDNA'], bd_activity: 'active', preferred_deal_stages: ['clinical_validation', 'phase2'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'AstraZeneca', asset: 'MRD companion diagnostic collaboration', indication: 'Lung cancer MRD', deal_type: 'Research collaboration', upfront_m: 15, total_value_m: 100, year: 2023 }], strategic_priorities: ['WGS-based MRD platform commercialization', 'Pharma MRD partnerships'], deal_size_range: '$5M-$200M', source: 'C2i 2024' },
  { company: 'Olema Oncology', company_type: 'biotech', headquarters: 'San Francisco, CA', market_cap_b: 2, revenue_b: 0.0, rd_spend_b: 0.2, therapeutic_areas: ['oncology'], pipeline_focus: ['palazestrant (complete ERa antagonist/CERAN)', 'ER+ breast cancer', 'endocrine resistance'], bd_activity: 'moderate', preferred_deal_stages: ['phase2', 'phase3'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'Self-funded', asset: 'Palazestrant Phase 3 (OPERA)', indication: 'ER+/HER2- mBC', deal_type: 'Internal', upfront_m: 0, total_value_m: 0, year: 2024 }], strategic_priorities: ['Complete ER antagonist differentiation vs SERDs', 'Oral convenience in breast cancer'], deal_size_range: '$20M-$1B', source: 'Olema 2024' },
  { company: 'Kinnate Biopharma', company_type: 'biotech', headquarters: 'San Diego, CA', market_cap_b: 0.2, revenue_b: 0.0, rd_spend_b: 0.05, therapeutic_areas: ['oncology'], pipeline_focus: ['exarafenib (pan-RAF inhibitor)', 'KIN-3248 (pan-FGFR)', 'BRAF-altered tumors'], bd_activity: 'moderate', preferred_deal_stages: ['phase1', 'phase2'], geography_footprint: ['US'], recent_deals: [{ partner: 'Self-funded', asset: 'Exarafenib Phase 2', indication: 'BRAF-altered solid tumors', deal_type: 'Internal', upfront_m: 0, total_value_m: 0, year: 2024 }], strategic_priorities: ['Pan-RAF and FGFR inhibitor platform'], deal_size_range: '$5M-$300M', source: 'Kinnate 2024' },
  { company: 'Chinook Therapeutics (Novartis nephrology)', company_type: 'biotech', headquarters: 'Seattle, WA (now Novartis)', market_cap_b: 220, revenue_b: 0.0, rd_spend_b: 0.2, therapeutic_areas: ['nephrology'], pipeline_focus: ['atrasentan (ETA antagonist)', 'zigakibart (anti-APRIL)', 'IgA nephropathy'], bd_activity: 'selective', preferred_deal_stages: ['phase3'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'Novartis', asset: 'Full company (nephrology pipeline)', indication: 'IgAN, FSGS', deal_type: 'Acquisition', upfront_m: 3500, total_value_m: 3500, year: 2023 }], strategic_priorities: ['Atrasentan and zigakibart for IgAN within Novartis'], deal_size_range: '$50M-$3.5B', source: 'Novartis Pipeline 2024' },
  { company: 'Keros Therapeutics', company_type: 'biotech', headquarters: 'Lexington, MA', market_cap_b: 2, revenue_b: 0.0, rd_spend_b: 0.15, therapeutic_areas: ['hematology', 'musculoskeletal'], pipeline_focus: ['elritercept (modified ActRIIA ligand trap)', 'myelofibrosis anemia', 'pulmonary arterial hypertension'], bd_activity: 'moderate', preferred_deal_stages: ['phase2', 'phase3'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'Self-funded', asset: 'Elritercept Phase 2/3', indication: 'MF-associated anemia', deal_type: 'Internal', upfront_m: 0, total_value_m: 0, year: 2024 }], strategic_priorities: ['TGF-beta superfamily ligand traps', 'Hematology-musculoskeletal pipeline'], deal_size_range: '$10M-$500M', source: 'Keros 2024' },
  { company: 'AbCellera Biologics', company_type: 'biotech', headquarters: 'Vancouver, BC, Canada', market_cap_b: 3, revenue_b: 0.2, rd_spend_b: 0.3, therapeutic_areas: ['oncology', 'immunology', 'infectious disease'], pipeline_focus: ['AI antibody discovery platform', 'ABCL635 (obesity GLP-1/GIP)', 'partnership-derived pipeline'], bd_activity: 'very_active', preferred_deal_stages: ['preclinical', 'phase1'], geography_footprint: ['US', 'EU5', 'Japan'], recent_deals: [{ partner: 'Eli Lilly', asset: 'Bamlanivimab and follow-on antibodies', indication: 'COVID-19, undisclosed', deal_type: 'Collaboration', upfront_m: 100, total_value_m: 500, year: 2020 }, { partner: 'Multiple pharma', asset: '200+ active programs on platform', indication: 'Multiple', deal_type: 'Technology platform', upfront_m: 0, total_value_m: 0, year: 2024 }], strategic_priorities: ['AI antibody discovery partnerships', 'Internal pipeline build-out (obesity)'], deal_size_range: '$10M-$1B', source: 'AbCellera 2024' },
  { company: 'Cerevel Therapeutics (AbbVie neuro)', company_type: 'biotech', headquarters: 'Cambridge, MA (now AbbVie)', market_cap_b: 200, revenue_b: 0.0, rd_spend_b: 0.2, therapeutic_areas: ['neuroscience'], pipeline_focus: ['emraclidine (M4 muscarinic agonist)', 'tavapadon (D1/D5 agonist)', 'schizophrenia', 'Parkinson disease'], bd_activity: 'selective', preferred_deal_stages: ['phase2', 'phase3'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'AbbVie', asset: 'Full company (neuro pipeline)', indication: 'Schizophrenia, PD', deal_type: 'Acquisition', upfront_m: 8700, total_value_m: 8700, year: 2024 }], strategic_priorities: ['Emraclidine Phase 3 schizophrenia within AbbVie', 'Tavapadon PD program'], deal_size_range: '$50M-$9B', source: 'AbbVie Pipeline 2024' },
  { company: 'Immunomedics (Gilead oncology)', company_type: 'biotech', headquarters: 'Morris Plains, NJ (now Gilead)', market_cap_b: 120, revenue_b: 2.0, rd_spend_b: 0.5, therapeutic_areas: ['oncology'], pipeline_focus: ['Trodelvy (sacituzumab govitecan)', 'TNBC', 'urothelial cancer', 'HR+/HER2- mBC'], bd_activity: 'selective', preferred_deal_stages: ['approved', 'phase3'], geography_footprint: ['US', 'EU5', 'Japan'], recent_deals: [{ partner: 'Gilead', asset: 'Full company (Trodelvy ADC)', indication: 'Breast, bladder cancer', deal_type: 'Acquisition', upfront_m: 21000, total_value_m: 21000, year: 2020 }], strategic_priorities: ['Trodelvy label expansion', 'Next-gen ADC combinations'], deal_size_range: '$100M-$21B', source: 'Gilead Oncology 2024' },
  { company: 'Iveric Bio (Astellas ophtho)', company_type: 'biotech', headquarters: 'Parsippany, NJ (now Astellas)', market_cap_b: 30, revenue_b: 0.0, rd_spend_b: 0.1, therapeutic_areas: ['ophthalmology'], pipeline_focus: ['IZERVAY (avacincaptad pegol)', 'geographic atrophy', 'complement C5 inhibition'], bd_activity: 'selective', preferred_deal_stages: ['approved'], geography_footprint: ['US', 'EU5', 'Japan'], recent_deals: [{ partner: 'Astellas', asset: 'Full company (IZERVAY)', indication: 'Geographic atrophy', deal_type: 'Acquisition', upfront_m: 5900, total_value_m: 5900, year: 2023 }], strategic_priorities: ['IZERVAY commercial launch in GA within Astellas'], deal_size_range: '$50M-$6B', source: 'Astellas Pipeline 2024' },
  { company: 'Seagen (Pfizer oncology ADC)', company_type: 'biotech', headquarters: 'Bothell, WA (now Pfizer)', market_cap_b: 290, revenue_b: 2.5, rd_spend_b: 1.0, therapeutic_areas: ['oncology'], pipeline_focus: ['ADCETRIS (brentuximab vedotin)', 'PADCEV (enfortumab vedotin)', 'TUKYSA (tucatinib)', 'ladiratuzumab vedotin'], bd_activity: 'selective', preferred_deal_stages: ['phase2', 'phase3', 'approved'], geography_footprint: ['US', 'EU5', 'Japan', 'China'], recent_deals: [{ partner: 'Pfizer', asset: 'Full company (ADC pipeline)', indication: 'Oncology (broad)', deal_type: 'Acquisition', upfront_m: 43000, total_value_m: 43000, year: 2023 }], strategic_priorities: ['PADCEV + Keytruda bladder cancer franchise', 'ADC pipeline within Pfizer'], deal_size_range: '$100M-$43B', source: 'Pfizer Pipeline 2024' },
  { company: 'CinCor Pharma (AZ cardio)', company_type: 'biotech', headquarters: 'Waltham, MA (now AZ)', market_cap_b: 270, revenue_b: 0.0, rd_spend_b: 0.1, therapeutic_areas: ['cardiovascular', 'nephrology'], pipeline_focus: ['baxdrostat (aldosterone synthase inhibitor)', 'treatment-resistant hypertension', 'CKD'], bd_activity: 'selective', preferred_deal_stages: ['phase2', 'phase3'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'AstraZeneca', asset: 'Full company (baxdrostat)', indication: 'Resistant hypertension', deal_type: 'Acquisition', upfront_m: 1800, total_value_m: 1800, year: 2023 }], strategic_priorities: ['Baxdrostat Phase 3 within AZ cardiovascular'], deal_size_range: '$50M-$2B', source: 'AZ Cardiovascular 2024' },
  { company: 'Provention Bio (Sanofi)', company_type: 'biotech', headquarters: 'Red Bank, NJ (now Sanofi)', market_cap_b: 140, revenue_b: 0.2, rd_spend_b: 0.05, therapeutic_areas: ['autoimmune', 'endocrinology'], pipeline_focus: ['teplizumab (anti-CD3)', 'type 1 diabetes delay', 'celiac disease'], bd_activity: 'selective', preferred_deal_stages: ['approved'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'Sanofi', asset: 'Full company (teplizumab/TZIELD)', indication: 'T1D delay', deal_type: 'Acquisition', upfront_m: 2900, total_value_m: 2900, year: 2023 }], strategic_priorities: ['TZIELD commercial launch for T1D prevention within Sanofi'], deal_size_range: '$50M-$3B', source: 'Sanofi Pipeline 2024' },
  { company: 'Aiolos Bio (GSK)', company_type: 'biotech', headquarters: 'Waltham, MA (now GSK)', market_cap_b: 80, revenue_b: 0.0, rd_spend_b: 0.1, therapeutic_areas: ['respiratory', 'immunology'], pipeline_focus: ['AIO-001 (anti-TSLP long-acting)', 'asthma', 'COPD'], bd_activity: 'selective', preferred_deal_stages: ['phase1'], geography_footprint: ['US', 'EU5'], recent_deals: [{ partner: 'GSK', asset: 'Full company (long-acting anti-TSLP)', indication: 'Asthma', deal_type: 'Acquisition', upfront_m: 1400, total_value_m: 1400, year: 2024 }], strategic_priorities: ['Long-acting anti-TSLP for asthma within GSK respiratory'], deal_size_range: '$50M-$1.5B', source: 'GSK Pipeline 2024' },
  { company: 'BlackThorn Therapeutics (Neumora)', company_type: 'biotech', headquarters: 'San Francisco, CA', market_cap_b: 1, revenue_b: 0.0, rd_spend_b: 0.15, therapeutic_areas: ['neuroscience'], pipeline_focus: ['navacaprant (KOR antagonist)', 'MDD', 'PTSD', 'circuit-based neuropsychiatry'], bd_activity: 'moderate', preferred_deal_stages: ['phase2', 'phase3'], geography_footprint: ['US'], recent_deals: [{ partner: 'Neurocrine', asset: 'KOR antagonist collaboration', indication: 'MDD', deal_type: 'Collaboration', upfront_m: 35, total_value_m: 400, year: 2022 }], strategic_priorities: ['KOR antagonist for depression and PTSD', 'Precision psychiatry platform'], deal_size_range: '$10M-$500M', source: 'Neumora/BlackThorn 2024' },
  { company: 'Vor Biopharma', company_type: 'biotech', headquarters: 'Cambridge, MA', market_cap_b: 0.2, revenue_b: 0.0, rd_spend_b: 0.08, therapeutic_areas: ['oncology', 'hematology'], pipeline_focus: ['trem-cel (CD33-deleted HSC)', 'engineered hematopoietic stem cells', 'AML'], bd_activity: 'moderate', preferred_deal_stages: ['phase1', 'phase2'], geography_footprint: ['US'], recent_deals: [{ partner: 'Self-funded', asset: 'Trem-cel Phase 1/2', indication: 'AML', deal_type: 'Internal', upfront_m: 0, total_value_m: 0, year: 2024 }], strategic_priorities: ['Engineered HSC + targeted therapy combinations for AML'], deal_size_range: '$5M-$300M', source: 'Vor 2024' },
  { company: 'Gritstone Bio', company_type: 'biotech', headquarters: 'Emeryville, CA', market_cap_b: 0.1, revenue_b: 0.0, rd_spend_b: 0.05, therapeutic_areas: ['oncology', 'infectious disease'], pipeline_focus: ['SLATE neoantigen immunotherapy', 'personalized cancer vaccines', 'CORAL universal COVID booster'], bd_activity: 'active', preferred_deal_stages: ['phase1', 'phase2'], geography_footprint: ['US'], recent_deals: [{ partner: 'Gilead', asset: 'HIV therapeutic vaccine collaboration', indication: 'HIV cure', deal_type: 'Collaboration', upfront_m: 30, total_value_m: 785, year: 2021 }], strategic_priorities: ['Neoantigen-based cancer vaccines', 'Universal pathogen vaccines'], deal_size_range: '$5M-$800M', source: 'Gritstone 2024' },
  { company: 'Heron Therapeutics', company_type: 'specialty_pharma', headquarters: 'San Diego, CA', market_cap_b: 0.5, revenue_b: 0.3, rd_spend_b: 0.05, therapeutic_areas: ['pain', 'oncology supportive care'], pipeline_focus: ['ZYNRELEF (bupivacaine/meloxicam)', 'CINVANTI (aprepitant injectable)', 'SUSTOL (granisetron)'], bd_activity: 'moderate', preferred_deal_stages: ['approved'], geography_footprint: ['US'], recent_deals: [{ partner: 'Self-funded', asset: 'ZYNRELEF commercial expansion', indication: 'Post-surgical pain', deal_type: 'Self-commercialization', upfront_m: 0, total_value_m: 0, year: 2024 }], strategic_priorities: ['Non-opioid pain management portfolio', 'CINVANTI/SUSTOL oncology supportive care'], deal_size_range: '$5M-$200M', source: 'Heron 2024' },

];



